id	sid	tid	token	lemma	pos
aji-148	1	1	_	_	PUNCT
aji-148	2	1	_	_	PUNCT
aji-148	3	1	_	_	PUNCT
aji-148	4	1	_	_	PUNCT
aji-148	5	1	_	_	PUNCT
aji-148	6	1	_	_	PUNCT
aji-148	7	1	_	_	PUNCT
aji-148	8	1	_	_	PUNCT
aji-148	9	1	_	_	PUNCT
aji-148	10	1	_	_	PUNCT
aji-148	11	1	_	_	PUNCT
aji-148	12	1	_	_	PUNCT
aji-148	13	1	_	_	PUNCT
aji-148	14	1	_	_	PUNCT
aji-148	15	1	_	_	PUNCT
aji-148	16	1	_	_	PUNCT
aji-148	17	1	_	_	PUNCT
aji-148	18	1	_	_	PUNCT
aji-148	19	1	_	_	PUNCT
aji-148	20	1	_	_	PUNCT
aji-148	21	1	_	_	PUNCT
aji-148	22	1	_	_	PUNCT
aji-148	23	1	_	_	PUNCT
aji-148	24	1	_	_	PUNCT
aji-148	25	1	_	_	PUNCT
aji-148	26	1	_	_	PUNCT
aji-148	27	1	_	_	PUNCT
aji-148	28	1	_	_	PUNCT
aji-148	29	1	_	_	PUNCT
aji-148	30	1	_	_	PUNCT
aji-148	31	1	_	_	PUNCT
aji-148	32	1	_	_	PUNCT
aji-148	33	1	_	_	PUNCT
aji-148	34	1	_	_	PUNCT
aji-148	35	1	_	_	PUNCT
aji-148	36	1	_	_	PUNCT
aji-148	37	1	_	_	PUNCT
aji-148	38	1	_	_	PUNCT
aji-148	39	1	_	_	PUNCT
aji-148	40	1	_	_	PUNCT
aji-148	41	1	_	_	PUNCT
aji-148	42	1	_	_	PUNCT
aji-148	43	1	_	_	PUNCT
aji-148	44	1	_	_	PUNCT
aji-148	45	1	_	_	PUNCT
aji-148	46	1	_	_	PUNCT
aji-148	47	1	_	_	PUNCT
aji-148	48	1	_	_	PUNCT
aji-148	49	1	_	_	PUNCT
aji-148	50	1	_	_	PUNCT
aji-148	51	1	_	_	PUNCT
aji-148	52	1	_	_	PUNCT
aji-148	53	1	_	_	PUNCT
aji-148	54	1	_	_	PUNCT
aji-148	55	1	_	_	PUNCT
aji-148	56	1	_	_	PUNCT
aji-148	57	1	_	_	PUNCT
aji-148	58	1	_	_	PUNCT
aji-148	59	1	_	_	PUNCT
aji-148	60	1	_	_	PUNCT
aji-148	61	1	_	_	PUNCT
aji-148	62	1	_	_	PUNCT
aji-148	63	1	_	_	PUNCT
aji-148	64	1	_	_	PUNCT
aji-148	65	1	_	_	PUNCT
aji-148	66	1	_	_	PUNCT
aji-148	67	1	_	_	PUNCT
aji-148	68	1	_	_	PUNCT
aji-148	69	1	_	_	PUNCT
aji-148	70	1	_	_	PUNCT
aji-148	71	1	_	_	PUNCT
aji-148	72	1	_	_	PUNCT
aji-148	73	1	_	_	PUNCT
aji-148	74	1	_	_	PUNCT
aji-148	75	1	_	_	PUNCT
aji-148	76	1	_	_	PUNCT
aji-148	77	1	_	_	PUNCT
aji-148	78	1	_	_	PUNCT
aji-148	79	1	_	_	PUNCT
aji-148	80	1	_	_	PUNCT
aji-148	81	1	_	_	PUNCT
aji-148	82	1	_	_	PUNCT
aji-148	83	1	_	_	PUNCT
aji-148	84	1	_	_	PUNCT
aji-148	85	1	_	_	PUNCT
aji-148	86	1	_	_	PUNCT
aji-148	87	1	_	_	PUNCT
aji-148	88	1	_	_	PUNCT
aji-148	89	1	_	_	PUNCT
aji-148	90	1	_	_	PUNCT
aji-148	91	1	_	_	PUNCT
aji-148	92	1	_	_	PUNCT
aji-148	93	1	_	_	PUNCT
aji-148	94	1	_	_	PUNCT
aji-148	95	1	_	_	PUNCT
aji-148	96	1	_	_	PUNCT
aji-148	97	1	_	_	PUNCT
aji-148	98	1	_	_	PUNCT
aji-148	99	1	_	_	PUNCT
aji-148	100	1	_	_	PUNCT
aji-148	101	1	_	_	PUNCT
aji-148	102	1	+	+	PUNCT
aji-148	102	2	+	+	PROPN
aji-148	102	3	md	md	PROPN
aji-148	102	4	/	/	SYM
aji-148	102	5	phd	phd	PROPN
aji-148	102	6	,	,	PUNCT
aji-148	102	7	senior	senior	ADJ
aji-148	102	8	faculty	faculty	NOUN
aji-148	102	9	of	of	ADP
aji-148	102	10	principal	principal	ADJ
aji-148	102	11	research	research	NOUN
aji-148	102	12	scientist	scientist	NOUN
aji-148	102	13	;	;	PUNCT
aji-148	102	14	#	#	NOUN
aji-148	102	15	alumni	alumnus	NOUN
aji-148	102	16	professor	professor	NOUN
aji-148	102	17	;	;	PUNCT
aji-148	102	18	*	*	PUNCT
aji-148	102	19	corresponding	correspond	VERB
aji-148	102	20	author	author	NOUN
aji-148	102	21	:	:	PUNCT
aji-148	102	22	e	e	NOUN
aji-148	102	23	-	-	NOUN
aji-148	102	24	mail	mail	NOUN
aji-148	102	25	:	:	PUNCT
aji-148	102	26	bli@augusta.edu	bli@augusta.edu	PROPN
aji-148	102	27	,	,	PUNCT
aji-148	102	28	brli1@juno.com	brli1@juno.com	X
aji-148	102	29	;	;	PUNCT
aji-148	102	30	cite	cite	VERB
aji-148	102	31	as	as	ADP
aji-148	102	32	:	:	PUNCT
aji-148	102	33	li	li	PROPN
aji-148	102	34	,	,	PUNCT
aji-148	102	35	shen	shen	NOUN
aji-148	102	36	,	,	PUNCT
aji-148	102	37	and	and	CCONJ
aji-148	102	38	biaoru	biaoru	PROPN
aji-148	102	39	li	li	PROPN
aji-148	102	40	.	.	PROPN
aji-148	102	41	2024	2024	NUM
aji-148	102	42	.	.	PUNCT
aji-148	103	1	“	"	PUNCT
aji-148	103	2	optimizing	optimize	VERB
aji-148	103	3	cancer	cancer	NOUN
aji-148	103	4	immunotherapy	immunotherapy	NOUN
aji-148	103	5	through	through	ADP
aji-148	103	6	combination	combination	NOUN
aji-148	103	7	therapies	therapy	NOUN
aji-148	103	8	:	:	PUNCT
aji-148	103	9	advances	advance	NOUN
aji-148	103	10	in	in	ADP
aji-148	103	11	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	103	12	,	,	PUNCT
aji-148	103	13	lymphodepletion	lymphodepletion	NOUN
aji-148	103	14	,	,	PUNCT
aji-148	103	15	and	and	CCONJ
aji-148	103	16	precision	precision	NOUN
aji-148	103	17	medicine	medicine	NOUN
aji-148	103	18	”	"	PUNCT
aji-148	103	19	.	.	PUNCT
aji-148	104	1	asian	asian	ADJ
aji-148	104	2	journal	journal	NOUN
aji-148	104	3	of	of	ADP
aji-148	104	4	immunology	immunology	NOUN
aji-148	104	5	7	7	NUM
aji-148	104	6	(	(	PUNCT
aji-148	104	7	1):247	1):247	PROPN
aji-148	104	8	-	-	SYM
aji-148	104	9	57	57	NUM
aji-148	104	10	.	.	PUNCT
aji-148	105	1	https://journalaji.com/index.php/aji/article/view/148	https://journalaji.com/index.php/aji/article/view/148	PROPN
aji-148	105	2	.	.	PUNCT
aji-148	105	3	asian	asian	ADJ
aji-148	105	4	journal	journal	NOUN
aji-148	105	5	of	of	ADP
aji-148	105	6	immunology	immunology	NOUN
aji-148	105	7	volume	volume	NOUN
aji-148	105	8	7	7	NUM
aji-148	105	9	,	,	PUNCT
aji-148	105	10	issue	issue	NOUN
aji-148	105	11	1	1	NUM
aji-148	105	12	,	,	PUNCT
aji-148	105	13	page	page	NOUN
aji-148	105	14	247	247	NUM
aji-148	105	15	-	-	SYM
aji-148	105	16	257	257	NUM
aji-148	105	17	,	,	PUNCT
aji-148	105	18	2024	2024	NUM
aji-148	105	19	;	;	PUNCT
aji-148	105	20	article	article	NOUN
aji-148	105	21	no.aji.126682	no.aji.126682	ADV
aji-148	105	22	optimizing	optimize	VERB
aji-148	105	23	cancer	cancer	NOUN
aji-148	105	24	immunotherapy	immunotherapy	NOUN
aji-148	105	25	through	through	ADP
aji-148	105	26	combination	combination	NOUN
aji-148	105	27	therapies	therapy	NOUN
aji-148	105	28	:	:	PUNCT
aji-148	105	29	advances	advance	NOUN
aji-148	105	30	in	in	ADP
aji-148	105	31	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	105	32	,	,	PUNCT
aji-148	105	33	lymphodepletion	lymphodepletion	NOUN
aji-148	105	34	,	,	PUNCT
aji-148	105	35	and	and	CCONJ
aji-148	105	36	precision	precision	NOUN
aji-148	105	37	medicine	medicine	PROPN
aji-148	105	38	shen	shen	PROPN
aji-148	105	39	li	li	PROPN
aji-148	105	40	a++	a++	PROPN
aji-148	105	41	and	and	CCONJ
aji-148	105	42	biaoru	biaoru	PROPN
aji-148	105	43	li	li	PROPN
aji-148	105	44	b	b	PROPN
aji-148	105	45	,	,	PUNCT
aji-148	105	46	c++	c++	NOUN
aji-148	105	47	#	#	SYM
aji-148	105	48	*	*	DET
aji-148	105	49	a	a	DET
aji-148	105	50	university	university	NOUN
aji-148	105	51	of	of	ADP
aji-148	105	52	chicago	chicago	PROPN
aji-148	105	53	medical	medical	ADJ
aji-148	105	54	center	center	NOUN
aji-148	105	55	,	,	PUNCT
aji-148	105	56	section	section	NOUN
aji-148	105	57	of	of	ADP
aji-148	105	58	general	general	ADJ
aji-148	105	59	surgery	surgery	NOUN
aji-148	105	60	,	,	PUNCT
aji-148	105	61	chicago	chicago	PROPN
aji-148	105	62	,	,	PUNCT
aji-148	105	63	il	il	PROPN
aji-148	105	64	60637	60637	NUM
aji-148	105	65	,	,	PUNCT
aji-148	105	66	usa	usa	PROPN
aji-148	105	67	.	.	PROPN
aji-148	106	1	b	b	PROPN
aji-148	106	2	department	department	NOUN
aji-148	106	3	of	of	ADP
aji-148	106	4	pediatrics	pediatric	NOUN
aji-148	106	5	and	and	CCONJ
aji-148	106	6	ga	ga	PROPN
aji-148	106	7	cancer	cancer	NOUN
aji-148	106	8	center	center	NOUN
aji-148	106	9	,	,	PUNCT
aji-148	106	10	children	child	NOUN
aji-148	106	11	hospital	hospital	NOUN
aji-148	106	12	at	at	ADP
aji-148	106	13	ga	ga	PROPN
aji-148	106	14	,	,	PUNCT
aji-148	106	15	augusta	augusta	PROPN
aji-148	106	16	,	,	PUNCT
aji-148	106	17	ga	ga	PROPN
aji-148	106	18	30913	30913	NUM
aji-148	106	19	,	,	PUNCT
aji-148	106	20	georgia	georgia	PROPN
aji-148	106	21	.	.	PUNCT
aji-148	107	1	c	c	PROPN
aji-148	107	2	school	school	NOUN
aji-148	107	3	of	of	ADP
aji-148	107	4	medicine	medicine	NOUN
aji-148	107	5	,	,	PUNCT
aji-148	107	6	cwru	cwru	PROPN
aji-148	107	7	,	,	PUNCT
aji-148	107	8	10900	10900	NUM
aji-148	107	9	euclid	euclid	PROPN
aji-148	107	10	ave	ave	PROPN
aji-148	107	11	,	,	PUNCT
aji-148	107	12	cleveland	cleveland	PROPN
aji-148	107	13	,	,	PUNCT
aji-148	107	14	oh	oh	INTJ
aji-148	107	15	44106	44106	NUM
aji-148	107	16	,	,	PUNCT
aji-148	107	17	usa	usa	PROPN
aji-148	107	18	.	.	PROPN
aji-148	107	19	authors	author	NOUN
aji-148	107	20	’	’	PART
aji-148	107	21	contributions	contribution	NOUN
aji-148	107	22	this	this	DET
aji-148	107	23	work	work	NOUN
aji-148	107	24	was	be	AUX
aji-148	107	25	carried	carry	VERB
aji-148	107	26	out	out	ADP
aji-148	107	27	in	in	ADP
aji-148	107	28	collaboration	collaboration	NOUN
aji-148	107	29	between	between	ADP
aji-148	107	30	both	both	DET
aji-148	107	31	authors	author	NOUN
aji-148	107	32	.	.	PUNCT
aji-148	108	1	both	both	DET
aji-148	108	2	authors	author	NOUN
aji-148	108	3	read	read	VERB
aji-148	108	4	and	and	CCONJ
aji-148	108	5	approved	approve	VERB
aji-148	108	6	the	the	DET
aji-148	108	7	final	final	ADJ
aji-148	108	8	manuscript	manuscript	NOUN
aji-148	108	9	.	.	PUNCT
aji-148	109	1	article	article	NOUN
aji-148	109	2	information	information	PROPN
aji-148	109	3	doi	doi	PROPN
aji-148	109	4	:	:	PUNCT
aji-148	109	5	https://doi.org/10.9734/aji/2024/v7i1148	https://doi.org/10.9734/aji/2024/v7i1148	PROPN
aji-148	109	6	open	open	ADJ
aji-148	109	7	peer	peer	NOUN
aji-148	109	8	review	review	NOUN
aji-148	109	9	history	history	NOUN
aji-148	109	10	:	:	PUNCT
aji-148	109	11	this	this	DET
aji-148	109	12	journal	journal	NOUN
aji-148	109	13	follows	follow	VERB
aji-148	109	14	the	the	DET
aji-148	109	15	advanced	advance	VERB
aji-148	109	16	open	open	ADJ
aji-148	109	17	peer	peer	NOUN
aji-148	109	18	review	review	NOUN
aji-148	109	19	policy	policy	NOUN
aji-148	109	20	.	.	PUNCT
aji-148	110	1	identity	identity	NOUN
aji-148	110	2	of	of	ADP
aji-148	110	3	the	the	DET
aji-148	110	4	reviewers	reviewer	NOUN
aji-148	110	5	,	,	PUNCT
aji-148	110	6	editor(s	editor(s	NOUN
aji-148	110	7	)	)	PUNCT
aji-148	110	8	and	and	CCONJ
aji-148	110	9	additional	additional	ADJ
aji-148	110	10	reviewers	reviewer	NOUN
aji-148	110	11	,	,	PUNCT
aji-148	110	12	peer	peer	NOUN
aji-148	110	13	review	review	NOUN
aji-148	110	14	comments	comment	NOUN
aji-148	110	15	,	,	PUNCT
aji-148	110	16	different	different	ADJ
aji-148	110	17	versions	version	NOUN
aji-148	110	18	of	of	ADP
aji-148	110	19	the	the	DET
aji-148	110	20	manuscript	manuscript	NOUN
aji-148	110	21	,	,	PUNCT
aji-148	110	22	comments	comment	NOUN
aji-148	110	23	of	of	ADP
aji-148	110	24	the	the	DET
aji-148	110	25	editors	editor	NOUN
aji-148	110	26	,	,	PUNCT
aji-148	110	27	etc	etc	X
aji-148	110	28	are	be	AUX
aji-148	110	29	available	available	ADJ
aji-148	110	30	here	here	ADV
aji-148	110	31	:	:	PUNCT
aji-148	110	32	https://www.sdiarticle5.com/review-history/126682	https://www.sdiarticle5.com/review-history/126682	NOUN
aji-148	110	33	received	receive	VERB
aji-148	110	34	:	:	PUNCT
aji-148	110	35	10/09/2024	10/09/2024	NUM
aji-148	110	36	accepted	accept	VERB
aji-148	110	37	:	:	PUNCT
aji-148	110	38	12/11/2024	12/11/2024	NUM
aji-148	110	39	published	publish	VERB
aji-148	110	40	:	:	PUNCT
aji-148	110	41	15/11/2024	15/11/2024	NUM
aji-148	110	42	abstract	abstract	ADJ
aji-148	110	43	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	110	44	was	be	AUX
aji-148	110	45	a	a	DET
aji-148	110	46	challenge	challenge	NOUN
aji-148	110	47	issue	issue	NOUN
aji-148	110	48	in	in	ADP
aji-148	110	49	an	an	DET
aji-148	110	50	early	early	ADJ
aji-148	110	51	clinical	clinical	ADJ
aji-148	110	52	study	study	NOUN
aji-148	110	53	.	.	PUNCT
aji-148	111	1	cytotoxic	cytotoxic	ADJ
aji-148	111	2	chemotherapy	chemotherapy	NOUN
aji-148	111	3	was	be	AUX
aji-148	111	4	immunosuppressive	immunosuppressive	ADJ
aji-148	111	5	while	while	SCONJ
aji-148	111	6	,	,	PUNCT
aji-148	111	7	in	in	ADP
aji-148	111	8	the	the	DET
aji-148	111	9	clinic	clinic	NOUN
aji-148	111	10	,	,	PUNCT
aji-148	111	11	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	111	12	demonstrated	demonstrate	VERB
aji-148	111	13	supporting	support	VERB
aji-148	111	14	immunotherapy	immunotherapy	NOUN
aji-148	111	15	.	.	PUNCT
aji-148	112	1	to	to	PART
aji-148	112	2	increase	increase	VERB
aji-148	112	3	act	act	NOUN
aji-148	112	4	(	(	PUNCT
aji-148	112	5	adoptive	adoptive	ADJ
aji-148	112	6	cell	cell	NOUN
aji-148	112	7	transfer	transfer	NOUN
aji-148	112	8	)	)	PUNCT
aji-148	112	9	immunotherapy	immunotherapy	NOUN
aji-148	112	10	and	and	CCONJ
aji-148	112	11	decrease	decrease	VERB
aji-148	112	12	the	the	DET
aji-148	112	13	effects	effect	NOUN
aji-148	112	14	review	review	NOUN
aji-148	112	15	article	article	NOUN
aji-148	112	16	mailto:bli@augusta.edu	mailto:bli@augusta.edu	VERB
aji-148	112	17	https://doi.org/10.9734/aji/2024/v7i1148	https://doi.org/10.9734/aji/2024/v7i1148	PROPN
aji-148	112	18	https://www.sdiarticle5.com/review-history/126682	https://www.sdiarticle5.com/review-history/126682	PROPN
aji-148	112	19	li	li	PROPN
aji-148	112	20	and	and	CCONJ
aji-148	112	21	li	li	PROPN
aji-148	112	22	;	;	PUNCT
aji-148	112	23	asian	asian	PROPN
aji-148	112	24	j.	j.	PROPN
aji-148	112	25	immunol	immunol	PROPN
aji-148	112	26	.	.	PROPN
aji-148	113	1	,	,	PUNCT
aji-148	113	2	vol	vol	NOUN
aji-148	113	3	.	.	PROPN
aji-148	114	1	7	7	NUM
aji-148	114	2	,	,	PUNCT
aji-148	114	3	no	no	INTJ
aji-148	114	4	.	.	NOUN
aji-148	114	5	1	1	NUM
aji-148	114	6	,	,	PUNCT
aji-148	114	7	pp	pp	ADJ
aji-148	114	8	.	.	PUNCT
aji-148	115	1	247	247	NUM
aji-148	115	2	-	-	SYM
aji-148	115	3	257	257	NUM
aji-148	115	4	,	,	PUNCT
aji-148	115	5	2024	2024	NUM
aji-148	115	6	;	;	PUNCT
aji-148	115	7	article	article	NOUN
aji-148	115	8	no.aji.126682	no.aji.126682	ADP
aji-148	115	9	248	248	NUM
aji-148	115	10	of	of	ADP
aji-148	115	11	chemotherapy	chemotherapy	NOUN
aji-148	115	12	for	for	ADP
aji-148	115	13	tumor	tumor	NOUN
aji-148	115	14	-	-	PUNCT
aji-148	115	15	infiltrating	infiltrate	VERB
aji-148	115	16	lymphocytes	lymphocyte	NOUN
aji-148	115	17	(	(	PUNCT
aji-148	115	18	tils	til	NOUN
aji-148	115	19	)	)	PUNCT
aji-148	115	20	to	to	PART
aji-148	115	21	treat	treat	VERB
aji-148	115	22	solid	solid	ADJ
aji-148	115	23	tumors	tumor	NOUN
aji-148	115	24	,	,	PUNCT
aji-148	115	25	we	we	PRON
aji-148	115	26	began	begin	VERB
aji-148	115	27	to	to	PART
aji-148	115	28	study	study	VERB
aji-148	115	29	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	115	30	by	by	ADP
aji-148	115	31	isolating	isolate	VERB
aji-148	115	32	and	and	CCONJ
aji-148	115	33	culturing	culture	VERB
aji-148	115	34	primary	primary	ADJ
aji-148	115	35	tumor	tumor	NOUN
aji-148	115	36	cells	cell	NOUN
aji-148	115	37	and	and	CCONJ
aji-148	115	38	immune	immune	ADJ
aji-148	115	39	cells	cell	NOUN
aji-148	115	40	from	from	ADP
aji-148	115	41	the	the	DET
aji-148	115	42	removed	remove	VERB
aji-148	115	43	solid	solid	ADJ
aji-148	115	44	tumor	tumor	NOUN
aji-148	115	45	tissues	tissue	NOUN
aji-148	115	46	before	before	ADP
aji-148	115	47	1994	1994	NUM
aji-148	115	48	.	.	PUNCT
aji-148	116	1	after	after	ADP
aji-148	116	2	about	about	ADV
aji-148	116	3	30	30	NUM
aji-148	116	4	-	-	SYM
aji-148	116	5	40	40	NUM
aji-148	116	6	years	year	NOUN
aji-148	116	7	of	of	ADP
aji-148	116	8	efforts	effort	NOUN
aji-148	116	9	,	,	PUNCT
aji-148	116	10	results	result	NOUN
aji-148	116	11	of	of	ADP
aji-148	116	12	optimizing	optimize	VERB
aji-148	116	13	combination	combination	NOUN
aji-148	116	14	treatment	treatment	NOUN
aji-148	116	15	have	have	AUX
aji-148	116	16	demonstrated	demonstrate	VERB
aji-148	116	17	that	that	SCONJ
aji-148	116	18	chemotherapy	chemotherapy	NOUN
aji-148	116	19	combined	combine	VERB
aji-148	116	20	with	with	ADP
aji-148	116	21	immunotherapy	immunotherapy	NOUN
aji-148	116	22	(	(	PUNCT
aji-148	116	23	called	call	VERB
aji-148	116	24	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	116	25	)	)	PUNCT
aji-148	116	26	is	be	AUX
aji-148	116	27	better	well	ADJ
aji-148	116	28	than	than	ADP
aji-148	116	29	monotherapy	monotherapy	NOUN
aji-148	116	30	;	;	PUNCT
aji-148	116	31	now	now	ADV
aji-148	116	32	there	there	PRON
aji-148	116	33	are	be	VERB
aji-148	116	34	four	four	NUM
aji-148	116	35	fields	field	NOUN
aji-148	116	36	to	to	PART
aji-148	116	37	be	be	AUX
aji-148	116	38	developed	develop	VERB
aji-148	116	39	for	for	ADP
aji-148	116	40	the	the	DET
aji-148	116	41	optimizing	optimizing	NOUN
aji-148	116	42	combination	combination	NOUN
aji-148	116	43	,	,	PUNCT
aji-148	116	44	including	include	VERB
aji-148	116	45	(	(	PUNCT
aji-148	116	46	1	1	NUM
aji-148	116	47	)	)	PUNCT
aji-148	116	48	lymphodepletion	lymphodepletion	NOUN
aji-148	116	49	(	(	PUNCT
aji-148	116	50	ld	ld	NOUN
aji-148	116	51	)	)	PUNCT
aji-148	116	52	supporting	support	VERB
aji-148	116	53	act	act	NOUN
aji-148	116	54	immunotherapy	immunotherapy	NOUN
aji-148	116	55	for	for	ADP
aji-148	116	56	advanced	advanced	ADJ
aji-148	116	57	cancer	cancer	NOUN
aji-148	116	58	,	,	PUNCT
aji-148	116	59	(	(	PUNCT
aji-148	116	60	2	2	X
aji-148	116	61	)	)	PUNCT
aji-148	116	62	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	116	63	(	(	PUNCT
aji-148	116	64	ci	ci	NOUN
aji-148	116	65	)	)	PUNCT
aji-148	116	66	supporting	support	VERB
aji-148	116	67	treatment	treatment	NOUN
aji-148	116	68	for	for	ADP
aji-148	116	69	advanced	advanced	ADJ
aji-148	116	70	cancer	cancer	NOUN
aji-148	116	71	,	,	PUNCT
aji-148	116	72	(	(	PUNCT
aji-148	116	73	3	3	X
aji-148	116	74	)	)	PUNCT
aji-148	116	75	immune	immune	ADJ
aji-148	116	76	checkpoint	checkpoint	NOUN
aji-148	116	77	inhibition	inhibition	NOUN
aji-148	116	78	(	(	PUNCT
aji-148	116	79	ici	ici	NOUN
aji-148	116	80	)	)	PUNCT
aji-148	116	81	combined	combine	VERB
aji-148	116	82	with	with	ADP
aji-148	116	83	immunotherapy	immunotherapy	NOUN
aji-148	116	84	,	,	PUNCT
aji-148	116	85	and	and	CCONJ
aji-148	116	86	(	(	PUNCT
aji-148	116	87	4	4	X
aji-148	116	88	)	)	PUNCT
aji-148	116	89	precision	precision	NOUN
aji-148	116	90	medicine	medicine	NOUN
aji-148	116	91	(	(	PUNCT
aji-148	116	92	pm	pm	NOUN
aji-148	116	93	)	)	PUNCT
aji-148	116	94	supporting	support	VERB
aji-148	116	95	immunotherapy	immunotherapy	NOUN
aji-148	116	96	for	for	ADP
aji-148	116	97	advanced	advanced	ADJ
aji-148	116	98	cancer	cancer	NOUN
aji-148	116	99	.	.	PUNCT
aji-148	117	1	precision	precision	NOUN
aji-148	117	2	therapy	therapy	NOUN
aji-148	117	3	can	can	AUX
aji-148	117	4	cover	cover	VERB
aji-148	117	5	all	all	DET
aji-148	117	6	three	three	NUM
aji-148	117	7	,	,	PUNCT
aji-148	117	8	as	as	SCONJ
aji-148	117	9	described	describe	VERB
aji-148	117	10	above	above	ADV
aji-148	117	11	,	,	PUNCT
aji-148	117	12	as	as	ADV
aji-148	117	13	well	well	ADV
aji-148	117	14	as	as	ADP
aji-148	117	15	ld	ld	PROPN
aji-148	117	16	,	,	PUNCT
aji-148	117	17	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	117	18	,	,	PUNCT
aji-148	117	19	and	and	CCONJ
aji-148	117	20	ici	ici	NOUN
aji-148	117	21	combination	combination	NOUN
aji-148	117	22	.	.	PUNCT
aji-148	118	1	techniques	technique	NOUN
aji-148	118	2	for	for	ADP
aji-148	118	3	precision	precision	NOUN
aji-148	118	4	therapy	therapy	NOUN
aji-148	118	5	include	include	VERB
aji-148	118	6	tumor	tumor	NOUN
aji-148	118	7	tissue	tissue	NOUN
aji-148	118	8	biobanks	biobank	NOUN
aji-148	118	9	,	,	PUNCT
aji-148	118	10	single	single	ADJ
aji-148	118	11	cell	cell	NOUN
aji-148	118	12	technique	technique	NOUN
aji-148	118	13	,	,	PUNCT
aji-148	118	14	clinical	clinical	ADJ
aji-148	118	15	genomics	genomic	NOUN
aji-148	118	16	,	,	PUNCT
aji-148	118	17	and	and	CCONJ
aji-148	118	18	artificial	artificial	ADJ
aji-148	118	19	intelligence	intelligence	NOUN
aji-148	118	20	to	to	PART
aji-148	118	21	support	support	VERB
aji-148	118	22	the	the	DET
aji-148	118	23	combination	combination	NOUN
aji-148	118	24	treatment	treatment	NOUN
aji-148	118	25	.	.	PUNCT
aji-148	119	1	overall	overall	ADV
aji-148	119	2	,	,	PUNCT
aji-148	119	3	the	the	DET
aji-148	119	4	latest	late	ADJ
aji-148	119	5	generation	generation	NOUN
aji-148	119	6	of	of	ADP
aji-148	119	7	optimizing	optimize	VERB
aji-148	119	8	combination	combination	NOUN
aji-148	119	9	therapies	therapy	NOUN
aji-148	119	10	is	be	AUX
aji-148	119	11	more	more	ADV
aji-148	119	12	specific	specific	ADJ
aji-148	119	13	and	and	CCONJ
aji-148	119	14	sensitive	sensitive	ADJ
aji-148	119	15	in	in	ADP
aji-148	119	16	treating	treat	VERB
aji-148	119	17	neoplastic	neoplastic	ADJ
aji-148	119	18	diseases	disease	NOUN
aji-148	119	19	than	than	ADP
aji-148	119	20	older	old	ADJ
aji-148	119	21	versions	version	NOUN
aji-148	119	22	with	with	ADP
aji-148	119	23	fewer	few	ADJ
aji-148	119	24	side	side	NOUN
aji-148	119	25	effects	effect	NOUN
aji-148	119	26	.	.	PUNCT
aji-148	120	1	based	base	VERB
aji-148	120	2	on	on	ADP
aji-148	120	3	30–40	30–40	NUM
aji-148	120	4	years	year	NOUN
aji-148	120	5	of	of	ADP
aji-148	120	6	r&d	r&d	NOUN
aji-148	120	7	to	to	PART
aji-148	120	8	improve	improve	VERB
aji-148	120	9	immunotherapy	immunotherapy	NOUN
aji-148	120	10	for	for	ADP
aji-148	120	11	patients	patient	NOUN
aji-148	120	12	with	with	ADP
aji-148	120	13	advanced	advanced	ADJ
aji-148	120	14	cancer	cancer	NOUN
aji-148	120	15	and	and	CCONJ
aji-148	120	16	based	base	VERB
aji-148	120	17	on	on	ADP
aji-148	120	18	increasing	increase	VERB
aji-148	120	19	research	research	NOUN
aji-148	120	20	,	,	PUNCT
aji-148	120	21	it	it	PRON
aji-148	120	22	is	be	AUX
aji-148	120	23	time	time	NOUN
aji-148	120	24	to	to	PART
aji-148	120	25	define	define	VERB
aji-148	120	26	combinations	combination	NOUN
aji-148	120	27	treatment	treatment	NOUN
aji-148	120	28	and	and	CCONJ
aji-148	120	29	evaluate	evaluate	VERB
aji-148	120	30	the	the	DET
aji-148	120	31	efficacy	efficacy	NOUN
aji-148	120	32	of	of	ADP
aji-148	120	33	optimizing	optimize	VERB
aji-148	120	34	combination	combination	NOUN
aji-148	120	35	treatments	treatment	NOUN
aji-148	120	36	for	for	ADP
aji-148	120	37	oncological	oncological	ADJ
aji-148	120	38	diseases	disease	NOUN
aji-148	120	39	keywords	keyword	NOUN
aji-148	120	40	:	:	PUNCT
aji-148	120	41	cancer	cancer	NOUN
aji-148	120	42	;	;	PUNCT
aji-148	121	1	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	121	2	;	;	PUNCT
aji-148	121	3	cytotoxic	cytotoxic	ADJ
aji-148	121	4	chemotherapy	chemotherapy	NOUN
aji-148	121	5	;	;	PUNCT
aji-148	121	6	oncological	oncological	ADJ
aji-148	121	7	diseases	disease	NOUN
aji-148	121	8	.	.	PUNCT
aji-148	122	1	1	1	X
aji-148	122	2	.	.	X
aji-148	122	3	introduction	introduction	NOUN
aji-148	122	4	in	in	ADP
aji-148	122	5	1986	1986	NUM
aji-148	122	6	,	,	PUNCT
aji-148	122	7	dr	dr	PROPN
aji-148	122	8	.	.	PROPN
aji-148	122	9	rosenberg	rosenberg	PROPN
aji-148	122	10	discovered	discover	VERB
aji-148	122	11	that	that	SCONJ
aji-148	122	12	isolated	isolated	ADJ
aji-148	122	13	and	and	CCONJ
aji-148	122	14	cultured	cultured	ADJ
aji-148	122	15	tumor	tumor	NOUN
aji-148	122	16	-	-	PUNCT
aji-148	122	17	infiltrating	infiltrate	VERB
aji-148	122	18	lymphocytes	lymphocyte	NOUN
aji-148	122	19	(	(	PUNCT
aji-148	122	20	tils	til	NOUN
aji-148	122	21	)	)	PUNCT
aji-148	122	22	from	from	ADP
aji-148	122	23	tumor	tumor	NOUN
aji-148	122	24	tissue	tissue	NOUN
aji-148	122	25	could	could	AUX
aji-148	122	26	be	be	AUX
aji-148	122	27	applied	apply	VERB
aji-148	122	28	to	to	ADP
aji-148	122	29	the	the	DET
aji-148	122	30	adoptive	adoptive	ADJ
aji-148	122	31	cell	cell	NOUN
aji-148	122	32	transfer	transfer	NOUN
aji-148	122	33	(	(	PUNCT
aji-148	122	34	act	act	PROPN
aji-148	122	35	)	)	PUNCT
aji-148	122	36	to	to	PART
aji-148	122	37	treat	treat	VERB
aji-148	122	38	advanced	advanced	ADJ
aji-148	122	39	melanoma	melanoma	NOUN
aji-148	123	1	[	[	X
aji-148	123	2	1	1	NUM
aji-148	123	3	]	]	PUNCT
aji-148	123	4	.	.	PUNCT
aji-148	124	1	in	in	ADP
aji-148	124	2	addition	addition	NOUN
aji-148	124	3	,	,	PUNCT
aji-148	124	4	they	they	PRON
aji-148	124	5	also	also	ADV
aji-148	124	6	used	use	VERB
aji-148	124	7	a	a	DET
aji-148	124	8	combined	combine	VERB
aji-148	124	9	ctx	ctx	NOUN
aji-148	124	10	before	before	ADP
aji-148	124	11	til	til	SCONJ
aji-148	124	12	infusion	infusion	NOUN
aji-148	124	13	therapy	therapy	NOUN
aji-148	124	14	for	for	ADP
aji-148	124	15	the	the	DET
aji-148	124	16	treatment	treatment	NOUN
aji-148	124	17	of	of	ADP
aji-148	124	18	tumor	tumor	NOUN
aji-148	124	19	patients	patient	NOUN
aji-148	124	20	so	so	SCONJ
aji-148	124	21	that	that	DET
aji-148	124	22	ctx	ctx	NOUN
aji-148	124	23	could	could	AUX
aji-148	124	24	eliminate	eliminate	VERB
aji-148	124	25	lymphocytes	lymphocyte	NOUN
aji-148	124	26	in	in	ADP
aji-148	124	27	vivo	vivo	NOUN
aji-148	124	28	to	to	PART
aji-148	124	29	support	support	NOUN
aji-148	124	30	act	act	PROPN
aji-148	124	31	immunotherapy	immunotherapy	NOUN
aji-148	125	1	[	[	X
aji-148	125	2	2	2	NUM
aji-148	125	3	]	]	PUNCT
aji-148	125	4	.	.	PUNCT
aji-148	126	1	lymphodepletion	lymphodepletion	NOUN
aji-148	126	2	(	(	PUNCT
aji-148	126	3	ld	ld	X
aji-148	126	4	)	)	PUNCT
aji-148	126	5	is	be	AUX
aji-148	126	6	routinely	routinely	ADV
aji-148	126	7	used	use	VERB
aji-148	126	8	in	in	ADP
aji-148	126	9	act	act	NOUN
aji-148	126	10	immunotherapy	immunotherapy	NOUN
aji-148	126	11	,	,	PUNCT
aji-148	126	12	such	such	ADJ
aji-148	126	13	as	as	ADP
aji-148	126	14	car	car	NOUN
aji-148	126	15	-	-	PUNCT
aji-148	126	16	t	t	NOUN
aji-148	126	17	and	and	CCONJ
aji-148	126	18	til	til	ADV
aji-148	126	19	therapy	therapy	NOUN
aji-148	126	20	[	[	X
aji-148	126	21	3	3	NUM
aji-148	126	22	-	-	SYM
aji-148	126	23	4	4	NUM
aji-148	126	24	]	]	PUNCT
aji-148	126	25	.	.	PUNCT
aji-148	127	1	after	after	ADP
aji-148	127	2	about	about	ADV
aji-148	127	3	four	four	NUM
aji-148	127	4	decades	decade	NOUN
aji-148	127	5	of	of	ADP
aji-148	127	6	efforts	effort	NOUN
aji-148	127	7	,	,	PUNCT
aji-148	127	8	some	some	DET
aji-148	127	9	research	research	NOUN
aji-148	127	10	on	on	ADP
aji-148	127	11	combination	combination	NOUN
aji-148	127	12	therapy	therapy	NOUN
aji-148	127	13	has	have	AUX
aji-148	127	14	demonstrated	demonstrate	VERB
aji-148	127	15	that	that	SCONJ
aji-148	127	16	chemotherapy	chemotherapy	NOUN
aji-148	127	17	coordinating	coordinate	VERB
aji-148	127	18	with	with	ADP
aji-148	127	19	immunotherapy	immunotherapy	NOUN
aji-148	127	20	(	(	PUNCT
aji-148	127	21	called	call	VERB
aji-148	127	22	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	127	23	)	)	PUNCT
aji-148	127	24	is	be	AUX
aji-148	127	25	better	well	ADJ
aji-148	127	26	than	than	ADP
aji-148	127	27	monotherapy	monotherapy	NOUN
aji-148	127	28	;	;	PUNCT
aji-148	127	29	however	however	ADV
aji-148	127	30	,	,	PUNCT
aji-148	127	31	understanding	understand	VERB
aji-148	127	32	regimens	regimen	NOUN
aji-148	127	33	of	of	ADP
aji-148	127	34	combination	combination	NOUN
aji-148	127	35	therapy	therapy	NOUN
aji-148	127	36	also	also	ADV
aji-148	127	37	includes	include	VERB
aji-148	127	38	chemotherapeutic	chemotherapeutic	ADJ
aji-148	127	39	drugs	drug	NOUN
aji-148	127	40	,	,	PUNCT
aji-148	127	41	optimal	optimal	ADJ
aji-148	127	42	drug	drug	NOUN
aji-148	127	43	dose	dose	PROPN
aji-148	127	44	,	,	PUNCT
aji-148	127	45	administration	administration	NOUN
aji-148	127	46	time	time	NOUN
aji-148	127	47	,	,	PUNCT
aji-148	127	48	and	and	CCONJ
aji-148	127	49	sequence	sequence	NOUN
aji-148	127	50	of	of	ADP
aji-148	127	51	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	127	52	is	be	AUX
aji-148	127	53	still	still	ADV
aji-148	127	54	not	not	PART
aji-148	127	55	clear	clear	ADJ
aji-148	127	56	[	[	X
aji-148	127	57	5	5	NUM
aji-148	127	58	-	-	SYM
aji-148	127	59	6	6	NUM
aji-148	127	60	]	]	PUNCT
aji-148	127	61	.	.	PUNCT
aji-148	128	1	we	we	PRON
aji-148	128	2	have	have	AUX
aji-148	128	3	discovered	discover	VERB
aji-148	128	4	the	the	DET
aji-148	128	5	“	"	PUNCT
aji-148	128	6	confused	confused	ADJ
aji-148	128	7	phenomenon	phenomenon	NOUN
aji-148	128	8	”	"	PUNCT
aji-148	128	9	in	in	ADP
aji-148	128	10	our	our	PRON
aji-148	128	11	early	early	ADJ
aji-148	128	12	study	study	NOUN
aji-148	128	13	.	.	PUNCT
aji-148	129	1	to	to	PART
aji-148	129	2	address	address	VERB
aji-148	129	3	the	the	DET
aji-148	129	4	phenomenon	phenomenon	NOUN
aji-148	129	5	,	,	PUNCT
aji-148	129	6	we	we	PRON
aji-148	129	7	began	begin	VERB
aji-148	129	8	to	to	PART
aji-148	129	9	study	study	VERB
aji-148	129	10	both	both	DET
aji-148	129	11	tumor	tumor	NOUN
aji-148	129	12	cells	cell	NOUN
aji-148	129	13	and	and	CCONJ
aji-148	129	14	immune	immune	ADJ
aji-148	129	15	cells	cell	NOUN
aji-148	129	16	from	from	ADP
aji-148	129	17	the	the	DET
aji-148	129	18	removed	remove	VERB
aji-148	129	19	same	same	ADJ
aji-148	129	20	solid	solid	ADJ
aji-148	129	21	tumor	tumor	NOUN
aji-148	129	22	tissues	tissue	NOUN
aji-148	129	23	,	,	PUNCT
aji-148	129	24	which	which	PRON
aji-148	129	25	were	be	AUX
aji-148	129	26	published	publish	VERB
aji-148	129	27	in	in	ADP
aji-148	129	28	1994	1994	NUM
aji-148	129	29	[	[	X
aji-148	129	30	7	7	NUM
aji-148	129	31	]	]	PUNCT
aji-148	129	32	.	.	PUNCT
aji-148	130	1	we	we	PRON
aji-148	130	2	aimed	aim	VERB
aji-148	130	3	to	to	PART
aji-148	130	4	increase	increase	VERB
aji-148	130	5	til	til	SCONJ
aji-148	130	6	act	act	NOUN
aji-148	130	7	efficacy	efficacy	NOUN
aji-148	130	8	and	and	CCONJ
aji-148	130	9	decrease	decrease	VERB
aji-148	130	10	chemotherapy	chemotherapy	NOUN
aji-148	130	11	toxicity	toxicity	NOUN
aji-148	130	12	to	to	PART
aji-148	130	13	act	act	VERB
aji-148	130	14	immunotherapy	immunotherapy	NOUN
aji-148	130	15	at	at	ADP
aji-148	130	16	that	that	DET
aji-148	130	17	time	time	NOUN
aji-148	130	18	.	.	PUNCT
aji-148	131	1	our	our	PRON
aji-148	131	2	strategies	strategy	NOUN
aji-148	131	3	included	include	VERB
aji-148	131	4	that	that	SCONJ
aji-148	131	5	both	both	CCONJ
aji-148	131	6	til	til	ADV
aji-148	131	7	and	and	CCONJ
aji-148	131	8	primary	primary	ADJ
aji-148	131	9	tumor	tumor	NOUN
aji-148	131	10	cells	cell	NOUN
aji-148	131	11	culture	culture	NOUN
aji-148	131	12	from	from	ADP
aji-148	131	13	the	the	DET
aji-148	131	14	solid	solid	ADJ
aji-148	131	15	tumor	tumor	NOUN
aji-148	131	16	tissues	tissue	NOUN
aji-148	131	17	so	so	SCONJ
aji-148	131	18	that	that	SCONJ
aji-148	131	19	the	the	DET
aji-148	131	20	cultured	cultured	ADJ
aji-148	131	21	tils	til	NOUN
aji-148	131	22	from	from	ADP
aji-148	131	23	solid	solid	ADJ
aji-148	131	24	tumors	tumor	NOUN
aji-148	131	25	are	be	AUX
aji-148	131	26	activated	activate	VERB
aji-148	131	27	and	and	CCONJ
aji-148	131	28	then	then	ADV
aji-148	131	29	infused	infuse	VERB
aji-148	131	30	into	into	ADP
aji-148	131	31	patients	patient	NOUN
aji-148	131	32	for	for	ADP
aji-148	131	33	act	act	NOUN
aji-148	131	34	immunotherapy	immunotherapy	NOUN
aji-148	131	35	.	.	PUNCT
aji-148	132	1	“	"	PUNCT
aji-148	132	2	at	at	ADP
aji-148	132	3	the	the	DET
aji-148	132	4	same	same	ADJ
aji-148	132	5	time	time	NOUN
aji-148	132	6	,	,	PUNCT
aji-148	132	7	the	the	DET
aji-148	132	8	primary	primary	ADJ
aji-148	132	9	tumor	tumor	NOUN
aji-148	132	10	cells	cell	NOUN
aji-148	132	11	from	from	ADP
aji-148	132	12	the	the	DET
aji-148	132	13	tumor	tumor	NOUN
aji-148	132	14	tissues	tissue	NOUN
aji-148	132	15	are	be	AUX
aji-148	132	16	utilized	utilize	VERB
aji-148	132	17	as	as	ADP
aji-148	132	18	in	in	ADP
aji-148	132	19	vivo	vivo	NOUN
aji-148	132	20	and	and	CCONJ
aji-148	132	21	in	in	ADP
aji-148	132	22	vitro	vitro	X
aji-148	132	23	chemosensitivity	chemosensitivity	NOUN
aji-148	132	24	tests	test	NOUN
aji-148	132	25	for	for	ADP
aji-148	132	26	specific	specific	ADJ
aji-148	132	27	chemotherapy	chemotherapy	NOUN
aji-148	132	28	drugs	drug	NOUN
aji-148	132	29	to	to	PART
aji-148	132	30	decrease	decrease	VERB
aji-148	132	31	chemotherapy	chemotherapy	NOUN
aji-148	132	32	toxicity	toxicity	NOUN
aji-148	132	33	to	to	PART
aji-148	132	34	act	act	VERB
aji-148	132	35	immunotherapy	immunotherapy	NOUN
aji-148	132	36	.	.	PUNCT
aji-148	133	1	as	as	ADP
aji-148	133	2	our	our	PRON
aji-148	133	3	early	early	ADJ
aji-148	133	4	report	report	NOUN
aji-148	133	5	for	for	ADP
aji-148	133	6	combination	combination	NOUN
aji-148	133	7	therapy	therapy	NOUN
aji-148	133	8	for	for	ADP
aji-148	133	9	patients	patient	NOUN
aji-148	133	10	with	with	ADP
aji-148	133	11	solid	solid	ADJ
aji-148	133	12	tumors	tumor	NOUN
aji-148	133	13	by	by	ADP
aji-148	133	14	til	til	ADV
aji-148	133	15	re	re	NOUN
aji-148	133	16	-	-	NOUN
aji-148	133	17	infusion	infusion	NOUN
aji-148	133	18	and	and	CCONJ
aji-148	133	19	chemotherapy	chemotherapy	NOUN
aji-148	133	20	using	use	VERB
aji-148	133	21	an	an	DET
aji-148	133	22	in	in	ADV
aji-148	133	23	vitro	vitro	X
aji-148	133	24	chemosensitivity	chemosensitivity	NOUN
aji-148	133	25	test	test	NOUN
aji-148	133	26	,	,	PUNCT
aji-148	133	27	we	we	PRON
aji-148	133	28	discovered	discover	VERB
aji-148	133	29	the	the	DET
aji-148	133	30	combination	combination	NOUN
aji-148	133	31	was	be	AUX
aji-148	133	32	better	well	ADJ
aji-148	133	33	than	than	ADP
aji-148	133	34	the	the	DET
aji-148	133	35	monotherapy	monotherapy	NOUN
aji-148	133	36	.	.	PUNCT
aji-148	134	1	following	follow	VERB
aji-148	134	2	thirty	thirty	NUM
aji-148	134	3	years	year	NOUN
aji-148	134	4	of	of	ADP
aji-148	134	5	research	research	NOUN
aji-148	134	6	for	for	ADP
aji-148	134	7	combination	combination	NOUN
aji-148	134	8	treatment	treatment	NOUN
aji-148	134	9	,	,	PUNCT
aji-148	134	10	we	we	PRON
aji-148	134	11	have	have	AUX
aji-148	134	12	developed	develop	VERB
aji-148	134	13	precision	precision	NOUN
aji-148	134	14	medicine	medicine	NOUN
aji-148	134	15	,	,	PUNCT
aji-148	134	16	including	include	VERB
aji-148	134	17	tumor	tumor	NOUN
aji-148	134	18	tissue	tissue	NOUN
aji-148	134	19	biobanks	biobank	NOUN
aji-148	134	20	,	,	PUNCT
aji-148	134	21	single	single	ADJ
aji-148	134	22	cell	cell	NOUN
aji-148	134	23	technique	technique	NOUN
aji-148	134	24	,	,	PUNCT
aji-148	134	25	clinical	clinical	ADJ
aji-148	134	26	genomics	genomic	NOUN
aji-148	134	27	,	,	PUNCT
aji-148	134	28	and	and	CCONJ
aji-148	134	29	artificial	artificial	ADJ
aji-148	134	30	intelligence	intelligence	NOUN
aji-148	134	31	to	to	PART
aji-148	134	32	support	support	VERB
aji-148	134	33	the	the	DET
aji-148	134	34	combination	combination	NOUN
aji-148	134	35	treatment	treatment	NOUN
aji-148	134	36	.	.	PUNCT
aji-148	135	1	overall	overall	ADV
aji-148	135	2	,	,	PUNCT
aji-148	135	3	the	the	DET
aji-148	135	4	latest	late	ADJ
aji-148	135	5	generation	generation	NOUN
aji-148	135	6	of	of	ADP
aji-148	135	7	combination	combination	NOUN
aji-148	135	8	therapies	therapy	NOUN
aji-148	135	9	is	be	AUX
aji-148	135	10	more	more	ADV
aji-148	135	11	specific	specific	ADJ
aji-148	135	12	and	and	CCONJ
aji-148	135	13	sensitive	sensitive	ADJ
aji-148	135	14	in	in	ADP
aji-148	135	15	treating	treat	VERB
aji-148	135	16	neoplastic	neoplastic	ADJ
aji-148	135	17	diseases	disease	NOUN
aji-148	135	18	than	than	ADP
aji-148	135	19	older	old	ADJ
aji-148	135	20	versions	version	NOUN
aji-148	135	21	with	with	ADP
aji-148	135	22	fewer	few	ADJ
aji-148	135	23	side	side	NOUN
aji-148	135	24	effects	effect	NOUN
aji-148	135	25	”	"	PUNCT
aji-148	136	1	[	[	X
aji-148	136	2	8	8	NUM
aji-148	136	3	-	-	SYM
aji-148	136	4	12	12	NUM
aji-148	136	5	]	]	PUNCT
aji-148	136	6	.	.	PUNCT
aji-148	137	1	based	base	VERB
aji-148	137	2	on	on	ADP
aji-148	137	3	30–40	30–40	NUM
aji-148	137	4	years	year	NOUN
aji-148	137	5	of	of	ADP
aji-148	137	6	r&d	r&d	NOUN
aji-148	137	7	to	to	PART
aji-148	137	8	improve	improve	VERB
aji-148	137	9	immunotherapy	immunotherapy	NOUN
aji-148	137	10	for	for	ADP
aji-148	137	11	patients	patient	NOUN
aji-148	137	12	with	with	ADP
aji-148	137	13	advanced	advanced	ADJ
aji-148	137	14	cancer	cancer	NOUN
aji-148	137	15	and	and	CCONJ
aji-148	137	16	based	base	VERB
aji-148	137	17	on	on	ADP
aji-148	137	18	increasing	increase	VERB
aji-148	137	19	research	research	NOUN
aji-148	137	20	,	,	PUNCT
aji-148	137	21	it	it	PRON
aji-148	137	22	is	be	AUX
aji-148	137	23	time	time	NOUN
aji-148	137	24	to	to	PART
aji-148	137	25	define	define	VERB
aji-148	137	26	combinations	combination	NOUN
aji-148	137	27	treatment	treatment	NOUN
aji-148	137	28	and	and	CCONJ
aji-148	137	29	evaluate	evaluate	VERB
aji-148	137	30	the	the	DET
aji-148	137	31	efficacy	efficacy	NOUN
aji-148	137	32	of	of	ADP
aji-148	137	33	combination	combination	NOUN
aji-148	137	34	treatments	treatment	NOUN
aji-148	137	35	for	for	ADP
aji-148	137	36	oncological	oncological	ADJ
aji-148	137	37	diseases	disease	NOUN
aji-148	137	38	.	.	PUNCT
aji-148	138	1	according	accord	VERB
aji-148	138	2	to	to	ADP
aji-148	138	3	the	the	DET
aji-148	138	4	current	current	ADJ
aji-148	138	5	publications	publication	NOUN
aji-148	138	6	,	,	PUNCT
aji-148	138	7	the	the	DET
aji-148	138	8	manual	manual	NOUN
aji-148	138	9	will	will	AUX
aji-148	138	10	introduce	introduce	VERB
aji-148	138	11	four	four	NUM
aji-148	138	12	sections	section	NOUN
aji-148	138	13	for	for	ADP
aji-148	138	14	optimizing	optimize	VERB
aji-148	138	15	combination	combination	NOUN
aji-148	138	16	therapy	therapy	NOUN
aji-148	138	17	:	:	PUNCT
aji-148	138	18	(	(	PUNCT
aji-148	138	19	1	1	X
aji-148	138	20	)	)	PUNCT
aji-148	138	21	lymphodepletion	lymphodepletion	NOUN
aji-148	138	22	(	(	PUNCT
aji-148	138	23	ld	ld	NOUN
aji-148	138	24	)	)	PUNCT
aji-148	138	25	supporting	support	VERB
aji-148	138	26	act	act	NOUN
aji-148	138	27	immunotherapy	immunotherapy	NOUN
aji-148	138	28	for	for	ADP
aji-148	138	29	advanced	advanced	ADJ
aji-148	138	30	cancer	cancer	NOUN
aji-148	138	31	,	,	PUNCT
aji-148	138	32	(	(	PUNCT
aji-148	138	33	2	2	X
aji-148	138	34	)	)	PUNCT
aji-148	138	35	coordinated	coordinated	ADJ
aji-148	138	36	therapy	therapy	NOUN
aji-148	138	37	(	(	PUNCT
aji-148	138	38	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	138	39	)	)	PUNCT
aji-148	138	40	supporting	support	VERB
aji-148	138	41	treatment	treatment	NOUN
aji-148	138	42	for	for	ADP
aji-148	138	43	advanced	advanced	ADJ
aji-148	138	44	cancer	cancer	NOUN
aji-148	138	45	,	,	PUNCT
aji-148	138	46	(	(	PUNCT
aji-148	138	47	3	3	X
aji-148	138	48	)	)	PUNCT
aji-148	138	49	immune	immune	ADJ
aji-148	138	50	checkpoint	checkpoint	NOUN
aji-148	138	51	inhibition	inhibition	NOUN
aji-148	138	52	(	(	PUNCT
aji-148	138	53	ici	ici	NOUN
aji-148	138	54	)	)	PUNCT
aji-148	138	55	combined	combine	VERB
aji-148	138	56	with	with	ADP
aji-148	138	57	immunotherapy	immunotherapy	NOUN
aji-148	138	58	,	,	PUNCT
aji-148	138	59	and	and	CCONJ
aji-148	138	60	(	(	PUNCT
aji-148	138	61	4	4	X
aji-148	138	62	)	)	PUNCT
aji-148	138	63	precision	precision	NOUN
aji-148	138	64	medicine	medicine	NOUN
aji-148	138	65	supporting	support	VERB
aji-148	138	66	immunotherapy	immunotherapy	NOUN
aji-148	138	67	for	for	ADP
aji-148	138	68	advanced	advanced	ADJ
aji-148	138	69	cancer	cancer	NOUN
aji-148	138	70	.	.	PUNCT
aji-148	139	1	li	li	PROPN
aji-148	139	2	and	and	CCONJ
aji-148	139	3	li	li	PROPN
aji-148	139	4	;	;	PUNCT
aji-148	139	5	asian	asian	PROPN
aji-148	139	6	j.	j.	PROPN
aji-148	139	7	immunol	immunol	PROPN
aji-148	139	8	.	.	PROPN
aji-148	139	9	,	,	PUNCT
aji-148	139	10	vol	vol	NOUN
aji-148	139	11	.	.	PROPN
aji-148	139	12	7	7	NUM
aji-148	139	13	,	,	PUNCT
aji-148	139	14	no	no	INTJ
aji-148	139	15	.	.	NOUN
aji-148	139	16	1	1	NUM
aji-148	139	17	,	,	PUNCT
aji-148	139	18	pp	pp	ADJ
aji-148	139	19	.	.	PUNCT
aji-148	140	1	247	247	NUM
aji-148	140	2	-	-	SYM
aji-148	140	3	257	257	NUM
aji-148	140	4	,	,	PUNCT
aji-148	140	5	2024	2024	NUM
aji-148	140	6	;	;	PUNCT
aji-148	140	7	article	article	NOUN
aji-148	140	8	no.aji.126682	no.aji.126682	ADP
aji-148	140	9	249	249	NUM
aji-148	140	10	2	2	NUM
aji-148	140	11	.	.	PUNCT
aji-148	141	1	lymphodepletion	lymphodepletion	NOUN
aji-148	141	2	supporting	support	VERB
aji-148	141	3	act	act	PROPN
aji-148	141	4	immunotherapy	immunotherapy	NOUN
aji-148	141	5	to	to	PART
aji-148	141	6	treat	treat	VERB
aji-148	141	7	advanced	advanced	ADJ
aji-148	141	8	cancer	cancer	NOUN
aji-148	141	9	over	over	ADP
aji-148	141	10	the	the	DET
aji-148	141	11	past	past	ADJ
aji-148	141	12	40	40	NUM
aji-148	141	13	years	year	NOUN
aji-148	141	14	,	,	PUNCT
aji-148	141	15	adoptive	adoptive	ADJ
aji-148	141	16	cell	cell	NOUN
aji-148	141	17	transfer	transfer	NOUN
aji-148	141	18	(	(	PUNCT
aji-148	141	19	act	act	PROPN
aji-148	141	20	)	)	PUNCT
aji-148	141	21	for	for	ADP
aji-148	141	22	the	the	DET
aji-148	141	23	treatment	treatment	NOUN
aji-148	141	24	of	of	ADP
aji-148	141	25	malignancies	malignancy	NOUN
aji-148	141	26	has	have	AUX
aji-148	141	27	been	be	AUX
aji-148	141	28	one	one	NUM
aji-148	141	29	of	of	ADP
aji-148	141	30	the	the	DET
aji-148	141	31	most	most	ADV
aji-148	141	32	dynamic	dynamic	ADJ
aji-148	141	33	and	and	CCONJ
aji-148	141	34	fruitful	fruitful	ADJ
aji-148	141	35	advances	advance	NOUN
aji-148	141	36	in	in	ADP
aji-148	141	37	cancer	cancer	NOUN
aji-148	141	38	therapy	therapy	NOUN
aji-148	141	39	[	[	X
aji-148	141	40	13	13	NUM
aji-148	141	41	-	-	SYM
aji-148	141	42	14	14	NUM
aji-148	141	43	]	]	PUNCT
aji-148	141	44	.	.	PUNCT
aji-148	142	1	to	to	PART
aji-148	142	2	support	support	VERB
aji-148	142	3	act	act	PROPN
aji-148	142	4	efficacy	efficacy	NOUN
aji-148	142	5	,	,	PUNCT
aji-148	142	6	in	in	ADP
aji-148	142	7	1986	1986	NUM
aji-148	142	8	,	,	PUNCT
aji-148	142	9	dr	dr	PROPN
aji-148	142	10	.	.	PROPN
aji-148	142	11	rosenberg	rosenberg	PROPN
aji-148	142	12	first	first	ADV
aji-148	142	13	used	use	VERB
aji-148	142	14	ctx	ctx	NOUN
aji-148	142	15	as	as	ADP
aji-148	142	16	lymphodepletion	lymphodepletion	NOUN
aji-148	142	17	(	(	PUNCT
aji-148	142	18	ld	ld	NOUN
aji-148	142	19	)	)	PUNCT
aji-148	142	20	to	to	PART
aji-148	142	21	support	support	VERB
aji-148	142	22	the	the	DET
aji-148	142	23	til	til	ADJ
aji-148	142	24	reinfusion	reinfusion	NOUN
aji-148	142	25	for	for	ADP
aji-148	142	26	overcoming	overcome	VERB
aji-148	142	27	immune	immune	ADJ
aji-148	142	28	tolerance	tolerance	NOUN
aji-148	142	29	in	in	ADP
aji-148	142	30	patients	patient	NOUN
aji-148	142	31	with	with	ADP
aji-148	142	32	metastatic	metastatic	ADJ
aji-148	142	33	melanoma	melanoma	NOUN
aji-148	143	1	[	[	X
aji-148	143	2	15	15	NUM
aji-148	143	3	]	]	PUNCT
aji-148	143	4	.	.	PUNCT
aji-148	144	1	other	other	ADJ
aji-148	144	2	solid	solid	ADJ
aji-148	144	3	tumor	tumor	NOUN
aji-148	144	4	diseases	disease	NOUN
aji-148	144	5	have	have	AUX
aji-148	144	6	also	also	ADV
aji-148	144	7	routinely	routinely	ADV
aji-148	144	8	used	use	VERB
aji-148	144	9	ld	ld	PROPN
aji-148	144	10	to	to	PART
aji-148	144	11	support	support	VERB
aji-148	144	12	til	til	ADV
aji-148	144	13	reinfusion	reinfusion	NOUN
aji-148	144	14	in	in	ADP
aji-148	144	15	clinics	clinic	NOUN
aji-148	144	16	[	[	X
aji-148	144	17	16	16	NUM
aji-148	144	18	-	-	SYM
aji-148	144	19	17	17	NUM
aji-148	144	20	]	]	PUNCT
aji-148	144	21	,	,	PUNCT
aji-148	144	22	as	as	SCONJ
aji-148	144	23	shown	show	VERB
aji-148	144	24	in	in	ADP
aji-148	144	25	fig	fig	NOUN
aji-148	144	26	.	.	PUNCT
aji-148	145	1	1	1	X
aji-148	145	2	.	.	X
aji-148	145	3	moreover	moreover	ADV
aji-148	145	4	,	,	PUNCT
aji-148	145	5	car	car	NOUN
aji-148	145	6	-	-	PUNCT
aji-148	145	7	t	t	NOUN
aji-148	145	8	(	(	PUNCT
aji-148	145	9	chimeric	chimeric	ADJ
aji-148	145	10	antigen	antigen	ADJ
aji-148	145	11	receptors	receptor	NOUN
aji-148	145	12	)	)	PUNCT
aji-148	145	13	has	have	AUX
aji-148	145	14	become	become	VERB
aji-148	145	15	an	an	DET
aji-148	145	16	essential	essential	ADJ
aji-148	145	17	antitumor	antitumor	PROPN
aji-148	145	18	therapy	therapy	NOUN
aji-148	145	19	component	component	NOUN
aji-148	145	20	[	[	X
aji-148	145	21	18	18	NUM
aji-148	145	22	]	]	PUNCT
aji-148	145	23	.	.	PUNCT
aji-148	146	1	however	however	ADV
aji-148	146	2	,	,	PUNCT
aji-148	146	3	a	a	DET
aji-148	146	4	significant	significant	ADJ
aji-148	146	5	number	number	NOUN
aji-148	146	6	of	of	ADP
aji-148	146	7	these	these	DET
aji-148	146	8	patients	patient	NOUN
aji-148	146	9	still	still	ADV
aji-148	146	10	relapse	relapse	VERB
aji-148	146	11	after	after	ADP
aji-148	146	12	car	car	NOUN
aji-148	146	13	-	-	PUNCT
aji-148	146	14	t	t	NOUN
aji-148	146	15	therapy	therapy	NOUN
aji-148	146	16	or	or	CCONJ
aji-148	146	17	become	become	VERB
aji-148	146	18	resistant	resistant	ADJ
aji-148	146	19	to	to	ADP
aji-148	146	20	cart	cart	NOUN
aji-148	146	21	therapy	therapy	NOUN
aji-148	146	22	[	[	X
aji-148	146	23	19	19	NUM
aji-148	146	24	-	-	SYM
aji-148	146	25	20	20	NUM
aji-148	146	26	]	]	PUNCT
aji-148	146	27	,	,	PUNCT
aji-148	146	28	so	so	SCONJ
aji-148	146	29	they	they	PRON
aji-148	146	30	need	need	VERB
aji-148	146	31	to	to	PART
aji-148	146	32	improve	improve	VERB
aji-148	146	33	the	the	DET
aji-148	146	34	efficacy	efficacy	NOUN
aji-148	146	35	of	of	ADP
aji-148	146	36	car	car	NOUN
aji-148	146	37	-	-	PUNCT
aji-148	146	38	t	t	NOUN
aji-148	146	39	therapy	therapy	NOUN
aji-148	146	40	by	by	ADP
aji-148	146	41	ld	ld	PROPN
aji-148	146	42	to	to	PART
aji-148	146	43	play	play	VERB
aji-148	146	44	an	an	DET
aji-148	146	45	essential	essential	ADJ
aji-148	146	46	role	role	NOUN
aji-148	146	47	in	in	ADP
aji-148	146	48	overcoming	overcome	VERB
aji-148	146	49	the	the	DET
aji-148	146	50	resistance	resistance	NOUN
aji-148	146	51	to	to	ADP
aji-148	146	52	car	car	NOUN
aji-148	146	53	-	-	PUNCT
aji-148	146	54	t	t	NOUN
aji-148	146	55	therapy	therapy	NOUN
aji-148	146	56	[	[	X
aji-148	146	57	21	21	NUM
aji-148	146	58	-	-	SYM
aji-148	146	59	22	22	NUM
aji-148	146	60	]	]	PUNCT
aji-148	146	61	.	.	PUNCT
aji-148	147	1	the	the	DET
aji-148	147	2	main	main	ADJ
aji-148	147	3	goals	goal	NOUN
aji-148	147	4	of	of	ADP
aji-148	147	5	ld	ld	PROPN
aji-148	147	6	are	be	AUX
aji-148	147	7	to	to	AUX
aji-148	147	8	(	(	PUNCT
aji-148	147	9	1	1	X
aji-148	147	10	)	)	PUNCT
aji-148	147	11	reduce	reduce	VERB
aji-148	147	12	endogenous	endogenous	ADJ
aji-148	147	13	lymphocytes	lymphocyte	NOUN
aji-148	147	14	to	to	PART
aji-148	147	15	inhibit	inhibit	VERB
aji-148	147	16	the	the	DET
aji-148	147	17	engraftment	engraftment	NOUN
aji-148	147	18	of	of	ADP
aji-148	147	19	car	car	NOUN
aji-148	147	20	-	-	PUNCT
aji-148	147	21	t	t	NOUN
aji-148	147	22	infusions	infusion	NOUN
aji-148	147	23	and	and	CCONJ
aji-148	147	24	support	support	VERB
aji-148	147	25	their	their	PRON
aji-148	147	26	long	long	ADJ
aji-148	147	27	-	-	PUNCT
aji-148	147	28	term	term	NOUN
aji-148	147	29	activity	activity	NOUN
aji-148	147	30	;	;	PUNCT
aji-148	147	31	(	(	PUNCT
aji-148	147	32	2	2	X
aji-148	147	33	)	)	PUNCT
aji-148	147	34	reduce	reduce	VERB
aji-148	147	35	tumor	tumor	NOUN
aji-148	147	36	cells	cell	NOUN
aji-148	147	37	to	to	PART
aji-148	147	38	avoid	avoid	VERB
aji-148	147	39	rapid	rapid	ADJ
aji-148	147	40	exhaustion	exhaustion	NOUN
aji-148	147	41	of	of	ADP
aji-148	147	42	car	car	NOUN
aji-148	147	43	-	-	PUNCT
aji-148	147	44	ts	ts	NOUN
aji-148	147	45	;	;	PUNCT
aji-148	147	46	and	and	CCONJ
aji-148	147	47	(	(	PUNCT
aji-148	147	48	3	3	X
aji-148	147	49	)	)	PUNCT
aji-148	147	50	prepare	prepare	VERB
aji-148	147	51	and	and	CCONJ
aji-148	147	52	reprogram	reprogram	VERB
aji-148	147	53	the	the	DET
aji-148	147	54	microenvironment	microenvironment	ADJ
aji-148	147	55	and	and	CCONJ
aji-148	147	56	soluble	soluble	ADJ
aji-148	147	57	factors	factor	NOUN
aji-148	147	58	to	to	PART
aji-148	147	59	ensure	ensure	VERB
aji-148	147	60	optimal	optimal	ADJ
aji-148	147	61	engraftment	engraftment	NOUN
aji-148	147	62	,	,	PUNCT
aji-148	147	63	homing	homing	NOUN
aji-148	147	64	,	,	PUNCT
aji-148	147	65	and	and	CCONJ
aji-148	147	66	long	long	ADJ
aji-148	147	67	-	-	PUNCT
aji-148	147	68	term	term	NOUN
aji-148	147	69	survival	survival	NOUN
aji-148	147	70	of	of	ADP
aji-148	147	71	car	car	NOUN
aji-148	147	72	-	-	PUNCT
aji-148	147	73	t	t	NOUN
aji-148	147	74	cells	cell	NOUN
aji-148	147	75	[	[	X
aji-148	147	76	23	23	NUM
aji-148	147	77	-	-	SYM
aji-148	147	78	25	25	NUM
aji-148	147	79	]	]	PUNCT
aji-148	147	80	.	.	PUNCT
aji-148	148	1	as	as	ADP
aji-148	148	2	in	in	ADP
aji-148	148	3	table	table	NOUN
aji-148	148	4	1	1	NUM
aji-148	148	5	,	,	PUNCT
aji-148	148	6	there	there	PRON
aji-148	148	7	are	be	VERB
aji-148	148	8	several	several	ADJ
aji-148	148	9	lds	ld	NOUN
aji-148	148	10	,	,	PUNCT
aji-148	148	11	such	such	ADJ
aji-148	148	12	as	as	ADP
aji-148	148	13	fludarabine	fludarabine	NOUN
aji-148	148	14	(	(	PUNCT
aji-148	148	15	flu	flu	NOUN
aji-148	148	16	)	)	PUNCT
aji-148	148	17	and	and	CCONJ
aji-148	148	18	cyclophosphamide	cyclophosphamide	PROPN
aji-148	148	19	(	(	PUNCT
aji-148	148	20	ctx	ctx	NOUN
aji-148	148	21	,	,	PUNCT
aji-148	148	22	cy	cy	PROPN
aji-148	148	23	)	)	PUNCT
aji-148	148	24	,	,	PUNCT
aji-148	148	25	and	and	CCONJ
aji-148	148	26	their	their	PRON
aji-148	148	27	combination	combination	NOUN
aji-148	148	28	is	be	AUX
aji-148	148	29	selectively	selectively	ADV
aji-148	148	30	used	use	VERB
aji-148	148	31	for	for	ADP
aji-148	148	32	individual	individual	ADJ
aji-148	148	33	situations	situation	NOUN
aji-148	148	34	.	.	PUNCT
aji-148	149	1	ld	ld	PROPN
aji-148	149	2	regimens	regimen	NOUN
aji-148	149	3	and	and	CCONJ
aji-148	149	4	doses	dose	NOUN
aji-148	149	5	vary	vary	VERB
aji-148	149	6	depending	depend	VERB
aji-148	149	7	on	on	ADP
aji-148	149	8	the	the	DET
aji-148	149	9	target	target	NOUN
aji-148	149	10	disease	disease	NOUN
aji-148	149	11	(	(	PUNCT
aji-148	149	12	such	such	ADJ
aji-148	149	13	as	as	ADP
aji-148	149	14	all	all	PRON
aji-148	149	15	,	,	PUNCT
aji-148	149	16	nhl	nhl	PROPN
aji-148	149	17	,	,	PUNCT
aji-148	149	18	mm	mm	PROPN
aji-148	149	19	,	,	PUNCT
aji-148	149	20	or	or	CCONJ
aji-148	149	21	solid	solid	ADJ
aji-148	149	22	tumors	tumor	NOUN
aji-148	149	23	)	)	PUNCT
aji-148	149	24	and	and	CCONJ
aji-148	149	25	the	the	DET
aji-148	149	26	source	source	NOUN
aji-148	149	27	of	of	ADP
aji-148	149	28	t	t	PROPN
aji-148	149	29	cells	cell	NOUN
aji-148	149	30	(	(	PUNCT
aji-148	149	31	autologous	autologous	ADJ
aji-148	149	32	vs.	vs.	ADP
aji-148	149	33	allogeneic	allogeneic	ADJ
aji-148	149	34	)	)	PUNCT
aji-148	150	1	[	[	X
aji-148	150	2	26	26	NUM
aji-148	150	3	-	-	SYM
aji-148	150	4	28	28	NUM
aji-148	150	5	]	]	PUNCT
aji-148	150	6	.	.	PUNCT
aji-148	151	1	because	because	SCONJ
aji-148	151	2	a	a	DET
aji-148	151	3	patient	patient	NOUN
aji-148	151	4	receives	receive	VERB
aji-148	151	5	ld	ld	NOUN
aji-148	151	6	with	with	ADP
aji-148	151	7	individual	individual	ADJ
aji-148	151	8	differences	difference	NOUN
aji-148	151	9	,	,	PUNCT
aji-148	151	10	personalized	personalized	ADJ
aji-148	151	11	regimens	regimen	NOUN
aji-148	151	12	still	still	ADV
aji-148	151	13	need	need	VERB
aji-148	151	14	to	to	PART
aji-148	151	15	be	be	AUX
aji-148	151	16	considered	consider	VERB
aji-148	151	17	for	for	ADP
aji-148	151	18	ld	ld	NOUN
aji-148	151	19	selection	selection	NOUN
aji-148	151	20	with	with	ADP
aji-148	151	21	their	their	PRON
aji-148	151	22	doses	dose	NOUN
aji-148	151	23	for	for	ADP
aji-148	151	24	the	the	DET
aji-148	151	25	new	new	ADJ
aji-148	151	26	til	til	NOUN
aji-148	151	27	or	or	CCONJ
aji-148	151	28	car	car	NOUN
aji-148	151	29	-	-	PUNCT
aji-148	151	30	t	t	NOUN
aji-148	151	31	therapy	therapy	NOUN
aji-148	151	32	approaches	approach	NOUN
aji-148	151	33	.	.	PUNCT
aji-148	152	1	fig	fig	NOUN
aji-148	152	2	.	.	PUNCT
aji-148	153	1	1	1	X
aji-148	153	2	.	.	X
aji-148	153	3	strategy	strategy	NOUN
aji-148	153	4	for	for	SCONJ
aji-148	153	5	ld	ld	PROPN
aji-148	153	6	to	to	PART
aji-148	153	7	increase	increase	VERB
aji-148	153	8	til	til	SCONJ
aji-148	153	9	efficacy	efficacy	PROPN
aji-148	153	10	nb	nb	PROPN
aji-148	153	11	.	.	PUNCT
aji-148	154	1	a	a	DET
aji-148	154	2	lymphodepletion	lymphodepletion	NOUN
aji-148	154	3	regimens	regimen	NOUN
aji-148	154	4	adding	add	VERB
aji-148	154	5	til	til	SCONJ
aji-148	154	6	treatment	treatment	NOUN
aji-148	154	7	to	to	PART
aji-148	154	8	increase	increase	VERB
aji-148	154	9	til	til	ADV
aji-148	154	10	efficacy	efficacy	NOUN
aji-148	154	11	.	.	PUNCT
aji-148	155	1	table	table	NOUN
aji-148	155	2	1	1	NUM
aji-148	155	3	.	.	PUNCT
aji-148	156	1	lymphodepletion	lymphodepletion	NOUN
aji-148	156	2	types	type	NOUN
aji-148	156	3	components	component	VERB
aji-148	156	4	common	common	ADJ
aji-148	156	5	lymphodepletion	lymphodepletion	NOUN
aji-148	156	6	common	common	ADJ
aji-148	156	7	usage	usage	NOUN
aji-148	156	8	fludarabine	fludarabine	NOUN
aji-148	156	9	purine	purine	NOUN
aji-148	156	10	analogue	analogue	NOUN
aji-148	156	11	car	car	NOUN
aji-148	156	12	-	-	PUNCT
aji-148	156	13	t	t	NOUN
aji-148	156	14	cll	cll	PROPN
aji-148	156	15	and	and	CCONJ
aji-148	156	16	indolent	indolent	ADJ
aji-148	156	17	nhl	nhl	PROPN
aji-148	156	18	cyclophosphamide	cyclophosphamide	VERB
aji-148	156	19	an	an	DET
aji-148	156	20	alkylating	alkylate	VERB
aji-148	156	21	agent	agent	NOUN
aji-148	156	22	til	til	ADV
aji-148	156	23	or	or	CCONJ
aji-148	156	24	car	car	NOUN
aji-148	156	25	-	-	PUNCT
aji-148	156	26	t	t	NOUN
aji-148	156	27	melanoma	melanoma	NOUN
aji-148	156	28	,	,	PUNCT
aji-148	156	29	lymphoma	lymphoma	NOUN
aji-148	156	30	,	,	PUNCT
aji-148	156	31	and	and	CCONJ
aji-148	156	32	indolent	indolent	ADJ
aji-148	156	33	nhl	nhl	PROPN
aji-148	156	34	flu	flu	NOUN
aji-148	156	35	and	and	CCONJ
aji-148	156	36	cy	cy	VERB
aji-148	156	37	both	both	DET
aji-148	156	38	action	action	NOUN
aji-148	156	39	car	car	NOUN
aji-148	156	40	-	-	PUNCT
aji-148	156	41	t	t	NOUN
aji-148	156	42	call	call	NOUN
aji-148	156	43	bendamustine	bendamustine	NOUN
aji-148	156	44	an	an	DET
aji-148	156	45	alkylating	alkylate	VERB
aji-148	156	46	agent	agent	NOUN
aji-148	156	47	car	car	NOUN
aji-148	156	48	-	-	PUNCT
aji-148	156	49	t	t	NOUN
aji-148	156	50	cll	cll	PROPN
aji-148	156	51	and	and	CCONJ
aji-148	156	52	other	other	ADJ
aji-148	156	53	band	band	NOUN
aji-148	156	54	t	t	NOUN
aji-148	156	55	-	-	PUNCT
aji-148	156	56	cell	cell	NOUN
aji-148	156	57	lymphomas	lymphoma	NOUN
aji-148	156	58	alemtuzumab	alemtuzumab	NOUN
aji-148	156	59	targeting	target	VERB
aji-148	156	60	car	car	NOUN
aji-148	156	61	-	-	PUNCT
aji-148	156	62	t	t	NOUN
aji-148	156	63	lymphoproliferative	lymphoproliferative	ADJ
aji-148	156	64	diseases	disease	NOUN
aji-148	156	65	oxaliplatin	oxaliplatin	ADV
aji-148	156	66	/	/	SYM
aji-148	156	67	cy	cy	AUX
aji-148	156	68	targeting	target	VERB
aji-148	156	69	car	car	NOUN
aji-148	156	70	-	-	PUNCT
aji-148	156	71	t	t	NOUN
aji-148	156	72	car	car	NOUN
aji-148	156	73	-	-	PUNCT
aji-148	156	74	t	t	NOUN
aji-148	156	75	to	to	ADP
aji-148	156	76	solid	solid	ADJ
aji-148	156	77	tumors	tumor	NOUN
aji-148	156	78	clofarabine	clofarabine	VERB
aji-148	156	79	anti	anti	ADJ
aji-148	156	80	-	-	ADJ
aji-148	156	81	leukemic	leukemic	ADJ
aji-148	156	82	agent	agent	NOUN
aji-148	156	83	car	car	NOUN
aji-148	156	84	-	-	PUNCT
aji-148	156	85	t	t	NOUN
aji-148	156	86	clinical	clinical	ADJ
aji-148	156	87	remission	remission	NOUN
aji-148	156	88	li	li	PROPN
aji-148	156	89	and	and	CCONJ
aji-148	156	90	li	li	PROPN
aji-148	156	91	;	;	PUNCT
aji-148	156	92	asian	asian	PROPN
aji-148	156	93	j.	j.	PROPN
aji-148	156	94	immunol	immunol	PROPN
aji-148	156	95	.	.	PROPN
aji-148	156	96	,	,	PUNCT
aji-148	156	97	vol	vol	NOUN
aji-148	156	98	.	.	PROPN
aji-148	157	1	7	7	NUM
aji-148	157	2	,	,	PUNCT
aji-148	157	3	no	no	INTJ
aji-148	157	4	.	.	NOUN
aji-148	157	5	1	1	NUM
aji-148	157	6	,	,	PUNCT
aji-148	157	7	pp	pp	ADJ
aji-148	157	8	.	.	PUNCT
aji-148	158	1	247	247	NUM
aji-148	158	2	-	-	SYM
aji-148	158	3	257	257	NUM
aji-148	158	4	,	,	PUNCT
aji-148	158	5	2024	2024	NUM
aji-148	158	6	;	;	PUNCT
aji-148	158	7	article	article	NOUN
aji-148	158	8	no.aji.126682	no.aji.126682	ADP
aji-148	158	9	250	250	NUM
aji-148	158	10	3	3	NUM
aji-148	158	11	.	.	PUNCT
aji-148	159	1	chemoimmunotherapy	chemoimmunotherapy	ADJ
aji-148	159	2	combinations	combination	NOUN
aji-148	159	3	supporting	support	VERB
aji-148	159	4	immunotherapy	immunotherapy	NOUN
aji-148	159	5	chemotherapy	chemotherapy	NOUN
aji-148	159	6	has	have	AUX
aji-148	159	7	been	be	AUX
aji-148	159	8	a	a	DET
aji-148	159	9	critical	critical	ADJ
aji-148	159	10	part	part	NOUN
aji-148	159	11	of	of	ADP
aji-148	159	12	cancer	cancer	NOUN
aji-148	159	13	treatment	treatment	NOUN
aji-148	159	14	for	for	ADP
aji-148	159	15	more	more	ADJ
aji-148	159	16	than	than	ADP
aji-148	159	17	70	70	NUM
aji-148	159	18	years	year	NOUN
aji-148	159	19	[	[	X
aji-148	159	20	29	29	NUM
aji-148	159	21	]	]	PUNCT
aji-148	159	22	.	.	PUNCT
aji-148	160	1	the	the	DET
aji-148	160	2	cytotoxic	cytotoxic	ADJ
aji-148	160	3	drugs	drug	NOUN
aji-148	160	4	kill	kill	VERB
aji-148	160	5	tumor	tumor	NOUN
aji-148	160	6	cells	cell	NOUN
aji-148	160	7	and	and	CCONJ
aji-148	160	8	inhibit	inhibit	VERB
aji-148	160	9	their	their	PRON
aji-148	160	10	proliferation	proliferation	NOUN
aji-148	160	11	through	through	ADP
aji-148	160	12	dna	dna	PROPN
aji-148	160	13	damage	damage	NOUN
aji-148	160	14	,	,	PUNCT
aji-148	160	15	inhibiting	inhibit	VERB
aji-148	160	16	dna	dna	NOUN
aji-148	160	17	replication	replication	NOUN
aji-148	160	18	and	and	CCONJ
aji-148	160	19	arresting	arresting	NOUN
aji-148	160	20	mitosis	mitosis	NOUN
aji-148	160	21	.	.	PUNCT
aji-148	161	1	however	however	ADV
aji-148	161	2	,	,	PUNCT
aji-148	161	3	cytotoxic	cytotoxic	ADJ
aji-148	161	4	chemotherapy	chemotherapy	NOUN
aji-148	161	5	is	be	AUX
aji-148	161	6	widely	widely	ADV
aji-148	161	7	considered	consider	VERB
aji-148	161	8	to	to	PART
aji-148	161	9	be	be	AUX
aji-148	161	10	immunosuppressive	immunosuppressive	ADJ
aji-148	161	11	because	because	SCONJ
aji-148	161	12	it	it	PRON
aji-148	161	13	can	can	AUX
aji-148	161	14	cause	cause	VERB
aji-148	161	15	dose	dose	NOUN
aji-148	161	16	-	-	PUNCT
aji-148	161	17	dependent	dependent	ADJ
aji-148	161	18	myelosuppression	myelosuppression	NOUN
aji-148	161	19	,	,	PUNCT
aji-148	161	20	suggesting	suggest	VERB
aji-148	161	21	antagonism	antagonism	NOUN
aji-148	161	22	with	with	ADP
aji-148	161	23	immunotherapy	immunotherapy	NOUN
aji-148	161	24	[	[	X
aji-148	161	25	30	30	NUM
aji-148	161	26	]	]	PUNCT
aji-148	161	27	.	.	PUNCT
aji-148	162	1	before	before	ADP
aji-148	162	2	1994	1994	NUM
aji-148	162	3	,	,	PUNCT
aji-148	162	4	to	to	PART
aji-148	162	5	increase	increase	VERB
aji-148	162	6	act	act	VERB
aji-148	162	7	immunotherapy	immunotherapy	NOUN
aji-148	162	8	and	and	CCONJ
aji-148	162	9	decrease	decrease	VERB
aji-148	162	10	side	side	ADJ
aji-148	162	11	effects	effect	NOUN
aji-148	162	12	from	from	ADP
aji-148	162	13	chemotherapy	chemotherapy	NOUN
aji-148	162	14	for	for	ADP
aji-148	162	15	til	til	ADV
aji-148	162	16	to	to	PART
aji-148	162	17	treat	treat	VERB
aji-148	162	18	solid	solid	ADJ
aji-148	162	19	tumors	tumor	NOUN
aji-148	162	20	,	,	PUNCT
aji-148	162	21	we	we	PRON
aji-148	162	22	began	begin	VERB
aji-148	162	23	to	to	PART
aji-148	162	24	study	study	VERB
aji-148	162	25	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	162	26	with	with	ADP
aji-148	162	27	techniques	technique	NOUN
aji-148	162	28	for	for	ADP
aji-148	162	29	primary	primary	ADJ
aji-148	162	30	tumor	tumor	NOUN
aji-148	162	31	cells	cell	NOUN
aji-148	162	32	and	and	CCONJ
aji-148	162	33	immune	immune	ADJ
aji-148	162	34	cell	cell	NOUN
aji-148	162	35	separation	separation	NOUN
aji-148	162	36	and	and	CCONJ
aji-148	162	37	culture	culture	NOUN
aji-148	162	38	from	from	ADP
aji-148	162	39	the	the	DET
aji-148	162	40	removed	remove	VERB
aji-148	162	41	solid	solid	ADJ
aji-148	162	42	tumor	tumor	NOUN
aji-148	162	43	tissues	tissue	NOUN
aji-148	162	44	[	[	X
aji-148	162	45	31	31	NUM
aji-148	162	46	-	-	SYM
aji-148	162	47	33	33	NUM
aji-148	162	48	]	]	PUNCT
aji-148	162	49	.	.	PUNCT
aji-148	163	1	that	that	DET
aji-148	163	2	time	time	NOUN
aji-148	163	3	,	,	PUNCT
aji-148	163	4	to	to	PART
aji-148	163	5	increase	increase	VERB
aji-148	163	6	til	til	ADV
aji-148	163	7	efficacy	efficacy	NOUN
aji-148	163	8	and	and	CCONJ
aji-148	163	9	decrease	decrease	VERB
aji-148	163	10	toxic	toxic	ADJ
aji-148	163	11	chemotherapy	chemotherapy	NOUN
aji-148	163	12	,	,	PUNCT
aji-148	163	13	we	we	PRON
aji-148	163	14	study	study	VERB
aji-148	163	15	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	163	16	through	through	ADP
aji-148	163	17	which	which	PRON
aji-148	163	18	the	the	DET
aji-148	163	19	cultured	cultured	ADJ
aji-148	163	20	tils	til	NOUN
aji-148	163	21	from	from	ADP
aji-148	163	22	solid	solid	ADJ
aji-148	163	23	tumors	tumor	NOUN
aji-148	163	24	are	be	AUX
aji-148	163	25	activated	activate	VERB
aji-148	163	26	and	and	CCONJ
aji-148	163	27	then	then	ADV
aji-148	163	28	infused	infuse	VERB
aji-148	163	29	into	into	ADP
aji-148	163	30	patients	patient	NOUN
aji-148	163	31	for	for	ADP
aji-148	163	32	adoptive	adoptive	ADJ
aji-148	163	33	immunotherapy	immunotherapy	NOUN
aji-148	163	34	.	.	PUNCT
aji-148	164	1	at	at	ADP
aji-148	164	2	the	the	DET
aji-148	164	3	same	same	ADJ
aji-148	164	4	time	time	NOUN
aji-148	164	5	,	,	PUNCT
aji-148	164	6	the	the	DET
aji-148	164	7	primary	primary	ADJ
aji-148	164	8	tumor	tumor	NOUN
aji-148	164	9	cells	cell	NOUN
aji-148	164	10	from	from	ADP
aji-148	164	11	the	the	DET
aji-148	164	12	tumor	tumor	NOUN
aji-148	164	13	tissues	tissue	NOUN
aji-148	164	14	are	be	AUX
aji-148	164	15	utilized	utilize	VERB
aji-148	164	16	as	as	ADP
aji-148	164	17	in	in	ADP
aji-148	164	18	vivo	vivo	NOUN
aji-148	164	19	and	and	CCONJ
aji-148	164	20	in	in	ADP
aji-148	164	21	vitro	vitro	X
aji-148	164	22	chemosensitivity	chemosensitivity	NOUN
aji-148	164	23	tests	test	NOUN
aji-148	164	24	for	for	ADP
aji-148	164	25	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	164	26	[	[	X
aji-148	164	27	34	34	NUM
aji-148	164	28	-	-	SYM
aji-148	164	29	35	35	NUM
aji-148	164	30	]	]	PUNCT
aji-148	164	31	,	,	PUNCT
aji-148	164	32	as	as	SCONJ
aji-148	164	33	shown	show	VERB
aji-148	164	34	in	in	ADP
aji-148	164	35	fig.2	fig.2	PROPN
aji-148	164	36	.	.	PUNCT
aji-148	165	1	after	after	ADP
aji-148	165	2	more	more	ADJ
aji-148	165	3	than	than	ADP
aji-148	165	4	thirty	thirty	NUM
aji-148	165	5	years	year	NOUN
aji-148	165	6	effort	effort	NOUN
aji-148	165	7	,	,	PUNCT
aji-148	165	8	now	now	ADV
aji-148	165	9	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	165	10	combination	combination	NOUN
aji-148	165	11	regimens	regimen	NOUN
aji-148	165	12	may	may	AUX
aji-148	165	13	have	have	AUX
aji-148	165	14	shown	show	VERB
aji-148	165	15	advantages	advantage	NOUN
aji-148	165	16	over	over	ADP
aji-148	165	17	monotherapy	monotherapy	NOUN
aji-148	165	18	:	:	PUNCT
aji-148	165	19	(	(	PUNCT
aji-148	165	20	1	1	X
aji-148	165	21	)	)	PUNCT
aji-148	165	22	they	they	PRON
aji-148	165	23	can	can	AUX
aji-148	165	24	maximize	maximize	VERB
aji-148	165	25	cancer	cancer	NOUN
aji-148	165	26	elimination	elimination	NOUN
aji-148	165	27	within	within	ADP
aji-148	165	28	the	the	DET
aji-148	165	29	range	range	NOUN
aji-148	165	30	of	of	ADP
aji-148	165	31	tolerable	tolerable	ADJ
aji-148	165	32	toxicity	toxicity	NOUN
aji-148	165	33	;	;	PUNCT
aji-148	165	34	(	(	PUNCT
aji-148	165	35	2	2	X
aji-148	165	36	)	)	PUNCT
aji-148	165	37	target	target	VERB
aji-148	165	38	a	a	DET
aji-148	165	39	wider	wide	ADJ
aji-148	165	40	range	range	NOUN
aji-148	165	41	of	of	ADP
aji-148	165	42	tumor	tumor	NOUN
aji-148	165	43	cells	cell	NOUN
aji-148	165	44	with	with	ADP
aji-148	165	45	different	different	ADJ
aji-148	165	46	genetic	genetic	ADJ
aji-148	165	47	and	and	CCONJ
aji-148	165	48	epigenetic	epigenetic	ADJ
aji-148	165	49	abnormalities	abnormality	NOUN
aji-148	165	50	in	in	ADP
aji-148	165	51	a	a	DET
aji-148	165	52	heterogeneous	heterogeneous	ADJ
aji-148	165	53	tumor	tumor	NOUN
aji-148	165	54	population	population	NOUN
aji-148	165	55	;	;	PUNCT
aji-148	165	56	(	(	PUNCT
aji-148	165	57	3	3	X
aji-148	165	58	)	)	PUNCT
aji-148	165	59	slow	slow	VERB
aji-148	165	60	the	the	DET
aji-148	165	61	development	development	NOUN
aji-148	165	62	of	of	ADP
aji-148	165	63	drug	drug	NOUN
aji-148	165	64	resistance	resistance	NOUN
aji-148	165	65	;	;	PUNCT
aji-148	165	66	(	(	PUNCT
aji-148	165	67	4	4	X
aji-148	165	68	)	)	PUNCT
aji-148	165	69	can	can	AUX
aji-148	165	70	shrink	shrink	VERB
aji-148	165	71	the	the	DET
aji-148	165	72	primary	primary	ADJ
aji-148	165	73	tumor	tumor	NOUN
aji-148	165	74	mass	mass	PROPN
aji-148	165	75	,	,	PUNCT
aji-148	165	76	reduce	reduce	VERB
aji-148	165	77	the	the	DET
aji-148	165	78	number	number	NOUN
aji-148	165	79	of	of	ADP
aji-148	165	80	act	act	NOUN
aji-148	165	81	cells	cell	NOUN
aji-148	165	82	providing	provide	VERB
aji-148	165	83	an	an	DET
aji-148	165	84	opportunity	opportunity	NOUN
aji-148	165	85	for	for	ADP
aji-148	165	86	their	their	PRON
aji-148	165	87	combination	combination	NOUN
aji-148	165	88	with	with	ADP
aji-148	165	89	immunotherapy	immunotherapy	NOUN
aji-148	165	90	;	;	PUNCT
aji-148	165	91	(	(	PUNCT
aji-148	165	92	5	5	X
aji-148	165	93	)	)	PUNCT
aji-148	165	94	some	some	DET
aji-148	165	95	chemotherapeutic	chemotherapeutic	ADJ
aji-148	165	96	agents	agent	NOUN
aji-148	165	97	may	may	AUX
aji-148	165	98	directly	directly	ADV
aji-148	165	99	stimulate	stimulate	VERB
aji-148	165	100	antitumor	antitumor	PROPN
aji-148	165	101	immunity	immunity	NOUN
aji-148	165	102	with	with	ADP
aji-148	165	103	low	low	ADJ
aji-148	165	104	infiltration	infiltration	NOUN
aji-148	165	105	of	of	ADP
aji-148	165	106	effector	effector	NOUN
aji-148	165	107	t	t	PROPN
aji-148	165	108	cells	cell	NOUN
aji-148	165	109	within	within	ADP
aji-148	165	110	the	the	DET
aji-148	165	111	tumor	tumor	NOUN
aji-148	165	112	[	[	X
aji-148	165	113	36	36	NUM
aji-148	165	114	-	-	SYM
aji-148	165	115	38	38	NUM
aji-148	165	116	]	]	PUNCT
aji-148	165	117	.	.	PUNCT
aji-148	166	1	now	now	ADV
aji-148	166	2	,	,	PUNCT
aji-148	166	3	we	we	PRON
aji-148	166	4	all	all	PRON
aji-148	166	5	know	know	VERB
aji-148	166	6	that	that	SCONJ
aji-148	166	7	the	the	DET
aji-148	166	8	rationale	rationale	NOUN
aji-148	166	9	in	in	ADP
aji-148	166	10	a	a	DET
aji-148	166	11	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	166	12	combination	combination	NOUN
aji-148	166	13	can	can	AUX
aji-148	166	14	eliminate	eliminate	VERB
aji-148	166	15	disseminated	disseminate	VERB
aji-148	166	16	and	and	CCONJ
aji-148	166	17	metastatic	metastatic	ADJ
aji-148	166	18	cancer	cancer	NOUN
aji-148	166	19	cells	cell	NOUN
aji-148	166	20	,	,	PUNCT
aji-148	166	21	although	although	SCONJ
aji-148	166	22	chemotherapy	chemotherapy	NOUN
aji-148	166	23	can	can	AUX
aji-148	166	24	cause	cause	VERB
aji-148	166	25	myelosuppression	myelosuppression	NOUN
aji-148	166	26	.	.	PUNCT
aji-148	167	1	4	4	NUM
aji-148	167	2	.	.	NOUN
aji-148	167	3	immune	immune	ADJ
aji-148	167	4	checkpoint	checkpoint	NOUN
aji-148	167	5	inhibiting	inhibit	VERB
aji-148	167	6	immune	immune	ADJ
aji-148	167	7	suppression	suppression	NOUN
aji-148	167	8	supporting	support	VERB
aji-148	167	9	immunotherapy	immunotherapy	NOUN
aji-148	167	10	now	now	ADV
aji-148	167	11	,	,	PUNCT
aji-148	167	12	a	a	DET
aji-148	167	13	suppression	suppression	NOUN
aji-148	167	14	of	of	ADP
aji-148	167	15	tumor	tumor	NOUN
aji-148	167	16	growth	growth	NOUN
aji-148	167	17	is	be	AUX
aji-148	167	18	emerging	emerge	VERB
aji-148	167	19	through	through	ADP
aji-148	167	20	target	target	NOUN
aji-148	167	21	checkpoints	checkpoint	NOUN
aji-148	167	22	as	as	ADP
aji-148	167	23	a	a	DET
aji-148	167	24	new	new	ADJ
aji-148	167	25	generation	generation	NOUN
aji-148	167	26	of	of	ADP
aji-148	167	27	antitumor	antitumor	PROPN
aji-148	167	28	therapy	therapy	NOUN
aji-148	167	29	.	.	PUNCT
aji-148	168	1	there	there	PRON
aji-148	168	2	are	be	VERB
aji-148	168	3	two	two	NUM
aji-148	168	4	kinds	kind	NOUN
aji-148	168	5	of	of	ADP
aji-148	168	6	molecularly	molecularly	ADV
aji-148	168	7	targeted	target	VERB
aji-148	168	8	checkpoint	checkpoint	NOUN
aji-148	168	9	inhibitors	inhibitor	NOUN
aji-148	168	10	.	.	PUNCT
aji-148	169	1	the	the	DET
aji-148	169	2	first	first	ADJ
aji-148	169	3	one	one	NOUN
aji-148	169	4	is	be	AUX
aji-148	169	5	specifically	specifically	ADV
aji-148	169	6	killing	kill	VERB
aji-148	169	7	tumors	tumor	NOUN
aji-148	169	8	within	within	ADP
aji-148	169	9	the	the	DET
aji-148	169	10	tumor	tumor	NOUN
aji-148	169	11	microenvironment	microenvironment	NOUN
aji-148	169	12	(	(	PUNCT
aji-148	169	13	tme	tme	NOUN
aji-148	169	14	)	)	PUNCT
aji-148	169	15	,	,	PUNCT
aji-148	169	16	inhibiting	inhibit	VERB
aji-148	169	17	the	the	DET
aji-148	169	18	occurrence	occurrence	NOUN
aji-148	169	19	and	and	CCONJ
aji-148	169	20	development	development	NOUN
aji-148	169	21	of	of	ADP
aji-148	169	22	tumors	tumor	NOUN
aji-148	169	23	[	[	X
aji-148	169	24	39	39	NUM
aji-148	169	25	]	]	PUNCT
aji-148	169	26	,	,	PUNCT
aji-148	169	27	and	and	CCONJ
aji-148	169	28	the	the	DET
aji-148	169	29	second	second	ADJ
aji-148	169	30	one	one	NOUN
aji-148	169	31	can	can	AUX
aji-148	169	32	target	target	VERB
aji-148	169	33	and	and	CCONJ
aji-148	169	34	inhibit	inhibit	VERB
aji-148	169	35	immunepathway	immunepathway	ADJ
aji-148	169	36	molecules	molecule	NOUN
aji-148	169	37	called	call	VERB
aji-148	169	38	the	the	DET
aji-148	169	39	tumor	tumor	NOUN
aji-148	169	40	immune	immune	ADJ
aji-148	169	41	microenvironment	microenvironment	NOUN
aji-148	169	42	(	(	PUNCT
aji-148	169	43	time	time	NOUN
aji-148	169	44	)	)	PUNCT
aji-148	170	1	[	[	X
aji-148	170	2	40	40	NUM
aji-148	170	3	]	]	PUNCT
aji-148	170	4	so	so	SCONJ
aji-148	170	5	that	that	SCONJ
aji-148	170	6	they	they	PRON
aji-148	170	7	can	can	AUX
aji-148	170	8	restore	restore	VERB
aji-148	170	9	immune	immune	ADJ
aji-148	170	10	cell	cell	NOUN
aji-148	170	11	activity	activity	NOUN
aji-148	170	12	and	and	CCONJ
aji-148	170	13	improve	improve	VERB
aji-148	170	14	the	the	DET
aji-148	170	15	body	body	NOUN
aji-148	170	16	's	's	PART
aji-148	170	17	antitumor	antitumor	PROPN
aji-148	170	18	immune	immune	ADJ
aji-148	170	19	function	function	NOUN
aji-148	170	20	.	.	PUNCT
aji-148	171	1	currently	currently	ADV
aji-148	171	2	,	,	PUNCT
aji-148	171	3	molecular	molecular	ADJ
aji-148	171	4	target	target	NOUN
aji-148	171	5	checkpoints	checkpoint	NOUN
aji-148	171	6	increasingly	increasingly	ADV
aji-148	171	7	studied	study	VERB
aji-148	171	8	within	within	ADP
aji-148	171	9	time	time	NOUN
aji-148	171	10	are	be	AUX
aji-148	171	11	named	name	VERB
aji-148	171	12	immune	immune	ADJ
aji-148	171	13	checkpoint	checkpoint	NOUN
aji-148	171	14	inhibitors	inhibitor	NOUN
aji-148	171	15	(	(	PUNCT
aji-148	171	16	icis	icis	NOUN
aji-148	171	17	)	)	PUNCT
aji-148	171	18	for	for	ADP
aji-148	171	19	pd-1	pd-1	ADV
aji-148	171	20	,	,	PUNCT
aji-148	171	21	pd	pd	PROPN
aji-148	171	22	-	-	PUNCT
aji-148	171	23	l1	l1	PROPN
aji-148	171	24	,	,	PUNCT
aji-148	171	25	ctla-4	ctla-4	NOUN
aji-148	171	26	,	,	PUNCT
aji-148	171	27	tim-3	tim-3	ADV
aji-148	171	28	,	,	PUNCT
aji-148	171	29	lag-3	lag-3	X
aji-148	171	30	,	,	PUNCT
aji-148	171	31	and	and	CCONJ
aji-148	171	32	siglec-15	siglec-15	PROPN
aji-148	171	33	by	by	ADP
aji-148	171	34	their	their	PRON
aji-148	171	35	corresponding	corresponding	ADJ
aji-148	171	36	molecular	molecular	ADJ
aji-148	171	37	target	target	NOUN
aji-148	171	38	inhibitors	inhibitor	NOUN
aji-148	171	39	.	.	PUNCT
aji-148	172	1	fig	fig	NOUN
aji-148	172	2	.	.	PUNCT
aji-148	173	1	2	2	X
aji-148	173	2	.	.	NOUN
aji-148	173	3	clinical	clinical	ADJ
aji-148	173	4	strategies	strategy	NOUN
aji-148	173	5	for	for	ADP
aji-148	173	6	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	173	7	to	to	PART
aji-148	173	8	increase	increase	VERB
aji-148	173	9	til	til	ADV
aji-148	173	10	efficacy	efficacy	NOUN
aji-148	173	11	.	.	PUNCT
aji-148	174	1	nb	nb	INTJ
aji-148	174	2	.	.	PUNCT
aji-148	175	1	a	a	DET
aji-148	175	2	clinical	clinical	ADJ
aji-148	175	3	procedure	procedure	NOUN
aji-148	175	4	combining	combine	VERB
aji-148	175	5	tils	til	NOUN
aji-148	175	6	with	with	ADP
aji-148	175	7	sensitive	sensitive	ADJ
aji-148	175	8	chemotherapeutic	chemotherapeutic	ADJ
aji-148	175	9	agents	agent	NOUN
aji-148	175	10	,	,	PUNCT
aji-148	175	11	which	which	PRON
aji-148	175	12	were	be	AUX
aji-148	175	13	screened	screen	VERB
aji-148	175	14	chemosensitivity	chemosensitivity	NOUN
aji-148	175	15	assay	assay	PROPN
aji-148	175	16	(	(	PUNCT
aji-148	175	17	csa	csa	PROPN
aji-148	175	18	)	)	PUNCT
aji-148	175	19	from	from	ADP
aji-148	175	20	til	til	SCONJ
aji-148	175	21	cytotoxicity	cytotoxicity	NOUN
aji-148	175	22	experiment	experiment	NOUN
aji-148	175	23	of	of	ADP
aji-148	175	24	patient	patient	NOUN
aji-148	175	25	’s	’s	PART
aji-148	175	26	autogenous	autogenous	ADJ
aji-148	175	27	tumor	tumor	NOUN
aji-148	175	28	cell	cell	NOUN
aji-148	175	29	to	to	PART
aji-148	175	30	increase	increase	VERB
aji-148	175	31	treatment	treatment	NOUN
aji-148	175	32	response	response	NOUN
aji-148	175	33	li	li	PROPN
aji-148	175	34	and	and	CCONJ
aji-148	175	35	li	li	PROPN
aji-148	175	36	;	;	PUNCT
aji-148	175	37	asian	asian	PROPN
aji-148	175	38	j.	j.	PROPN
aji-148	175	39	immunol	immunol	PROPN
aji-148	175	40	.	.	PROPN
aji-148	175	41	,	,	PUNCT
aji-148	175	42	vol	vol	NOUN
aji-148	175	43	.	.	PROPN
aji-148	175	44	7	7	NUM
aji-148	175	45	,	,	PUNCT
aji-148	175	46	no	no	INTJ
aji-148	175	47	.	.	NOUN
aji-148	175	48	1	1	NUM
aji-148	175	49	,	,	PUNCT
aji-148	175	50	pp	pp	ADJ
aji-148	175	51	.	.	PUNCT
aji-148	176	1	247	247	NUM
aji-148	176	2	-	-	SYM
aji-148	176	3	257	257	NUM
aji-148	176	4	,	,	PUNCT
aji-148	176	5	2024	2024	NUM
aji-148	176	6	;	;	PUNCT
aji-148	176	7	article	article	NOUN
aji-148	176	8	no.aji.126682	no.aji.126682	ADP
aji-148	176	9	251	251	NUM
aji-148	176	10	table	table	NOUN
aji-148	176	11	2	2	NUM
aji-148	176	12	.	.	PUNCT
aji-148	176	13	ici	ici	NOUN
aji-148	176	14	combination	combination	NOUN
aji-148	176	15	types	type	NOUN
aji-148	176	16	common	common	ADJ
aji-148	176	17	ici	ici	NOUN
aji-148	176	18	type	type	NOUN
aji-148	176	19	supporting	support	VERB
aji-148	176	20	item	item	NOUN
aji-148	176	21	ici	ici	PROPN
aji-148	176	22	-	-	PUNCT
aji-148	176	23	ici	ici	PROPN
aji-148	176	24	nivolumab	nivolumab	PROPN
aji-148	176	25	ipilimumab	ipilimumab	PROPN
aji-148	176	26	ici	ici	PROPN
aji-148	176	27	-	-	PUNCT
aji-148	176	28	act	act	NOUN
aji-148	176	29	nivolumab	nivolumab	NOUN
aji-148	176	30	car	car	NOUN
aji-148	176	31	-	-	PUNCT
aji-148	176	32	t	t	PROPN
aji-148	176	33	/	/	SYM
aji-148	176	34	til	til	NOUN
aji-148	176	35	ici	ici	NOUN
aji-148	176	36	-	-	PUNCT
aji-148	176	37	chemotherapy	chemotherapy	NOUN
aji-148	176	38	nivolumab	nivolumab	NOUN
aji-148	176	39	chemotherapy	chemotherapy	NOUN
aji-148	176	40	ici	ici	PROPN
aji-148	176	41	antiangiogenic	antiangiogenic	PROPN
aji-148	176	42	nivolumab	nivolumab	X
aji-148	176	43	antiangiogenic	antiangiogenic	NOUN
aji-148	176	44	therapy	therapy	NOUN
aji-148	176	45	ici	ici	NOUN
aji-148	176	46	-	-	PUNCT
aji-148	176	47	vaccine	vaccine	NOUN
aji-148	176	48	nivolumab	nivolumab	ADP
aji-148	176	49	hpv16	hpv16	NOUN
aji-148	176	50	specific	specific	ADJ
aji-148	176	51	peptide	peptide	NOUN
aji-148	176	52	vaccine	vaccine	NOUN
aji-148	176	53	ici	ici	NOUN
aji-148	176	54	-	-	PUNCT
aji-148	176	55	radiation	radiation	NOUN
aji-148	176	56	nivolumab	nivolumab	NOUN
aji-148	176	57	ionizing	ionize	VERB
aji-148	176	58	radiation	radiation	NOUN
aji-148	176	59	ici	ici	PROPN
aji-148	176	60	-	-	PUNCT
aji-148	176	61	tme	tme	PROPN
aji-148	176	62	nivolumab	nivolumab	NOUN
aji-148	176	63	targeting	target	VERB
aji-148	176	64	tgfβ	tgfβ	ADJ
aji-148	176	65	ici	ici	NOUN
aji-148	176	66	-	-	PUNCT
aji-148	176	67	cytokine	cytokine	VERB
aji-148	176	68	nivolumab	nivolumab	NOUN
aji-148	176	69	il2	il2	NOUN
aji-148	176	70	/	/	SYM
aji-148	176	71	ifn	ifn	PROPN
aji-148	176	72	-	-	PUNCT
aji-148	176	73	gamma	gamma	PROPN
aji-148	176	74	icis	icis	PROPN
aji-148	176	75	were	be	AUX
aji-148	176	76	initially	initially	ADV
aji-148	176	77	approved	approve	VERB
aji-148	176	78	for	for	ADP
aji-148	176	79	the	the	DET
aji-148	176	80	treatment	treatment	NOUN
aji-148	176	81	of	of	ADP
aji-148	176	82	melanoma	melanoma	NOUN
aji-148	176	83	.	.	PUNCT
aji-148	177	1	due	due	ADP
aji-148	177	2	to	to	ADP
aji-148	177	3	single	single	ADJ
aji-148	177	4	-	-	PUNCT
aji-148	177	5	agent	agent	NOUN
aji-148	177	6	icis	icis	NOUN
aji-148	177	7	'	'	PART
aji-148	177	8	failure	failure	NOUN
aji-148	177	9	,	,	PUNCT
aji-148	177	10	combination	combination	NOUN
aji-148	177	11	regimens	regimen	NOUN
aji-148	177	12	involving	involve	VERB
aji-148	177	13	icis	icis	NOUN
aji-148	177	14	have	have	AUX
aji-148	177	15	been	be	AUX
aji-148	177	16	investigated	investigate	VERB
aji-148	177	17	,	,	PUNCT
aji-148	177	18	such	such	ADJ
aji-148	177	19	as	as	ADP
aji-148	177	20	ici	ici	NOUN
aji-148	177	21	-	-	PUNCT
aji-148	177	22	act	act	PROPN
aji-148	177	23	,	,	PUNCT
aji-148	177	24	ici	ici	NOUN
aji-148	177	25	-	-	PUNCT
aji-148	177	26	chemotherapy	chemotherapy	NOUN
aji-148	177	27	,	,	PUNCT
aji-148	177	28	and	and	CCONJ
aji-148	177	29	ici	ici	NOUN
aji-148	177	30	antiangiogenic	antiangiogenic	ADJ
aji-148	177	31	doublets	doublet	NOUN
aji-148	177	32	,	,	PUNCT
aji-148	177	33	as	as	SCONJ
aji-148	177	34	shown	show	VERB
aji-148	177	35	in	in	ADP
aji-148	177	36	table	table	NOUN
aji-148	177	37	2	2	NUM
aji-148	177	38	.	.	NOUN
aji-148	177	39	nivolumab	nivolumab	NOUN
aji-148	177	40	and	and	CCONJ
aji-148	177	41	ipilimumab	ipilimumab	NOUN
aji-148	177	42	have	have	AUX
aji-148	177	43	shown	show	VERB
aji-148	177	44	initial	initial	ADJ
aji-148	177	45	success	success	NOUN
aji-148	177	46	in	in	ADP
aji-148	177	47	melanoma	melanoma	NOUN
aji-148	177	48	and	and	CCONJ
aji-148	177	49	renal	renal	ADJ
aji-148	177	50	cell	cell	NOUN
aji-148	177	51	carcinoma	carcinoma	NOUN
aji-148	177	52	(	(	PUNCT
aji-148	177	53	rcc	rcc	PROPN
aji-148	177	54	)	)	PUNCT
aji-148	177	55	.	.	PUNCT
aji-148	178	1	ici	ici	PROPN
aji-148	178	2	-	-	PUNCT
aji-148	178	3	ici	ici	NOUN
aji-148	178	4	combination	combination	NOUN
aji-148	178	5	therapy	therapy	NOUN
aji-148	178	6	is	be	AUX
aji-148	178	7	a	a	DET
aji-148	178	8	viable	viable	ADJ
aji-148	178	9	approach	approach	NOUN
aji-148	178	10	to	to	PART
aji-148	178	11	overcome	overcome	VERB
aji-148	178	12	treatment	treatment	NOUN
aji-148	178	13	resistance	resistance	NOUN
aji-148	178	14	.	.	PUNCT
aji-148	179	1	novel	novel	ADJ
aji-148	179	2	combination	combination	NOUN
aji-148	179	3	strategies	strategy	NOUN
aji-148	179	4	to	to	PART
aji-148	179	5	overcome	overcome	VERB
aji-148	179	6	ici	ici	NOUN
aji-148	179	7	resistance	resistance	NOUN
aji-148	179	8	rapidly	rapidly	ADV
aji-148	179	9	evolve	evolve	VERB
aji-148	179	10	,	,	PUNCT
aji-148	179	11	with	with	ADP
aji-148	179	12	many	many	ADJ
aji-148	179	13	clinical	clinical	ADJ
aji-148	179	14	trials	trial	NOUN
aji-148	179	15	underway	underway	ADV
aji-148	179	16	.	.	PUNCT
aji-148	180	1	bispecific	bispecific	NOUN
aji-148	180	2	antibodies	antibody	NOUN
aji-148	180	3	(	(	PUNCT
aji-148	180	4	bsabs	bsab	NOUN
aji-148	180	5	)	)	PUNCT
aji-148	180	6	allow	allow	VERB
aji-148	180	7	the	the	DET
aji-148	180	8	targeting	targeting	NOUN
aji-148	180	9	of	of	ADP
aji-148	180	10	specific	specific	ADJ
aji-148	180	11	resistance	resistance	NOUN
aji-148	180	12	mechanisms	mechanism	NOUN
aji-148	180	13	in	in	ADP
aji-148	180	14	a	a	DET
aji-148	180	15	single	single	ADJ
aji-148	180	16	molecule	molecule	NOUN
aji-148	180	17	,	,	PUNCT
aji-148	180	18	and	and	CCONJ
aji-148	180	19	dual	dual	ADJ
aji-148	180	20	checkpoint	checkpoint	NOUN
aji-148	180	21	inhibition	inhibition	NOUN
aji-148	180	22	of	of	ADP
aji-148	180	23	pd	pd	PROPN
aji-148	180	24	-	-	PROPN
aji-148	180	25	l1	l1	PROPN
aji-148	180	26	and	and	CCONJ
aji-148	180	27	lag-3	lag-3	ADV
aji-148	180	28	is	be	AUX
aji-148	180	29	an	an	DET
aji-148	180	30	example	example	NOUN
aji-148	180	31	that	that	PRON
aji-148	180	32	has	have	AUX
aji-148	180	33	shown	show	VERB
aji-148	180	34	promising	promise	VERB
aji-148	180	35	preclinical	preclinical	ADJ
aji-148	180	36	results	result	NOUN
aji-148	180	37	.	.	PUNCT
aji-148	181	1	other	other	ADJ
aji-148	181	2	bsabs	bsab	NOUN
aji-148	181	3	combine	combine	VERB
aji-148	181	4	icis	icis	PROPN
aji-148	181	5	with	with	ADP
aji-148	181	6	non	non	ADJ
aji-148	181	7	-	-	ADJ
aji-148	181	8	ici	ici	ADJ
aji-148	181	9	immunotherapies	immunotherapy	NOUN
aji-148	181	10	,	,	PUNCT
aji-148	181	11	such	such	ADJ
aji-148	181	12	as	as	ADP
aji-148	181	13	pd	pd	PROPN
aji-148	181	14	-	-	PROPN
aji-148	181	15	l1	l1	PROPN
aji-148	181	16	antibodies	antibodie	VERB
aji-148	181	17	and	and	CCONJ
aji-148	181	18	transforming	transform	VERB
aji-148	181	19	growth	growth	NOUN
aji-148	181	20	factor	factor	NOUN
aji-148	181	21	-	-	PUNCT
aji-148	181	22	β	β	X
aji-148	181	23	(	(	PUNCT
aji-148	181	24	tgf	tgf	PROPN
aji-148	181	25	-	-	PUNCT
aji-148	181	26	β	β	NOUN
aji-148	181	27	)	)	PUNCT
aji-148	181	28	traps	trap	NOUN
aji-148	181	29	,	,	PUNCT
aji-148	181	30	a	a	DET
aji-148	181	31	key	key	ADJ
aji-148	181	32	player	player	NOUN
aji-148	181	33	in	in	ADP
aji-148	181	34	the	the	DET
aji-148	181	35	development	development	NOUN
aji-148	181	36	of	of	ADP
aji-148	181	37	an	an	DET
aji-148	181	38	immunosuppressive	immunosuppressive	ADJ
aji-148	181	39	tumor	tumor	NOUN
aji-148	181	40	microenvironment	microenvironment	NOUN
aji-148	181	41	(	(	PUNCT
aji-148	181	42	tme	tme	NOUN
aji-148	181	43	)	)	PUNCT
aji-148	181	44	.	.	PUNCT
aji-148	182	1	other	other	ADJ
aji-148	182	2	forms	form	NOUN
aji-148	182	3	of	of	ADP
aji-148	182	4	ici	ici	PROPN
aji-148	182	5	immunotherapy	immunotherapy	NOUN
aji-148	182	6	are	be	AUX
aji-148	182	7	also	also	ADV
aji-148	182	8	encouraging	encouraging	ADJ
aji-148	182	9	,	,	PUNCT
aji-148	182	10	including	include	VERB
aji-148	182	11	immunostimulatory	immunostimulatory	ADJ
aji-148	182	12	cytokines	cytokine	NOUN
aji-148	182	13	(	(	PUNCT
aji-148	182	14	e.g.	e.g.	ADV
aji-148	182	15	,	,	PUNCT
aji-148	182	16	recombinant	recombinant	ADJ
aji-148	182	17	interleukin-2	interleukin-2	NOUN
aji-148	182	18	,	,	PUNCT
aji-148	182	19	interferon	interferon	NOUN
aji-148	182	20	-	-	PUNCT
aji-148	182	21	α	α	NOUN
aji-148	182	22	)	)	PUNCT
aji-148	182	23	,	,	PUNCT
aji-148	182	24	cancer	cancer	NOUN
aji-148	182	25	vaccines	vaccine	NOUN
aji-148	182	26	,	,	PUNCT
aji-148	182	27	and	and	CCONJ
aji-148	182	28	adoptive	adoptive	ADJ
aji-148	182	29	cell	cell	NOUN
aji-148	182	30	therapy	therapy	NOUN
aji-148	182	31	.	.	PUNCT
aji-148	183	1	combining	combine	VERB
aji-148	183	2	vaccine	vaccine	NOUN
aji-148	183	3	therapies	therapy	NOUN
aji-148	183	4	with	with	ADP
aji-148	183	5	icis	icis	NOUN
aji-148	183	6	may	may	AUX
aji-148	183	7	enhance	enhance	VERB
aji-148	183	8	antitumor	antitumor	PROPN
aji-148	183	9	effects	effect	NOUN
aji-148	183	10	in	in	ADP
aji-148	183	11	preclinical	preclinical	ADJ
aji-148	183	12	models	model	NOUN
aji-148	183	13	.	.	PUNCT
aji-148	184	1	combining	combine	VERB
aji-148	184	2	car	car	NOUN
aji-148	184	3	-	-	PUNCT
aji-148	184	4	t	t	PROPN
aji-148	184	5	with	with	ADP
aji-148	184	6	icis	icis	PROPN
aji-148	184	7	may	may	AUX
aji-148	184	8	overcome	overcome	VERB
aji-148	184	9	some	some	PRON
aji-148	184	10	of	of	ADP
aji-148	184	11	the	the	DET
aji-148	184	12	resistance	resistance	NOUN
aji-148	184	13	mechanisms	mechanism	NOUN
aji-148	184	14	encountered	encounter	VERB
aji-148	184	15	.	.	PUNCT
aji-148	185	1	in	in	ADP
aji-148	185	2	addition	addition	NOUN
aji-148	185	3	,	,	PUNCT
aji-148	185	4	a	a	DET
aji-148	185	5	combination	combination	NOUN
aji-148	185	6	of	of	ADP
aji-148	185	7	icis	icis	NOUN
aji-148	185	8	with	with	ADP
aji-148	185	9	ionizing	ionize	VERB
aji-148	185	10	radiation	radiation	NOUN
aji-148	185	11	and	and	CCONJ
aji-148	185	12	icis	icis	NOUN
aji-148	185	13	with	with	ADP
aji-148	185	14	targeted	target	VERB
aji-148	185	15	therapies	therapy	NOUN
aji-148	185	16	for	for	ADP
aji-148	185	17	cellular	cellular	ADJ
aji-148	185	18	processes	process	NOUN
aji-148	185	19	,	,	PUNCT
aji-148	185	20	including	include	VERB
aji-148	185	21	dna	dna	PROPN
aji-148	185	22	damage	damage	NOUN
aji-148	185	23	repair	repair	NOUN
aji-148	185	24	,	,	PUNCT
aji-148	185	25	phosphatidylinositol	phosphatidylinositol	NOUN
aji-148	185	26	3	3	NUM
aji-148	185	27	-	-	PUNCT
aji-148	185	28	kinase	kinase	NOUN
aji-148	185	29	,	,	PUNCT
aji-148	185	30	and	and	CCONJ
aji-148	185	31	histone	histone	NOUN
aji-148	185	32	deacetylase	deacetylase	NOUN
aji-148	185	33	pathways	pathway	NOUN
aji-148	185	34	.	.	PUNCT
aji-148	186	1	a	a	DET
aji-148	186	2	logical	logical	ADJ
aji-148	186	3	approach	approach	NOUN
aji-148	186	4	to	to	ADP
aji-148	186	5	combination	combination	NOUN
aji-148	186	6	study	study	NOUN
aji-148	186	7	design	design	NOUN
aji-148	186	8	is	be	AUX
aji-148	186	9	needed	need	VERB
aji-148	186	10	to	to	PART
aji-148	186	11	maximize	maximize	VERB
aji-148	186	12	patient	patient	ADJ
aji-148	186	13	benefit	benefit	NOUN
aji-148	186	14	[	[	X
aji-148	186	15	41	41	NUM
aji-148	186	16	]	]	PUNCT
aji-148	186	17	.	.	PUNCT
aji-148	187	1	fig	fig	NOUN
aji-148	187	2	.	.	PUNCT
aji-148	188	1	3	3	X
aji-148	188	2	.	.	X
aji-148	188	3	strategies	strategy	NOUN
aji-148	188	4	for	for	ADP
aji-148	188	5	precision	precision	NOUN
aji-148	188	6	medicine	medicine	NOUN
aji-148	188	7	for	for	ADP
aji-148	188	8	personalized	personalize	VERB
aji-148	188	9	t	t	PROPN
aji-148	188	10	-	-	PUNCT
aji-148	188	11	cell	cell	NOUN
aji-148	188	12	therapy	therapy	NOUN
aji-148	188	13	to	to	PART
aji-148	188	14	increase	increase	VERB
aji-148	188	15	t	t	NOUN
aji-148	188	16	-	-	PUNCT
aji-148	188	17	cell	cell	NOUN
aji-148	188	18	efficacy	efficacy	NOUN
aji-148	188	19	nb	nb	INTJ
aji-148	188	20	.	.	PROPN
aji-148	189	1	a	a	PRON
aji-148	189	2	)	)	PUNCT
aji-148	189	3	improving	improve	VERB
aji-148	189	4	til	til	ADV
aji-148	189	5	immune	immune	NOUN
aji-148	189	6	-	-	PUNCT
aji-148	189	7	response	response	NOUN
aji-148	189	8	in	in	ADP
aji-148	189	9	experiment	experiment	NOUN
aji-148	189	10	such	such	ADJ
aji-148	189	11	as	as	ADP
aji-148	189	12	discover	discover	VERB
aji-148	189	13	quiescent	quiescent	ADJ
aji-148	189	14	genes	gene	NOUN
aji-148	189	15	for	for	ADP
aji-148	189	16	til	til	ADV
aji-148	189	17	and	and	CCONJ
aji-148	189	18	neo	neo	NOUN
aji-148	189	19	-	-	NOUN
aji-148	189	20	antigen	antigen	ADJ
aji-148	189	21	from	from	ADP
aji-148	189	22	tumor	tumor	NOUN
aji-148	189	23	cells	cell	NOUN
aji-148	189	24	;	;	PUNCT
aji-148	189	25	and	and	CCONJ
aji-148	189	26	rebuilding	rebuild	VERB
aji-148	189	27	immune	immune	NOUN
aji-148	189	28	-	-	PUNCT
aji-148	189	29	response	response	NOUN
aji-148	189	30	for	for	ADP
aji-148	189	31	til	til	ADV
aji-148	189	32	or	or	CCONJ
aji-148	189	33	set	set	VERB
aji-148	189	34	up	up	ADP
aji-148	189	35	car	car	NOUN
aji-148	189	36	-	-	PUNCT
aji-148	189	37	t	t	PROPN
aji-148	189	38	or	or	CCONJ
aji-148	189	39	tcr	tcr	PROPN
aji-148	189	40	-	-	PUNCT
aji-148	189	41	t	t	PROPN
aji-148	189	42	cells	cell	NOUN
aji-148	189	43	;	;	PUNCT
aji-148	189	44	b	b	X
aji-148	189	45	)	)	PUNCT
aji-148	189	46	ici	ici	NOUN
aji-148	189	47	improving	improve	VERB
aji-148	189	48	t	t	NOUN
aji-148	189	49	-	-	PUNCT
aji-148	189	50	cell	cell	NOUN
aji-148	189	51	to	to	PART
aji-148	189	52	attack	attack	VERB
aji-148	189	53	tumor	tumor	NOUN
aji-148	189	54	cells	cell	NOUN
aji-148	189	55	;	;	PUNCT
aji-148	189	56	c	c	X
aji-148	189	57	)	)	PUNCT
aji-148	189	58	targeting	target	VERB
aji-148	189	59	block	block	NOUN
aji-148	189	60	to	to	PART
aji-148	189	61	increase	increase	VERB
aji-148	189	62	t	t	NOUN
aji-148	189	63	-	-	PUNCT
aji-148	189	64	cell	cell	NOUN
aji-148	189	65	activity	activity	NOUN
aji-148	189	66	;	;	PUNCT
aji-148	189	67	d	d	X
aji-148	189	68	)	)	PUNCT
aji-148	189	69	tme	tme	PROPN
aji-148	189	70	block	block	NOUN
aji-148	189	71	to	to	PART
aji-148	189	72	increase	increase	VERB
aji-148	189	73	t	t	NOUN
aji-148	189	74	-	-	PUNCT
aji-148	189	75	cell	cell	NOUN
aji-148	189	76	activity	activity	NOUN
aji-148	189	77	;	;	PUNCT
aji-148	189	78	d	d	X
aji-148	189	79	)	)	PUNCT
aji-148	189	80	epigenetics	epigenetic	NOUN
aji-148	189	81	treatment	treatment	NOUN
aji-148	189	82	improving	improve	VERB
aji-148	189	83	t	t	NOUN
aji-148	189	84	-	-	PUNCT
aji-148	189	85	cell	cell	NOUN
aji-148	189	86	to	to	PART
aji-148	189	87	attack	attack	VERB
aji-148	189	88	tumor	tumor	NOUN
aji-148	189	89	cells	cell	NOUN
aji-148	189	90	;	;	PUNCT
aji-148	189	91	and	and	CCONJ
aji-148	189	92	e	e	X
aji-148	189	93	)	)	PUNCT
aji-148	189	94	chemotherapy	chemotherapy	NOUN
aji-148	189	95	to	to	PART
aji-148	189	96	increase	increase	VERB
aji-148	189	97	t	t	NOUN
aji-148	189	98	-	-	PUNCT
aji-148	189	99	cell	cell	NOUN
aji-148	189	100	attack	attack	NOUN
aji-148	189	101	tumor	tumor	NOUN
aji-148	189	102	cells	cell	NOUN
aji-148	189	103	.	.	PUNCT
aji-148	190	1	li	li	PROPN
aji-148	190	2	and	and	CCONJ
aji-148	190	3	li	li	PROPN
aji-148	190	4	;	;	PUNCT
aji-148	190	5	asian	asian	PROPN
aji-148	190	6	j.	j.	PROPN
aji-148	190	7	immunol	immunol	PROPN
aji-148	190	8	.	.	PROPN
aji-148	190	9	,	,	PUNCT
aji-148	190	10	vol	vol	NOUN
aji-148	190	11	.	.	PROPN
aji-148	190	12	7	7	NUM
aji-148	190	13	,	,	PUNCT
aji-148	190	14	no	no	INTJ
aji-148	190	15	.	.	NOUN
aji-148	190	16	1	1	NUM
aji-148	190	17	,	,	PUNCT
aji-148	190	18	pp	pp	ADJ
aji-148	190	19	.	.	PUNCT
aji-148	191	1	247	247	NUM
aji-148	191	2	-	-	SYM
aji-148	191	3	257	257	NUM
aji-148	191	4	,	,	PUNCT
aji-148	191	5	2024	2024	NUM
aji-148	191	6	;	;	PUNCT
aji-148	191	7	article	article	NOUN
aji-148	191	8	no.aji.126682	no.aji.126682	ADP
aji-148	191	9	252	252	NUM
aji-148	191	10	fig	fig	NOUN
aji-148	191	11	.	.	PUNCT
aji-148	192	1	4	4	X
aji-148	192	2	.	.	X
aji-148	192	3	strategies	strategy	NOUN
aji-148	192	4	for	for	ADP
aji-148	192	5	combination	combination	NOUN
aji-148	192	6	therapy	therapy	NOUN
aji-148	192	7	to	to	PART
aji-148	192	8	support	support	VERB
aji-148	192	9	immunotherapy	immunotherapy	NOUN
aji-148	192	10	5	5	NUM
aji-148	192	11	.	.	PUNCT
aji-148	193	1	a	a	DET
aji-148	193	2	new	new	ADJ
aji-148	193	3	generation	generation	NOUN
aji-148	193	4	of	of	ADP
aji-148	193	5	precision	precision	NOUN
aji-148	193	6	medicine	medicine	NOUN
aji-148	193	7	supporting	support	VERB
aji-148	193	8	immunotherapy	immunotherapy	NOUN
aji-148	193	9	according	accord	VERB
aji-148	193	10	to	to	ADP
aji-148	193	11	those	those	PRON
aji-148	193	12	discussed	discuss	VERB
aji-148	193	13	above	above	ADV
aji-148	193	14	,	,	PUNCT
aji-148	193	15	distinct	distinct	ADJ
aji-148	193	16	ld	ld	PROPN
aji-148	193	17	,	,	PUNCT
aji-148	193	18	chemotherapy	chemotherapy	NOUN
aji-148	193	19	,	,	PUNCT
aji-148	193	20	and	and	CCONJ
aji-148	193	21	ici	ici	NOUN
aji-148	193	22	are	be	AUX
aji-148	193	23	different	different	ADJ
aji-148	193	24	for	for	ADP
aji-148	193	25	individual	individual	ADJ
aji-148	193	26	patients	patient	NOUN
aji-148	193	27	.	.	PUNCT
aji-148	194	1	of	of	ADP
aji-148	194	2	course	course	ADV
aji-148	194	3	,	,	PUNCT
aji-148	194	4	all	all	DET
aji-148	194	5	combinations	combination	NOUN
aji-148	194	6	should	should	AUX
aji-148	194	7	differ	differ	VERB
aji-148	194	8	from	from	ADP
aji-148	194	9	one	one	NUM
aji-148	194	10	person	person	NOUN
aji-148	194	11	to	to	ADP
aji-148	194	12	another	another	PRON
aji-148	194	13	.	.	PUNCT
aji-148	195	1	following	follow	VERB
aji-148	195	2	thirty	thirty	NUM
aji-148	195	3	years	year	NOUN
aji-148	195	4	of	of	ADP
aji-148	195	5	research	research	NOUN
aji-148	195	6	,	,	PUNCT
aji-148	195	7	a	a	DET
aji-148	195	8	new	new	ADJ
aji-148	195	9	generation	generation	NOUN
aji-148	195	10	of	of	ADP
aji-148	195	11	precision	precision	NOUN
aji-148	195	12	medicine	medicine	NOUN
aji-148	195	13	techniques	technique	NOUN
aji-148	195	14	is	be	AUX
aji-148	195	15	emerging	emerge	VERB
aji-148	195	16	[	[	PUNCT
aji-148	195	17	42	42	NUM
aji-148	195	18	-	-	SYM
aji-148	195	19	44	44	NUM
aji-148	195	20	]	]	PUNCT
aji-148	195	21	.	.	PUNCT
aji-148	196	1	“	"	PUNCT
aji-148	196	2	to	to	PART
aji-148	196	3	address	address	VERB
aji-148	196	4	the	the	DET
aji-148	196	5	issues	issue	NOUN
aji-148	196	6	,	,	PUNCT
aji-148	196	7	successful	successful	ADJ
aji-148	196	8	precision	precision	NOUN
aji-148	196	9	medicine	medicine	NOUN
aji-148	196	10	for	for	ADP
aji-148	196	11	tumor	tumor	NOUN
aji-148	196	12	disease	disease	NOUN
aji-148	196	13	has	have	AUX
aji-148	196	14	involved	involve	VERB
aji-148	196	15	immune	immune	ADJ
aji-148	196	16	cells	cell	NOUN
aji-148	196	17	/	/	SYM
aji-148	196	18	primary	primary	ADJ
aji-148	196	19	cell	cell	NOUN
aji-148	196	20	culture	culture	NOUN
aji-148	196	21	,	,	PUNCT
aji-148	196	22	tumor	tumor	NOUN
aji-148	196	23	tissue	tissue	NOUN
aji-148	196	24	biobanks	biobank	NOUN
aji-148	196	25	,	,	PUNCT
aji-148	196	26	single	single	ADJ
aji-148	196	27	cell	cell	NOUN
aji-148	196	28	technique	technique	NOUN
aji-148	196	29	,	,	PUNCT
aji-148	196	30	clinical	clinical	ADJ
aji-148	196	31	genomics	genomic	NOUN
aji-148	196	32	,	,	PUNCT
aji-148	196	33	and	and	CCONJ
aji-148	196	34	artificial	artificial	ADJ
aji-148	196	35	intelligence	intelligence	NOUN
aji-148	196	36	in	in	ADP
aji-148	196	37	our	our	PRON
aji-148	196	38	laboratory	laboratory	NOUN
aji-148	196	39	”	"	PUNCT
aji-148	197	1	[	[	X
aji-148	197	2	45	45	NUM
aji-148	197	3	-	-	SYM
aji-148	197	4	50	50	NUM
aji-148	197	5	]	]	PUNCT
aji-148	197	6	.	.	PUNCT
aji-148	198	1	“	"	PUNCT
aji-148	198	2	moreover	moreover	ADV
aji-148	198	3	,	,	PUNCT
aji-148	198	4	precision	precision	NOUN
aji-148	198	5	medicine	medicine	NOUN
aji-148	198	6	is	be	AUX
aji-148	198	7	discovering	discover	VERB
aji-148	198	8	driver	driver	NOUN
aji-148	198	9	genes	gene	NOUN
aji-148	198	10	,	,	PUNCT
aji-148	198	11	tumor	tumor	NOUN
aji-148	198	12	proliferation	proliferation	NOUN
aji-148	198	13	,	,	PUNCT
aji-148	198	14	and	and	CCONJ
aji-148	198	15	tumor	tumor	NOUN
aji-148	198	16	metastasis	metastasis	NOUN
aji-148	198	17	genes	gene	NOUN
aji-148	198	18	according	accord	VERB
aji-148	198	19	to	to	ADP
aji-148	198	20	the	the	DET
aji-148	198	21	updated	update	VERB
aji-148	198	22	strategy	strategy	NOUN
aji-148	198	23	”	"	PUNCT
aji-148	199	1	[	[	X
aji-148	199	2	51	51	NUM
aji-148	199	3	]	]	PUNCT
aji-148	199	4	.	.	PUNCT
aji-148	200	1	once	once	SCONJ
aji-148	200	2	we	we	PRON
aji-148	200	3	find	find	VERB
aji-148	200	4	distinct	distinct	ADJ
aji-148	200	5	biomarkers	biomarker	NOUN
aji-148	200	6	in	in	ADP
aji-148	200	7	dna	dna	PROPN
aji-148	200	8	level	level	NOUN
aji-148	200	9	(	(	PUNCT
aji-148	200	10	snp	snp	NOUN
aji-148	200	11	and	and	CCONJ
aji-148	200	12	epigenetics	epigenetic	NOUN
aji-148	200	13	)	)	PUNCT
aji-148	200	14	,	,	PUNCT
aji-148	200	15	rna	rna	NOUN
aji-148	200	16	level	level	NOUN
aji-148	200	17	microrna	microrna	PROPN
aji-148	200	18	,	,	PUNCT
aji-148	200	19	picorna	picorna	PROPN
aji-148	200	20	,	,	PUNCT
aji-148	200	21	non	non	ADJ
aji-148	200	22	-	-	ADJ
aji-148	200	23	coding	code	VERB
aji-148	200	24	rna	rna	NOUN
aji-148	200	25	)	)	PUNCT
aji-148	200	26	,	,	PUNCT
aji-148	200	27	and	and	CCONJ
aji-148	200	28	protein	protein	NOUN
aji-148	200	29	level	level	NOUN
aji-148	200	30	,	,	PUNCT
aji-148	200	31	we	we	PRON
aji-148	200	32	can	can	AUX
aji-148	200	33	develop	develop	VERB
aji-148	200	34	precision	precision	NOUN
aji-148	200	35	medicine	medicine	NOUN
aji-148	200	36	as	as	ADP
aji-148	200	37	fig-3	fig-3	X
aji-148	200	38	to	to	PART
aji-148	200	39	support	support	VERB
aji-148	200	40	immunotherapy	immunotherapy	NOUN
aji-148	200	41	.	.	PUNCT
aji-148	201	1	a.	a.	NOUN
aji-148	201	2	specific	specific	ADJ
aji-148	201	3	personalized	personalize	VERB
aji-148	201	4	combination	combination	NOUN
aji-148	201	5	immunotherapy	immunotherapy	NOUN
aji-148	201	6	can	can	AUX
aji-148	201	7	be	be	AUX
aji-148	201	8	discovered	discover	VERB
aji-148	201	9	“	"	PUNCT
aji-148	201	10	in	in	ADP
aji-148	201	11	the	the	DET
aji-148	201	12	early	early	ADJ
aji-148	201	13	period	period	NOUN
aji-148	201	14	,	,	PUNCT
aji-148	201	15	we	we	PRON
aji-148	201	16	developed	develop	VERB
aji-148	201	17	til	til	SCONJ
aji-148	201	18	culture	culture	NOUN
aji-148	201	19	for	for	ADP
aji-148	201	20	clinical	clinical	ADJ
aji-148	201	21	applications	application	NOUN
aji-148	201	22	by	by	ADP
aji-148	201	23	cultured	cultured	ADJ
aji-148	201	24	til	til	ADJ
aji-148	201	25	infusion	infusion	NOUN
aji-148	201	26	in	in	ADP
aji-148	201	27	vivo	vivo	NOUN
aji-148	201	28	for	for	ADP
aji-148	201	29	adoptive	adoptive	ADJ
aji-148	201	30	cell	cell	NOUN
aji-148	201	31	therapy	therapy	NOUN
aji-148	201	32	(	(	PUNCT
aji-148	201	33	act	act	PROPN
aji-148	201	34	)	)	PUNCT
aji-148	201	35	from	from	ADP
aji-148	201	36	solid	solid	ADJ
aji-148	201	37	tumors	tumor	NOUN
aji-148	201	38	.	.	PUNCT
aji-148	202	1	after	after	ADP
aji-148	202	2	twenty	twenty	NUM
aji-148	202	3	-	-	PUNCT
aji-148	202	4	five	five	NUM
aji-148	202	5	efforts	effort	NOUN
aji-148	202	6	,	,	PUNCT
aji-148	202	7	we	we	PRON
aji-148	202	8	successfully	successfully	ADV
aji-148	202	9	developed	develop	VERB
aji-148	202	10	our	our	PRON
aji-148	202	11	laboratory	laboratory	NOUN
aji-148	202	12	's	's	PART
aji-148	202	13	single	single	ADJ
aji-148	202	14	-	-	PUNCT
aji-148	202	15	cell	cell	NOUN
aji-148	202	16	techniques	technique	NOUN
aji-148	202	17	,	,	PUNCT
aji-148	202	18	clinical	clinical	ADJ
aji-148	202	19	genomics	genomic	NOUN
aji-148	202	20	,	,	PUNCT
aji-148	202	21	and	and	CCONJ
aji-148	202	22	artificial	artificial	ADJ
aji-148	202	23	intelligence	intelligence	NOUN
aji-148	202	24	.	.	PUNCT
aji-148	203	1	after	after	ADP
aji-148	203	2	,	,	PUNCT
aji-148	203	3	we	we	PRON
aji-148	203	4	used	use	VERB
aji-148	203	5	single	single	ADJ
aji-148	203	6	-	-	PUNCT
aji-148	203	7	cell	cell	NOUN
aji-148	203	8	genomics	genomics	NOUN
aji-148	203	9	analysis	analysis	NOUN
aji-148	203	10	to	to	PART
aji-148	203	11	discover	discover	VERB
aji-148	203	12	a	a	DET
aji-148	203	13	set	set	NOUN
aji-148	203	14	of	of	ADP
aji-148	203	15	upregulated	upregulated	ADJ
aji-148	203	16	quiescent	quiescent	ADJ
aji-148	203	17	genes	gene	NOUN
aji-148	203	18	such	such	ADJ
aji-148	203	19	as	as	ADP
aji-148	203	20	tob	tob	PROPN
aji-148	203	21	,	,	PUNCT
aji-148	203	22	lklf	lklf	NOUN
aji-148	203	23	,	,	PUNCT
aji-148	203	24	tgf	tgf	PROPN
aji-148	203	25	-	-	PUNCT
aji-148	203	26	β	β	PROPN
aji-148	203	27	,	,	PUNCT
aji-148	203	28	erf	erf	NOUN
aji-148	203	29	,	,	PUNCT
aji-148	203	30	and	and	CCONJ
aji-148	203	31	rest	rest	NOUN
aji-148	203	32	/	/	SYM
aji-148	203	33	nrsf	nrsf	NOUN
aji-148	203	34	from	from	ADP
aji-148	203	35	the	the	DET
aji-148	203	36	t	t	PROPN
aji-148	203	37	-	-	PUNCT
aji-148	203	38	cells	cell	NOUN
aji-148	203	39	”	"	PUNCT
aji-148	204	1	[	[	X
aji-148	204	2	52	52	NUM
aji-148	204	3	-	-	SYM
aji-148	204	4	55	55	NUM
aji-148	204	5	]	]	PUNCT
aji-148	204	6	.	.	PUNCT
aji-148	205	1	“	"	PUNCT
aji-148	205	2	moreover	moreover	ADV
aji-148	205	3	,	,	PUNCT
aji-148	205	4	after	after	ADP
aji-148	205	5	thirty	thirty	NUM
aji-148	205	6	years	year	NOUN
aji-148	205	7	of	of	ADP
aji-148	205	8	effort	effort	NOUN
aji-148	205	9	,	,	PUNCT
aji-148	205	10	we	we	PRON
aji-148	205	11	know	know	VERB
aji-148	205	12	that	that	SCONJ
aji-148	205	13	til	til	ADV
aji-148	205	14	is	be	AUX
aji-148	205	15	a	a	DET
aji-148	205	16	group	group	NOUN
aji-148	205	17	of	of	ADP
aji-148	205	18	heterogeneous	heterogeneous	ADJ
aji-148	205	19	immune	immune	ADJ
aji-148	205	20	cells	cell	NOUN
aji-148	205	21	,	,	PUNCT
aji-148	205	22	so	so	SCONJ
aji-148	205	23	we	we	PRON
aji-148	205	24	can	can	AUX
aji-148	205	25	perform	perform	VERB
aji-148	205	26	ex	ex	PRON
aji-148	205	27	vivo	vivo	ADJ
aji-148	205	28	heterogeneous	heterogeneous	ADJ
aji-148	205	29	til	til	SCONJ
aji-148	205	30	determining	determine	VERB
aji-148	205	31	immune	immune	ADJ
aji-148	205	32	characteristics	characteristic	NOUN
aji-148	205	33	to	to	PART
aji-148	205	34	kill	kill	VERB
aji-148	205	35	autologous	autologous	ADJ
aji-148	205	36	tumor	tumor	NOUN
aji-148	205	37	cells	cell	NOUN
aji-148	205	38	and	and	CCONJ
aji-148	205	39	then	then	ADV
aji-148	205	40	treat	treat	VERB
aji-148	205	41	the	the	DET
aji-148	205	42	tumor	tumor	NOUN
aji-148	205	43	patients	patient	NOUN
aji-148	205	44	based	base	VERB
aji-148	205	45	on	on	ADP
aji-148	205	46	immune	immune	ADJ
aji-148	205	47	characteristics	characteristic	NOUN
aji-148	205	48	for	for	ADP
aji-148	205	49	the	the	DET
aji-148	205	50	tumor	tumor	NOUN
aji-148	205	51	diseases	disease	NOUN
aji-148	205	52	[	[	X
aji-148	205	53	56	56	NUM
aji-148	205	54	]	]	PUNCT
aji-148	205	55	.	.	PUNCT
aji-148	206	1	now	now	ADV
aji-148	206	2	we	we	PRON
aji-148	206	3	can	can	AUX
aji-148	206	4	measure	measure	VERB
aji-148	206	5	quiescent	quiescent	ADJ
aji-148	206	6	status	status	NOUN
aji-148	206	7	in	in	ADP
aji-148	206	8	the	the	DET
aji-148	206	9	heterogeneous	heterogeneous	ADJ
aji-148	206	10	immune	immune	ADJ
aji-148	206	11	cells	cell	NOUN
aji-148	206	12	such	such	ADJ
aji-148	206	13	as	as	ADP
aji-148	206	14	cd3	cd3	PROPN
aji-148	206	15	+	+	PROPN
aji-148	206	16	t	t	NOUN
aji-148	206	17	-	-	PUNCT
aji-148	206	18	cell	cell	NOUN
aji-148	206	19	(	(	PUNCT
aji-148	206	20	cd8	cd8	PROPN
aji-148	206	21	+	+	PROPN
aji-148	206	22	t	t	PROPN
aji-148	206	23	-	-	PUNCT
aji-148	206	24	cell	cell	NOUN
aji-148	206	25	and	and	CCONJ
aji-148	206	26	cd4	cd4	PROPN
aji-148	206	27	+	+	PROPN
aji-148	206	28	t	t	NOUN
aji-148	206	29	-	-	PUNCT
aji-148	206	30	cell	cell	NOUN
aji-148	206	31	)	)	PUNCT
aji-148	206	32	,	,	PUNCT
aji-148	206	33	cd19	cd19	PROPN
aji-148	206	34	+	+	NUM
aji-148	206	35	bcell	bcell	NOUN
aji-148	206	36	(	(	PUNCT
aji-148	206	37	tumor	tumor	NOUN
aji-148	206	38	-	-	PUNCT
aji-148	206	39	infiltrating	infiltrate	VERB
aji-148	206	40	b	b	NOUN
aji-148	206	41	-	-	PUNCT
aji-148	206	42	cells	cell	NOUN
aji-148	206	43	,	,	PUNCT
aji-148	206	44	til	til	NOUN
aji-148	206	45	-	-	PUNCT
aji-148	206	46	b	b	NOUN
aji-148	206	47	)	)	PUNCT
aji-148	206	48	,	,	PUNCT
aji-148	206	49	cd16+/cd56	cd16+/cd56	PROPN
aji-148	206	50	+	+	NOUN
aji-148	206	51	nk	nk	PROPN
aji-148	206	52	cell	cell	NOUN
aji-148	206	53	(	(	PUNCT
aji-148	206	54	natural	natural	ADJ
aji-148	206	55	killer	killer	NOUN
aji-148	206	56	cell	cell	NOUN
aji-148	206	57	)	)	PUNCT
aji-148	206	58	,	,	PUNCT
aji-148	206	59	cd16+/cd56+/cd3	cd16+/cd56+/cd3	VERB
aji-148	206	60	+	+	CCONJ
aji-148	206	61	nkt	nkt	NOUN
aji-148	206	62	cell	cell	NOUN
aji-148	206	63	(	(	PUNCT
aji-148	206	64	natural	natural	ADJ
aji-148	206	65	killer	killer	NOUN
aji-148	206	66	tcell	tcell	NOUN
aji-148	206	67	)	)	PUNCT
aji-148	206	68	,	,	PUNCT
aji-148	206	69	and	and	CCONJ
aji-148	206	70	other	other	ADJ
aji-148	206	71	immune	immune	ADJ
aji-148	206	72	-	-	PUNCT
aji-148	206	73	cells	cell	NOUN
aji-148	206	74	(	(	PUNCT
aji-148	206	75	macrophage	macrophage	ADJ
aji-148	206	76	and	and	CCONJ
aji-148	206	77	neutrophil	neutrophil	ADJ
aji-148	206	78	)	)	PUNCT
aji-148	206	79	.	.	PUNCT
aji-148	207	1	finally	finally	ADV
aji-148	207	2	,	,	PUNCT
aji-148	207	3	the	the	DET
aji-148	207	4	specific	specific	ADJ
aji-148	207	5	immune	immune	ADJ
aji-148	207	6	cells	cell	NOUN
aji-148	207	7	that	that	PRON
aji-148	207	8	have	have	AUX
aji-148	207	9	been	be	AUX
aji-148	207	10	specifically	specifically	ADV
aji-148	207	11	contacted	contact	VERB
aji-148	207	12	to	to	PART
aji-148	207	13	correspond	correspond	VERB
aji-148	207	14	with	with	ADP
aji-148	207	15	the	the	DET
aji-148	207	16	tumor	tumor	NOUN
aji-148	207	17	antigen	antigen	NOUN
aji-148	207	18	of	of	ADP
aji-148	207	19	tumor	tumor	NOUN
aji-148	207	20	cells	cell	NOUN
aji-148	207	21	will	will	AUX
aji-148	207	22	be	be	AUX
aji-148	207	23	cultured	cultured	ADJ
aji-148	207	24	for	for	ADP
aji-148	207	25	precision	precision	NOUN
aji-148	207	26	immunotherapy	immunotherapy	NOUN
aji-148	207	27	.	.	PUNCT
aji-148	208	1	as	as	SCONJ
aji-148	208	2	we	we	PRON
aji-148	208	3	all	all	PRON
aji-148	208	4	know	know	VERB
aji-148	208	5	above	above	ADV
aji-148	208	6	,	,	PUNCT
aji-148	208	7	if	if	SCONJ
aji-148	208	8	we	we	PRON
aji-148	208	9	discover	discover	VERB
aji-148	208	10	the	the	DET
aji-148	208	11	higher	high	ADJ
aji-148	208	12	expression	expression	NOUN
aji-148	208	13	of	of	ADP
aji-148	208	14	checkpoint	checkpoint	NOUN
aji-148	208	15	-	-	PUNCT
aji-148	208	16	inhibiting	inhibit	VERB
aji-148	208	17	molecules	molecule	NOUN
aji-148	208	18	such	such	ADJ
aji-148	208	19	as	as	ADP
aji-148	208	20	pd-1	pd-1	NOUN
aji-148	208	21	,	,	PUNCT
aji-148	208	22	which	which	PRON
aji-148	208	23	blocks	block	VERB
aji-148	208	24	immune	immune	ADJ
aji-148	208	25	cells	cell	NOUN
aji-148	208	26	,	,	PUNCT
aji-148	208	27	we	we	PRON
aji-148	208	28	can	can	AUX
aji-148	208	29	also	also	ADV
aji-148	208	30	further	far	ADV
aji-148	208	31	stimulate	stimulate	VERB
aji-148	208	32	immune	immune	ADJ
aji-148	208	33	cells	cell	NOUN
aji-148	208	34	with	with	ADP
aji-148	208	35	pd-1	pd-1	VERB
aji-148	208	36	inhibitors	inhibitor	NOUN
aji-148	208	37	to	to	PART
aji-148	208	38	combine	combine	VERB
aji-148	208	39	with	with	ADP
aji-148	208	40	the	the	DET
aji-148	208	41	specific	specific	ADJ
aji-148	208	42	immune	immune	ADJ
aji-148	208	43	cells	cell	NOUN
aji-148	208	44	for	for	ADP
aji-148	208	45	personalized	personalized	ADJ
aji-148	208	46	immunotherapy	immunotherapy	NOUN
aji-148	208	47	”	"	PUNCT
aji-148	209	1	[	[	X
aji-148	209	2	57	57	NUM
aji-148	209	3	-	-	SYM
aji-148	209	4	58	58	NUM
aji-148	209	5	]	]	PUNCT
aji-148	209	6	.	.	PUNCT
aji-148	210	1	b.	b.	PROPN
aji-148	211	1	molecular	molecular	ADJ
aji-148	211	2	therapeutic	therapeutic	ADJ
aji-148	211	3	targeting	targeting	NOUN
aji-148	211	4	can	can	AUX
aji-148	211	5	be	be	AUX
aji-148	211	6	discovered	discover	VERB
aji-148	211	7	molecular	molecular	ADJ
aji-148	211	8	targeted	target	VERB
aji-148	211	9	therapies	therapy	NOUN
aji-148	211	10	are	be	AUX
aji-148	211	11	advanced	advanced	ADJ
aji-148	211	12	therapeutic	therapeutic	ADJ
aji-148	211	13	techniques	technique	NOUN
aji-148	211	14	that	that	PRON
aji-148	211	15	interfere	interfere	VERB
aji-148	211	16	with	with	ADP
aji-148	211	17	specific	specific	ADJ
aji-148	211	18	molecules	molecule	NOUN
aji-148	211	19	to	to	PART
aji-148	211	20	block	block	VERB
aji-148	211	21	cancer	cancer	NOUN
aji-148	211	22	growth	growth	NOUN
aji-148	211	23	,	,	PUNCT
aji-148	211	24	progression	progression	NOUN
aji-148	211	25	,	,	PUNCT
aji-148	211	26	and	and	CCONJ
aji-148	211	27	metastasis	metastasis	NOUN
aji-148	211	28	[	[	PUNCT
aji-148	211	29	59	59	NUM
aji-148	211	30	-	-	SYM
aji-148	211	31	60	60	NUM
aji-148	211	32	]	]	PUNCT
aji-148	211	33	.	.	PUNCT
aji-148	212	1	now	now	ADV
aji-148	212	2	,	,	PUNCT
aji-148	212	3	molecular	molecular	ADJ
aji-148	212	4	targeted	target	VERB
aji-148	212	5	therapies	therapy	NOUN
aji-148	212	6	approved	approve	VERB
aji-148	212	7	by	by	ADP
aji-148	212	8	the	the	DET
aji-148	212	9	food	food	NOUN
aji-148	212	10	and	and	CCONJ
aji-148	212	11	drug	drug	PROPN
aji-148	212	12	administration	administration	PROPN
aji-148	212	13	(	(	PUNCT
aji-148	212	14	fda	fda	PROPN
aji-148	212	15	)	)	PUNCT
aji-148	212	16	have	have	AUX
aji-148	212	17	demonstrated	demonstrate	VERB
aji-148	212	18	remarkable	remarkable	ADJ
aji-148	212	19	clinical	clinical	ADJ
aji-148	212	20	success	success	NOUN
aji-148	212	21	in	in	ADP
aji-148	212	22	the	the	DET
aji-148	212	23	treatment	treatment	NOUN
aji-148	212	24	of	of	ADP
aji-148	212	25	a	a	DET
aji-148	212	26	li	li	PROPN
aji-148	212	27	and	and	CCONJ
aji-148	212	28	li	li	PROPN
aji-148	212	29	;	;	PUNCT
aji-148	212	30	asian	asian	PROPN
aji-148	212	31	j.	j.	PROPN
aji-148	212	32	immunol	immunol	PROPN
aji-148	212	33	.	.	PROPN
aji-148	212	34	,	,	PUNCT
aji-148	212	35	vol	vol	NOUN
aji-148	212	36	.	.	PROPN
aji-148	213	1	7	7	NUM
aji-148	213	2	,	,	PUNCT
aji-148	213	3	no	no	INTJ
aji-148	213	4	.	.	NOUN
aji-148	213	5	1	1	NUM
aji-148	213	6	,	,	PUNCT
aji-148	213	7	pp	pp	ADJ
aji-148	213	8	.	.	PUNCT
aji-148	214	1	247	247	NUM
aji-148	214	2	-	-	SYM
aji-148	214	3	257	257	NUM
aji-148	214	4	,	,	PUNCT
aji-148	214	5	2024	2024	NUM
aji-148	214	6	;	;	PUNCT
aji-148	214	7	article	article	NOUN
aji-148	214	8	no.aji.126682	no.aji.126682	ADV
aji-148	214	9	253	253	NUM
aji-148	214	10	myriad	myriad	NOUN
aji-148	214	11	of	of	ADP
aji-148	214	12	cancer	cancer	NOUN
aji-148	214	13	types	type	NOUN
aji-148	214	14	,	,	PUNCT
aji-148	214	15	including	include	VERB
aji-148	214	16	breast	breast	NOUN
aji-148	214	17	,	,	PUNCT
aji-148	214	18	leukemia	leukemia	NOUN
aji-148	214	19	,	,	PUNCT
aji-148	214	20	colorectal	colorectal	NOUN
aji-148	214	21	,	,	PUNCT
aji-148	214	22	lung	lung	NOUN
aji-148	214	23	,	,	PUNCT
aji-148	214	24	and	and	CCONJ
aji-148	214	25	ovarian	ovarian	ADJ
aji-148	214	26	cancers	cancer	NOUN
aji-148	214	27	.	.	PUNCT
aji-148	215	1	we	we	PRON
aji-148	215	2	can	can	AUX
aji-148	215	3	also	also	ADV
aji-148	215	4	further	far	ADV
aji-148	215	5	develop	develop	VERB
aji-148	215	6	immune	immune	ADJ
aji-148	215	7	cells	cell	NOUN
aji-148	215	8	with	with	ADP
aji-148	215	9	molecular	molecular	ADJ
aji-148	215	10	targeted	target	VERB
aji-148	215	11	therapies	therapy	NOUN
aji-148	215	12	to	to	PART
aji-148	215	13	combine	combine	VERB
aji-148	215	14	with	with	ADP
aji-148	215	15	specific	specific	ADJ
aji-148	215	16	immune	immune	ADJ
aji-148	215	17	cells	cell	NOUN
aji-148	215	18	to	to	PART
aji-148	215	19	create	create	VERB
aji-148	215	20	personalized	personalized	ADJ
aji-148	215	21	immunotherapy	immunotherapy	NOUN
aji-148	215	22	.	.	PUNCT
aji-148	216	1	c.	c.	PROPN
aji-148	216	2	tme	tme	PROPN
aji-148	216	3	targeting	target	VERB
aji-148	216	4	gene	gene	NOUN
aji-148	216	5	can	can	AUX
aji-148	216	6	be	be	AUX
aji-148	216	7	discovered	discover	VERB
aji-148	216	8	“	"	PUNCT
aji-148	216	9	tumor	tumor	NOUN
aji-148	216	10	microenvironment	microenvironment	NOUN
aji-148	216	11	(	(	PUNCT
aji-148	216	12	tme	tme	NOUN
aji-148	216	13	)	)	PUNCT
aji-148	216	14	and	and	CCONJ
aji-148	216	15	tumor	tumor	NOUN
aji-148	216	16	cells	cell	NOUN
aji-148	216	17	in	in	ADP
aji-148	216	18	tumor	tumor	NOUN
aji-148	216	19	tissue	tissue	NOUN
aji-148	216	20	take	take	VERB
aji-148	216	21	many	many	ADJ
aji-148	216	22	strategies	strategy	NOUN
aji-148	216	23	to	to	PART
aji-148	216	24	evade	evade	VERB
aji-148	216	25	the	the	DET
aji-148	216	26	host	host	NOUN
aji-148	216	27	immune	immune	ADJ
aji-148	216	28	response	response	NOUN
aji-148	216	29	by	by	ADP
aji-148	216	30	creating	create	VERB
aji-148	216	31	many	many	ADJ
aji-148	216	32	immune	immune	ADJ
aji-148	216	33	-	-	PUNCT
aji-148	216	34	suppressive	suppressive	ADJ
aji-148	216	35	factors	factor	NOUN
aji-148	216	36	[	[	X
aji-148	216	37	61	61	NUM
aji-148	216	38	]	]	PUNCT
aji-148	216	39	.	.	PUNCT
aji-148	217	1	thus	thus	ADV
aji-148	217	2	,	,	PUNCT
aji-148	217	3	we	we	PRON
aji-148	217	4	can	can	AUX
aji-148	217	5	use	use	VERB
aji-148	217	6	the	the	DET
aji-148	217	7	strategy	strategy	NOUN
aji-148	217	8	from	from	ADP
aji-148	217	9	tme	tme	PRON
aji-148	217	10	to	to	PART
aji-148	217	11	be	be	AUX
aji-148	217	12	personalized	personalize	VERB
aji-148	217	13	therapy	therapy	NOUN
aji-148	217	14	.	.	PUNCT
aji-148	218	1	tme	tme	PROPN
aji-148	218	2	consists	consist	VERB
aji-148	218	3	of	of	ADP
aji-148	218	4	tissues	tissue	NOUN
aji-148	218	5	,	,	PUNCT
aji-148	218	6	cells	cell	NOUN
aji-148	218	7	,	,	PUNCT
aji-148	218	8	and	and	CCONJ
aji-148	218	9	signaling	signal	VERB
aji-148	218	10	molecules	molecule	NOUN
aji-148	218	11	in	in	ADP
aji-148	218	12	tumor	tumor	NOUN
aji-148	218	13	tissue	tissue	NOUN
aji-148	218	14	,	,	PUNCT
aji-148	218	15	affecting	affect	VERB
aji-148	218	16	the	the	DET
aji-148	218	17	immune	immune	ADJ
aji-148	218	18	response	response	NOUN
aji-148	218	19	to	to	ADP
aji-148	218	20	tumor	tumor	NOUN
aji-148	218	21	cells	cell	NOUN
aji-148	218	22	.	.	PUNCT
aji-148	219	1	furthermore	furthermore	ADV
aji-148	219	2	,	,	PUNCT
aji-148	219	3	tme	tme	X
aji-148	219	4	elements	element	NOUN
aji-148	219	5	of	of	ADP
aji-148	219	6	tissues	tissue	NOUN
aji-148	219	7	,	,	PUNCT
aji-148	219	8	cells	cell	NOUN
aji-148	219	9	,	,	PUNCT
aji-148	219	10	and	and	CCONJ
aji-148	219	11	molecule	molecule	NOUN
aji-148	219	12	factors	factor	NOUN
aji-148	219	13	include	include	VERB
aji-148	219	14	those	those	PRON
aji-148	219	15	during	during	ADP
aji-148	219	16	the	the	DET
aji-148	219	17	early	early	ADJ
aji-148	219	18	period	period	NOUN
aji-148	219	19	of	of	ADP
aji-148	219	20	tumor	tumor	NOUN
aji-148	219	21	tissues	tissue	NOUN
aji-148	219	22	and	and	CCONJ
aji-148	219	23	those	those	PRON
aji-148	219	24	in	in	ADP
aji-148	219	25	an	an	DET
aji-148	219	26	aggressive	aggressive	ADJ
aji-148	219	27	period	period	NOUN
aji-148	219	28	in	in	ADP
aji-148	219	29	tumor	tumor	NOUN
aji-148	219	30	tissues	tissue	NOUN
aji-148	219	31	.	.	PUNCT
aji-148	220	1	identifying	identify	VERB
aji-148	220	2	and	and	CCONJ
aji-148	220	3	regulating	regulate	VERB
aji-148	220	4	tme	tme	NOUN
aji-148	220	5	cells	cell	NOUN
aji-148	220	6	and	and	CCONJ
aji-148	220	7	regulating	regulate	VERB
aji-148	220	8	molecules	molecule	NOUN
aji-148	220	9	such	such	ADJ
aji-148	220	10	as	as	ADP
aji-148	220	11	extracellular	extracellular	ADJ
aji-148	220	12	matrix	matrix	NOUN
aji-148	220	13	(	(	PUNCT
aji-148	220	14	ecm	ecm	PROPN
aji-148	220	15	)	)	PUNCT
aji-148	220	16	and	and	CCONJ
aji-148	220	17	pathways	pathway	NOUN
aji-148	220	18	such	such	ADJ
aji-148	220	19	as	as	ADP
aji-148	220	20	adenosine	adenosine	NOUN
aji-148	220	21	(	(	PUNCT
aji-148	220	22	ado	ado	NOUN
aji-148	220	23	)	)	PUNCT
aji-148	220	24	and	and	CCONJ
aji-148	220	25	indole-2,3	indole-2,3	NOUN
aji-148	220	26	-	-	PUNCT
aji-148	220	27	dioxygenase	dioxygenase	NOUN
aji-148	220	28	(	(	PUNCT
aji-148	220	29	ido	ido	PROPN
aji-148	220	30	)	)	PUNCT
aji-148	220	31	may	may	AUX
aji-148	220	32	guide	guide	VERB
aji-148	220	33	a	a	DET
aji-148	220	34	new	new	ADJ
aji-148	220	35	generation	generation	NOUN
aji-148	220	36	of	of	ADP
aji-148	220	37	precision	precision	NOUN
aji-148	220	38	medicine	medicine	NOUN
aji-148	220	39	so	so	SCONJ
aji-148	220	40	that	that	SCONJ
aji-148	220	41	we	we	PRON
aji-148	220	42	can	can	AUX
aji-148	220	43	use	use	VERB
aji-148	220	44	tme	tme	NOUN
aji-148	220	45	targeting	target	VERB
aji-148	220	46	components	component	NOUN
aji-148	220	47	to	to	PART
aji-148	220	48	combine	combine	VERB
aji-148	220	49	with	with	ADP
aji-148	220	50	the	the	DET
aji-148	220	51	specific	specific	ADJ
aji-148	220	52	immune	immune	ADJ
aji-148	220	53	cells	cell	NOUN
aji-148	220	54	to	to	ADP
aji-148	220	55	personalized	personalized	ADJ
aji-148	220	56	immunotherapy	immunotherapy	NOUN
aji-148	220	57	”	"	PUNCT
aji-148	221	1	[	[	X
aji-148	221	2	5	5	NUM
aji-148	221	3	]	]	PUNCT
aji-148	221	4	.	.	PUNCT
aji-148	222	1	d.	d.	PROPN
aji-148	222	2	epigenetics	epigenetic	NOUN
aji-148	222	3	targeting	target	VERB
aji-148	222	4	can	can	AUX
aji-148	222	5	be	be	AUX
aji-148	222	6	discovered	discover	VERB
aji-148	222	7	epigenetic	epigenetic	ADJ
aji-148	222	8	therapy	therapy	NOUN
aji-148	222	9	is	be	AUX
aji-148	222	10	based	base	VERB
aji-148	222	11	on	on	ADP
aji-148	222	12	methylation	methylation	NOUN
aji-148	222	13	assay	assay	NOUN
aji-148	222	14	and	and	CCONJ
aji-148	222	15	ptm	ptm	PROPN
aji-148	222	16	histone	histone	PROPN
aji-148	222	17	assay	assay	VERB
aji-148	223	1	[	[	X
aji-148	223	2	62	62	NUM
aji-148	223	3	-	-	SYM
aji-148	223	4	65	65	NUM
aji-148	223	5	]	]	PUNCT
aji-148	223	6	.	.	PUNCT
aji-148	224	1	methylated	methylate	VERB
aji-148	224	2	cytosines	cytosine	NOUN
aji-148	224	3	recruit	recruit	NOUN
aji-148	224	4	protein	protein	NOUN
aji-148	224	5	complexes	complex	NOUN
aji-148	224	6	that	that	PRON
aji-148	224	7	promote	promote	VERB
aji-148	224	8	functionally	functionally	ADV
aji-148	224	9	inactive	inactive	ADJ
aji-148	224	10	heterochromatin	heterochromatin	NOUN
aji-148	224	11	under	under	ADP
aji-148	224	12	a	a	DET
aji-148	224	13	global	global	ADJ
aji-148	224	14	decrease	decrease	NOUN
aji-148	224	15	in	in	ADP
aji-148	224	16	dna	dna	PROPN
aji-148	224	17	methylation	methylation	NOUN
aji-148	224	18	,	,	PUNCT
aji-148	224	19	such	such	ADJ
aji-148	224	20	as	as	ADP
aji-148	224	21	5	5	NUM
aji-148	224	22	-	-	PUNCT
aji-148	224	23	azacitidine	azacitidine	ADJ
aji-148	224	24	(	(	PUNCT
aji-148	224	25	aza	aza	NOUN
aji-148	224	26	)	)	PUNCT
aji-148	224	27	and	and	CCONJ
aji-148	224	28	decitabine	decitabine	NOUN
aji-148	224	29	(	(	PUNCT
aji-148	224	30	dec	dec	PROPN
aji-148	224	31	)	)	PUNCT
aji-148	224	32	,	,	PUNCT
aji-148	224	33	by	by	ADP
aji-148	224	34	inhibiting	inhibit	VERB
aji-148	224	35	dnmt1	dnmt1	NOUN
aji-148	224	36	.	.	PUNCT
aji-148	225	1	epigenetic	epigenetic	ADJ
aji-148	225	2	therapy	therapy	NOUN
aji-148	225	3	based	base	VERB
aji-148	225	4	on	on	ADP
aji-148	225	5	ptm	ptm	PROPN
aji-148	225	6	histone	histone	PROPN
aji-148	225	7	assay	assay	NOUN
aji-148	225	8	is	be	AUX
aji-148	225	9	hdac	hdac	NOUN
aji-148	225	10	inhabitation	inhabitation	NOUN
aji-148	225	11	,	,	PUNCT
aji-148	225	12	which	which	PRON
aji-148	225	13	removes	remove	VERB
aji-148	225	14	the	the	DET
aji-148	225	15	acetyl	acetyl	NOUN
aji-148	225	16	groups	group	NOUN
aji-148	225	17	from	from	ADP
aji-148	225	18	the	the	DET
aji-148	225	19	lysine	lysine	NOUN
aji-148	225	20	residues	residue	NOUN
aji-148	225	21	to	to	PART
aji-148	225	22	apply	apply	VERB
aji-148	225	23	for	for	ADP
aji-148	225	24	an	an	DET
aji-148	225	25	option	option	NOUN
aji-148	225	26	for	for	ADP
aji-148	225	27	tumor	tumor	NOUN
aji-148	225	28	treatment	treatment	NOUN
aji-148	225	29	so	so	SCONJ
aji-148	225	30	that	that	SCONJ
aji-148	225	31	we	we	PRON
aji-148	225	32	can	can	AUX
aji-148	225	33	use	use	VERB
aji-148	225	34	epigenetic	epigenetic	ADJ
aji-148	225	35	therapy	therapy	NOUN
aji-148	225	36	to	to	PART
aji-148	225	37	combine	combine	VERB
aji-148	225	38	with	with	ADP
aji-148	225	39	the	the	DET
aji-148	225	40	specific	specific	ADJ
aji-148	225	41	immune	immune	ADJ
aji-148	225	42	cells	cell	NOUN
aji-148	225	43	for	for	ADP
aji-148	225	44	personalized	personalized	ADJ
aji-148	225	45	immunotherapy	immunotherapy	NOUN
aji-148	225	46	.	.	PUNCT
aji-148	226	1	e.	e.	PROPN
aji-148	226	2	specific	specific	PROPN
aji-148	226	3	chemotherapy	chemotherapy	NOUN
aji-148	226	4	can	can	AUX
aji-148	226	5	be	be	AUX
aji-148	226	6	discovered	discover	VERB
aji-148	226	7	customized	customized	ADJ
aji-148	226	8	chemotherapy	chemotherapy	NOUN
aji-148	226	9	has	have	AUX
aji-148	226	10	now	now	ADV
aji-148	226	11	been	be	AUX
aji-148	226	12	applied	apply	VERB
aji-148	226	13	to	to	ADP
aji-148	226	14	the	the	DET
aji-148	226	15	field	field	NOUN
aji-148	226	16	of	of	ADP
aji-148	226	17	cancer	cancer	NOUN
aji-148	227	1	[	[	X
aji-148	227	2	66	66	NUM
aji-148	227	3	-	-	SYM
aji-148	227	4	70	70	NUM
aji-148	227	5	]	]	PUNCT
aji-148	227	6	.	.	PUNCT
aji-148	228	1	according	accord	VERB
aji-148	228	2	to	to	ADP
aji-148	228	3	genomic	genomic	ADJ
aji-148	228	4	data	datum	NOUN
aji-148	228	5	,	,	PUNCT
aji-148	228	6	we	we	PRON
aji-148	228	7	can	can	AUX
aji-148	228	8	also	also	ADV
aji-148	228	9	use	use	VERB
aji-148	228	10	personalized	personalized	ADJ
aji-148	228	11	chemotherapy	chemotherapy	NOUN
aji-148	228	12	to	to	PART
aji-148	228	13	develop	develop	VERB
aji-148	228	14	immunotherapy	immunotherapy	NOUN
aji-148	228	15	with	with	ADP
aji-148	228	16	specific	specific	ADJ
aji-148	228	17	immune	immune	ADJ
aji-148	228	18	cells	cell	NOUN
aji-148	228	19	and	and	CCONJ
aji-148	228	20	specific	specific	ADJ
aji-148	228	21	chemotherapy	chemotherapy	NOUN
aji-148	228	22	for	for	ADP
aji-148	228	23	personalized	personalized	ADJ
aji-148	228	24	immunotherapy	immunotherapy	NOUN
aji-148	228	25	.	.	PUNCT
aji-148	229	1	6	6	NUM
aji-148	229	2	.	.	X
aji-148	229	3	conclusion	conclusion	NOUN
aji-148	229	4	the	the	DET
aji-148	229	5	"	"	PUNCT
aji-148	229	6	foe	foe	NOUN
aji-148	229	7	"	"	PUNCT
aji-148	229	8	or	or	CCONJ
aji-148	229	9	"	"	PUNCT
aji-148	229	10	friend	friend	NOUN
aji-148	229	11	"	"	PUNCT
aji-148	229	12	of	of	ADP
aji-148	229	13	chemotherapy	chemotherapy	NOUN
aji-148	229	14	combined	combine	VERB
aji-148	229	15	with	with	ADP
aji-148	229	16	immunotherapy	immunotherapy	NOUN
aji-148	229	17	is	be	AUX
aji-148	229	18	a	a	DET
aji-148	229	19	long	long	ADJ
aji-148	229	20	-	-	PUNCT
aji-148	229	21	term	term	NOUN
aji-148	229	22	puzzling	puzzle	VERB
aji-148	229	23	issue	issue	NOUN
aji-148	229	24	.	.	PUNCT
aji-148	230	1	cytotoxic	cytotoxic	ADJ
aji-148	230	2	chemotherapy	chemotherapy	NOUN
aji-148	230	3	is	be	AUX
aji-148	230	4	considered	consider	VERB
aji-148	230	5	to	to	PART
aji-148	230	6	be	be	AUX
aji-148	230	7	immunosuppressive	immunosuppressive	ADJ
aji-148	230	8	while	while	SCONJ
aji-148	230	9	it	it	PRON
aji-148	230	10	is	be	AUX
aji-148	230	11	recommended	recommend	VERB
aji-148	230	12	to	to	PART
aji-148	230	13	support	support	VERB
aji-148	230	14	immunotherapy	immunotherapy	NOUN
aji-148	230	15	in	in	ADP
aji-148	230	16	clinical	clinical	ADJ
aji-148	230	17	application	application	NOUN
aji-148	230	18	,	,	PUNCT
aji-148	230	19	to	to	PART
aji-148	230	20	increase	increase	VERB
aji-148	230	21	act	act	NOUN
aji-148	230	22	immunotherapy	immunotherapy	NOUN
aji-148	230	23	,	,	PUNCT
aji-148	230	24	and	and	CCONJ
aji-148	230	25	to	to	PART
aji-148	230	26	reduce	reduce	VERB
aji-148	230	27	the	the	DET
aji-148	230	28	side	side	NOUN
aji-148	230	29	effects	effect	NOUN
aji-148	230	30	of	of	ADP
aji-148	230	31	chemotherapy	chemotherapy	NOUN
aji-148	230	32	,	,	PUNCT
aji-148	230	33	we	we	PRON
aji-148	230	34	have	have	AUX
aji-148	230	35	experienced	experience	VERB
aji-148	230	36	several	several	ADJ
aji-148	230	37	decades	decade	NOUN
aji-148	230	38	to	to	PART
aji-148	230	39	study	study	VERB
aji-148	230	40	the	the	DET
aji-148	230	41	mechanism	mechanism	NOUN
aji-148	230	42	using	use	VERB
aji-148	230	43	isolating	isolate	VERB
aji-148	230	44	and	and	CCONJ
aji-148	230	45	culturing	culture	VERB
aji-148	230	46	primary	primary	ADJ
aji-148	230	47	tumor	tumor	NOUN
aji-148	230	48	cells	cell	NOUN
aji-148	230	49	and	and	CCONJ
aji-148	230	50	immune	immune	ADJ
aji-148	230	51	cells	cell	NOUN
aji-148	230	52	from	from	ADP
aji-148	230	53	patient	patient	ADJ
aji-148	230	54	specimens	specimen	NOUN
aji-148	230	55	such	such	ADJ
aji-148	230	56	as	as	ADP
aji-148	230	57	resected	resect	VERB
aji-148	230	58	solid	solid	ADJ
aji-148	230	59	tumor	tumor	NOUN
aji-148	230	60	tissues	tissue	NOUN
aji-148	230	61	.	.	PUNCT
aji-148	231	1	after	after	ADP
aji-148	231	2	about	about	ADV
aji-148	231	3	30	30	NUM
aji-148	231	4	-	-	SYM
aji-148	231	5	40	40	NUM
aji-148	231	6	years	year	NOUN
aji-148	231	7	of	of	ADP
aji-148	231	8	effort	effort	NOUN
aji-148	231	9	,	,	PUNCT
aji-148	231	10	the	the	DET
aji-148	231	11	optimizing	optimizing	NOUN
aji-148	231	12	combination	combination	NOUN
aji-148	231	13	has	have	AUX
aji-148	231	14	proved	prove	VERB
aji-148	231	15	that	that	SCONJ
aji-148	231	16	chemotherapy	chemotherapy	NOUN
aji-148	231	17	combined	combine	VERB
aji-148	231	18	with	with	ADP
aji-148	231	19	immunotherapy	immunotherapy	NOUN
aji-148	231	20	is	be	AUX
aji-148	231	21	superior	superior	ADJ
aji-148	231	22	to	to	ADP
aji-148	231	23	monotherapy	monotherapy	NOUN
aji-148	231	24	.	.	PUNCT
aji-148	232	1	based	base	VERB
aji-148	232	2	on	on	ADP
aji-148	232	3	our	our	PRON
aji-148	232	4	current	current	ADJ
aji-148	232	5	publications	publication	NOUN
aji-148	232	6	,	,	PUNCT
aji-148	232	7	including	include	VERB
aji-148	232	8	other	other	ADJ
aji-148	232	9	clinical	clinical	ADJ
aji-148	232	10	laboratory	laboratory	NOUN
aji-148	232	11	work	work	NOUN
aji-148	232	12	,	,	PUNCT
aji-148	232	13	the	the	DET
aji-148	232	14	manual	manual	NOUN
aji-148	232	15	introduced	introduce	VERB
aji-148	232	16	four	four	NUM
aji-148	232	17	areas	area	NOUN
aji-148	232	18	of	of	ADP
aji-148	232	19	combination	combination	NOUN
aji-148	232	20	therapy	therapy	NOUN
aji-148	232	21	:	:	PUNCT
aji-148	232	22	lymphodepletion	lymphodepletion	NOUN
aji-148	232	23	(	(	PUNCT
aji-148	232	24	ld	ld	PROPN
aji-148	232	25	)	)	PUNCT
aji-148	232	26	,	,	PUNCT
aji-148	232	27	chemoimmunotherapy	chemoimmunotherapy	NOUN
aji-148	232	28	(	(	PUNCT
aji-148	232	29	ci	ci	NOUN
aji-148	232	30	)	)	PUNCT
aji-148	232	31	,	,	PUNCT
aji-148	232	32	ici	ici	PROPN
aji-148	232	33	combined	combine	VERB
aji-148	232	34	with	with	ADP
aji-148	232	35	immunotherapy	immunotherapy	NOUN
aji-148	232	36	,	,	PUNCT
aji-148	232	37	and	and	CCONJ
aji-148	232	38	precision	precision	NOUN
aji-148	232	39	medicine	medicine	NOUN
aji-148	232	40	(	(	PUNCT
aji-148	232	41	pm	pm	NOUN
aji-148	232	42	)	)	PUNCT
aji-148	232	43	supporting	support	VERB
aji-148	232	44	immunotherapy	immunotherapy	NOUN
aji-148	232	45	as	as	ADP
aji-148	232	46	fig	fig	NOUN
aji-148	232	47	.	.	PUNCT
aji-148	233	1	4	4	X
aji-148	233	2	.	.	X
aji-148	233	3	precision	precision	NOUN
aji-148	233	4	medicine	medicine	NOUN
aji-148	233	5	based	base	VERB
aji-148	233	6	on	on	ADP
aji-148	233	7	patients	patient	NOUN
aji-148	233	8	’	'	PUNCT
aji-148	233	9	information	information	NOUN
aji-148	233	10	includes	include	VERB
aji-148	233	11	patient	patient	ADJ
aji-148	233	12	specimen	speciman	NOUN
aji-148	233	13	biobanks	biobank	NOUN
aji-148	233	14	,	,	PUNCT
aji-148	233	15	single	single	ADJ
aji-148	233	16	-	-	PUNCT
aji-148	233	17	cell	cell	NOUN
aji-148	233	18	technologies	technology	NOUN
aji-148	233	19	,	,	PUNCT
aji-148	233	20	clinical	clinical	ADJ
aji-148	233	21	genomics	genomic	NOUN
aji-148	233	22	,	,	PUNCT
aji-148	233	23	and	and	CCONJ
aji-148	233	24	artificial	artificial	ADJ
aji-148	233	25	intelligence	intelligence	NOUN
aji-148	233	26	to	to	PART
aji-148	233	27	support	support	VERB
aji-148	233	28	combination	combination	NOUN
aji-148	233	29	therapy	therapy	NOUN
aji-148	233	30	.	.	PUNCT
aji-148	234	1	based	base	VERB
aji-148	234	2	on	on	ADP
aji-148	234	3	30	30	NUM
aji-148	234	4	-	-	SYM
aji-148	234	5	40	40	NUM
aji-148	234	6	years	year	NOUN
aji-148	234	7	of	of	ADP
aji-148	234	8	r&d	r&d	NOUN
aji-148	234	9	to	to	PART
aji-148	234	10	improve	improve	VERB
aji-148	234	11	patient	patient	ADJ
aji-148	234	12	immunotherapy	immunotherapy	NOUN
aji-148	234	13	,	,	PUNCT
aji-148	234	14	now	now	ADV
aji-148	234	15	is	be	AUX
aji-148	234	16	an	an	DET
aji-148	234	17	excellent	excellent	ADJ
aji-148	234	18	time	time	NOUN
aji-148	234	19	to	to	PART
aji-148	234	20	define	define	VERB
aji-148	234	21	combination	combination	NOUN
aji-148	234	22	therapy	therapy	NOUN
aji-148	234	23	and	and	CCONJ
aji-148	234	24	evaluate	evaluate	VERB
aji-148	234	25	its	its	PRON
aji-148	234	26	efficacy	efficacy	NOUN
aji-148	234	27	in	in	ADP
aji-148	234	28	oncological	oncological	ADJ
aji-148	234	29	diseases	disease	NOUN
aji-148	234	30	.	.	PUNCT
aji-148	235	1	disclaimer	disclaimer	NOUN
aji-148	235	2	(	(	PUNCT
aji-148	235	3	artificial	artificial	ADJ
aji-148	235	4	intelligence	intelligence	NOUN
aji-148	235	5	)	)	PUNCT
aji-148	235	6	author(s	author(s	NOUN
aji-148	235	7	)	)	PUNCT
aji-148	235	8	hereby	hereby	ADV
aji-148	235	9	declares	declare	VERB
aji-148	235	10	that	that	SCONJ
aji-148	235	11	no	no	PRON
aji-148	235	12	generative	generative	NOUN
aji-148	235	13	ai	ai	VERB
aji-148	235	14	technologies	technology	NOUN
aji-148	235	15	such	such	ADJ
aji-148	235	16	as	as	ADP
aji-148	235	17	large	large	ADJ
aji-148	235	18	language	language	NOUN
aji-148	235	19	models	model	NOUN
aji-148	235	20	(	(	PUNCT
aji-148	235	21	chatgpt	chatgpt	NOUN
aji-148	235	22	,	,	PUNCT
aji-148	235	23	copilot	copilot	NOUN
aji-148	235	24	,	,	PUNCT
aji-148	235	25	etc	etc	X
aji-148	235	26	)	)	PUNCT
aji-148	235	27	and	and	CCONJ
aji-148	235	28	text	text	NOUN
aji-148	235	29	-	-	PUNCT
aji-148	235	30	to	to	ADP
aji-148	235	31	-	-	PUNCT
aji-148	235	32	image	image	NOUN
aji-148	235	33	generators	generator	NOUN
aji-148	235	34	have	have	AUX
aji-148	235	35	been	be	AUX
aji-148	235	36	used	use	VERB
aji-148	235	37	during	during	ADP
aji-148	235	38	writing	writing	NOUN
aji-148	235	39	or	or	CCONJ
aji-148	235	40	editing	editing	NOUN
aji-148	235	41	of	of	ADP
aji-148	235	42	this	this	DET
aji-148	235	43	manuscript	manuscript	NOUN
aji-148	235	44	.	.	PUNCT
aji-148	236	1	details	detail	NOUN
aji-148	236	2	of	of	ADP
aji-148	236	3	the	the	DET
aji-148	236	4	machine	machine	NOUN
aji-148	236	5	-	-	PUNCT
aji-148	236	6	learning	learning	NOUN
aji-148	236	7	(	(	PUNCT
aji-148	236	8	ai	ai	NOUN
aji-148	236	9	)	)	PUNCT
aji-148	236	10	usage	usage	NOUN
aji-148	236	11	is	be	AUX
aji-148	236	12	given	give	VERB
aji-148	236	13	below	below	ADP
aji-148	236	14	:	:	PUNCT
aji-148	236	15	1	1	NUM
aji-148	236	16	.	.	NOUN
aji-148	236	17	cytoscape	cytoscape	NOUN
aji-148	236	18	platform	platform	NOUN
aji-148	236	19	integrated	integrate	VERB
aji-148	236	20	by	by	ADP
aji-148	236	21	topology	topology	NOUN
aji-148	236	22	algorithm	algorithm	NOUN
aji-148	236	23	.	.	PUNCT
aji-148	237	1	2	2	X
aji-148	237	2	.	.	X
aji-148	237	3	galaxy	galaxy	NOUN
aji-148	237	4	server	server	NOUN
aji-148	237	5	for	for	ADP
aji-148	237	6	next	next	ADJ
aji-148	237	7	generation	generation	NOUN
aji-148	237	8	sequencing	sequence	VERB
aji-148	237	9	analysis	analysis	NOUN
aji-148	237	10	.	.	PUNCT
aji-148	238	1	3	3	X
aji-148	238	2	.	.	X
aji-148	238	3	gene	gene	NOUN
aji-148	238	4	chip	chip	NOUN
aji-148	238	5	expression	expression	NOUN
aji-148	238	6	console	console	NOUN
aji-148	238	7	for	for	ADP
aji-148	238	8	microarray	microarray	NOUN
aji-148	238	9	data	datum	NOUN
aji-148	238	10	for	for	ADP
aji-148	238	11	gene	gene	NOUN
aji-148	238	12	expression	expression	NOUN
aji-148	238	13	and	and	CCONJ
aji-148	238	14	brb	brb	AUX
aji-148	238	15	array	array	VERB
aji-148	238	16	tool	tool	NOUN
aji-148	238	17	for	for	ADP
aji-148	238	18	gene	gene	NOUN
aji-148	238	19	expression	expression	NOUN
aji-148	238	20	signature	signature	NOUN
aji-148	238	21	(	(	PUNCT
aji-148	238	22	ges	ge	NOUN
aji-148	238	23	)	)	PUNCT
aji-148	238	24	.	.	PUNCT
aji-148	239	1	acknowledgments	acknowledgment	NOUN
aji-148	239	2	under	under	ADP
aji-148	239	3	the	the	DET
aji-148	239	4	support	support	NOUN
aji-148	239	5	of	of	ADP
aji-148	239	6	dr	dr	PROPN
aji-148	239	7	.	.	PROPN
aji-148	239	8	h.	h.	PROPN
aji-148	239	9	d.	d.	PROPN
aji-148	239	10	preisler	preisler	PROPN
aji-148	239	11	,	,	PUNCT
aji-148	239	12	we	we	PRON
aji-148	239	13	have	have	AUX
aji-148	239	14	set	set	VERB
aji-148	239	15	up	up	ADP
aji-148	239	16	a	a	DET
aji-148	239	17	method	method	NOUN
aji-148	239	18	to	to	PART
aji-148	239	19	analyze	analyze	VERB
aji-148	239	20	genomic	genomic	ADJ
aji-148	239	21	profiles	profile	NOUN
aji-148	239	22	from	from	ADP
aji-148	239	23	tumor	tumor	NOUN
aji-148	239	24	cells	cell	NOUN
aji-148	239	25	and	and	CCONJ
aji-148	239	26	til	til	NOUN
aji-148	239	27	.	.	PUNCT
aji-148	240	1	this	this	DET
aji-148	240	2	work	work	NOUN
aji-148	240	3	was	be	AUX
aji-148	240	4	supported	support	VERB
aji-148	240	5	by	by	ADP
aji-148	240	6	li	li	PROPN
aji-148	240	7	and	and	CCONJ
aji-148	240	8	li	li	PROPN
aji-148	240	9	;	;	PUNCT
aji-148	240	10	asian	asian	PROPN
aji-148	240	11	j.	j.	PROPN
aji-148	240	12	immunol	immunol	PROPN
aji-148	240	13	.	.	PROPN
aji-148	240	14	,	,	PUNCT
aji-148	240	15	vol	vol	NOUN
aji-148	240	16	.	.	PROPN
aji-148	241	1	7	7	NUM
aji-148	241	2	,	,	PUNCT
aji-148	241	3	no	no	INTJ
aji-148	241	4	.	.	NOUN
aji-148	241	5	1	1	NUM
aji-148	241	6	,	,	PUNCT
aji-148	241	7	pp	pp	ADJ
aji-148	241	8	.	.	PUNCT
aji-148	242	1	247	247	NUM
aji-148	242	2	-	-	SYM
aji-148	242	3	257	257	NUM
aji-148	242	4	,	,	PUNCT
aji-148	242	5	2024	2024	NUM
aji-148	242	6	;	;	PUNCT
aji-148	242	7	article	article	NOUN
aji-148	242	8	no.aji.126682	no.aji.126682	ADP
aji-148	242	9	254	254	NUM
aji-148	242	10	the	the	DET
aji-148	242	11	national	national	PROPN
aji-148	242	12	cancer	cancer	PROPN
aji-148	242	13	institute	institute	PROPN
aji-148	242	14	irg-91	irg-91	PROPN
aji-148	242	15	-	-	PUNCT
aji-148	242	16	022	022	NUM
aji-148	242	17	-	-	PUNCT
aji-148	242	18	09	09	NUM
aji-148	242	19	,	,	PUNCT
aji-148	242	20	usa	usa	PROPN
aji-148	242	21	(	(	PUNCT
aji-148	242	22	to	to	PART
aji-148	242	23	bl	bl	VERB
aji-148	242	24	)	)	PUNCT
aji-148	242	25	.	.	PUNCT
aji-148	243	1	mentions	mention	NOUN
aji-148	243	2	of	of	ADP
aji-148	243	3	trade	trade	NOUN
aji-148	243	4	names	name	NOUN
aji-148	243	5	or	or	CCONJ
aji-148	243	6	commercial	commercial	ADJ
aji-148	243	7	products	product	NOUN
aji-148	243	8	in	in	ADP
aji-148	243	9	this	this	DET
aji-148	243	10	article	article	NOUN
aji-148	243	11	are	be	AUX
aji-148	243	12	solely	solely	ADV
aji-148	243	13	for	for	ADP
aji-148	243	14	the	the	DET
aji-148	243	15	purpose	purpose	NOUN
aji-148	243	16	of	of	ADP
aji-148	243	17	providing	provide	VERB
aji-148	243	18	specific	specific	ADJ
aji-148	243	19	information	information	NOUN
aji-148	243	20	and	and	CCONJ
aji-148	243	21	do	do	AUX
aji-148	243	22	not	not	PART
aji-148	243	23	imply	imply	VERB
aji-148	243	24	recommendation	recommendation	NOUN
aji-148	243	25	.	.	PUNCT
aji-148	244	1	consent	consent	NOUN
aji-148	244	2	it	it	PRON
aji-148	244	3	is	be	AUX
aji-148	244	4	not	not	PART
aji-148	244	5	applicable	applicable	ADJ
aji-148	244	6	.	.	PUNCT
aji-148	245	1	ethical	ethical	ADJ
aji-148	245	2	approval	approval	NOUN
aji-148	245	3	it	it	PRON
aji-148	245	4	is	be	AUX
aji-148	245	5	not	not	PART
aji-148	245	6	applicable	applicable	ADJ
aji-148	245	7	.	.	PUNCT
aji-148	246	1	competing	compete	VERB
aji-148	246	2	interests	interest	NOUN
aji-148	246	3	authors	author	NOUN
aji-148	246	4	have	have	AUX
aji-148	246	5	declared	declare	VERB
aji-148	246	6	that	that	SCONJ
aji-148	246	7	no	no	DET
aji-148	246	8	competing	compete	VERB
aji-148	246	9	interests	interest	NOUN
aji-148	246	10	exist	exist	VERB
aji-148	246	11	.	.	PUNCT
aji-148	247	1	references	reference	NOUN
aji-148	247	2	1	1	NUM
aji-148	247	3	.	.	PUNCT
aji-148	247	4	rosenberg	rosenberg	PROPN
aji-148	247	5	sa	sa	PROPN
aji-148	247	6	,	,	PUNCT
aji-148	247	7	spiess	spiess	NOUN
aji-148	247	8	p	p	NOUN
aji-148	247	9	,	,	PUNCT
aji-148	247	10	lafreniere	lafreniere	ADV
aji-148	247	11	r.	r.	PROPN
aji-148	247	12	a	a	DET
aji-148	247	13	new	new	ADJ
aji-148	247	14	approach	approach	NOUN
aji-148	247	15	to	to	ADP
aji-148	247	16	the	the	DET
aji-148	247	17	adoptive	adoptive	ADJ
aji-148	247	18	immunotherapy	immunotherapy	NOUN
aji-148	247	19	of	of	ADP
aji-148	247	20	cancer	cancer	NOUN
aji-148	247	21	with	with	ADP
aji-148	247	22	tumorinfiltrating	tumorinfiltrate	VERB
aji-148	247	23	lymphocytes	lymphocyte	NOUN
aji-148	247	24	.	.	PUNCT
aji-148	248	1	science	science	NOUN
aji-148	248	2	.	.	PUNCT
aji-148	249	1	1986;233(4770):1318	1986;233(4770):1318	NUM
aji-148	249	2	-	-	SYM
aji-148	249	3	21	21	NUM
aji-148	249	4	.	.	PUNCT
aji-148	250	1	2	2	X
aji-148	250	2	.	.	X
aji-148	250	3	muul	muul	PROPN
aji-148	250	4	lm	lm	PROPN
aji-148	250	5	,	,	PUNCT
aji-148	250	6	spiess	spiess	PROPN
aji-148	250	7	pj	pj	PROPN
aji-148	250	8	,	,	PUNCT
aji-148	250	9	director	director	NOUN
aji-148	250	10	ep	ep	PROPN
aji-148	250	11	,	,	PUNCT
aji-148	250	12	rosenberg	rosenberg	PROPN
aji-148	250	13	sa	sa	PROPN
aji-148	250	14	.	.	PUNCT
aji-148	251	1	identification	identification	NOUN
aji-148	251	2	of	of	ADP
aji-148	251	3	specific	specific	ADJ
aji-148	251	4	cytolytic	cytolytic	ADJ
aji-148	251	5	immune	immune	ADJ
aji-148	251	6	responses	response	NOUN
aji-148	251	7	against	against	ADP
aji-148	251	8	autologous	autologous	ADJ
aji-148	251	9	tumor	tumor	NOUN
aji-148	251	10	in	in	ADP
aji-148	251	11	humans	human	NOUN
aji-148	251	12	bearing	bear	VERB
aji-148	251	13	malignant	malignant	ADJ
aji-148	251	14	melanoma	melanoma	NOUN
aji-148	251	15	.	.	PUNCT
aji-148	252	1	j	j	PROPN
aji-148	252	2	immunol	immunol	NOUN
aji-148	252	3	.	.	PUNCT
aji-148	253	1	1987;138(3):989	1987;138(3):989	NUM
aji-148	253	2	-	-	SYM
aji-148	253	3	95	95	NUM
aji-148	253	4	.	.	PUNCT
aji-148	254	1	3	3	X
aji-148	254	2	.	.	X
aji-148	254	3	rosenberg	rosenberg	PROPN
aji-148	254	4	sa	sa	PROPN
aji-148	254	5	,	,	PUNCT
aji-148	254	6	packard	packard	PROPN
aji-148	254	7	bs	bs	NOUN
aji-148	254	8	,	,	PUNCT
aji-148	254	9	aebersold	aebersold	PROPN
aji-148	254	10	pm	pm	PROPN
aji-148	254	11	,	,	PUNCT
aji-148	254	12	solomon	solomon	PROPN
aji-148	254	13	d.	d.	PROPN
aji-148	254	14	use	use	NOUN
aji-148	254	15	of	of	ADP
aji-148	254	16	tumor	tumor	NOUN
aji-148	254	17	-	-	PUNCT
aji-148	254	18	infiltrating	infiltrate	VERB
aji-148	254	19	lymphocytes	lymphocyte	NOUN
aji-148	254	20	and	and	CCONJ
aji-148	254	21	interleukin-2	interleukin-2	NOUN
aji-148	254	22	in	in	ADP
aji-148	254	23	the	the	DET
aji-148	254	24	immunotherapy	immunotherapy	NOUN
aji-148	254	25	of	of	ADP
aji-148	254	26	patients	patient	NOUN
aji-148	254	27	with	with	ADP
aji-148	254	28	metastatic	metastatic	ADJ
aji-148	254	29	melanoma	melanoma	NOUN
aji-148	254	30	.	.	PUNCT
aji-148	255	1	a	a	DET
aji-148	255	2	preliminary	preliminary	ADJ
aji-148	255	3	report	report	NOUN
aji-148	255	4	.	.	PUNCT
aji-148	256	1	n	n	PRON
aji-148	256	2	engl	engl	PROPN
aji-148	256	3	j	j	PROPN
aji-148	256	4	med	med	PROPN
aji-148	256	5	.	.	PUNCT
aji-148	257	1	1988;319(25):1676	1988;319(25):1676	NUM
aji-148	257	2	-	-	SYM
aji-148	257	3	80	80	NUM
aji-148	257	4	.	.	PUNCT
aji-148	258	1	4	4	X
aji-148	258	2	.	.	X
aji-148	258	3	ram	ram	NOUN
aji-148	258	4	r	r	NOUN
aji-148	258	5	,	,	PUNCT
aji-148	258	6	amit	amit	PROPN
aji-148	258	7	o	o	NOUN
aji-148	258	8	,	,	PUNCT
aji-148	258	9	perry	perry	PROPN
aji-148	258	10	c	c	PROPN
aji-148	258	11	,	,	PUNCT
aji-148	258	12	herishanu	herishanu	PROPN
aji-148	258	13	y.	y.	NOUN
aji-148	258	14	addition	addition	NOUN
aji-148	258	15	of	of	ADP
aji-148	258	16	nivolumab	nivolumab	NOUN
aji-148	258	17	tailored	tailor	VERB
aji-148	258	18	by	by	ADP
aji-148	258	19	expansion	expansion	NOUN
aji-148	258	20	of	of	ADP
aji-148	258	21	car	car	NOUN
aji-148	258	22	-	-	PUNCT
aji-148	258	23	t	t	NOUN
aji-148	258	24	cells	cell	NOUN
aji-148	258	25	in	in	ADP
aji-148	258	26	patients	patient	NOUN
aji-148	258	27	with	with	ADP
aji-148	258	28	stable	stable	ADJ
aji-148	258	29	/	/	SYM
aji-148	258	30	progressive	progressive	ADJ
aji-148	258	31	large	large	ADJ
aji-148	258	32	b	b	NOUN
aji-148	258	33	cell	cell	NOUN
aji-148	258	34	lymphoma	lymphoma	NOUN
aji-148	258	35	at	at	ADP
aji-148	258	36	lymphodepletion	lymphodepletion	NOUN
aji-148	258	37	a	a	DET
aji-148	258	38	phase	phase	NOUN
aji-148	258	39	2	2	NUM
aji-148	258	40	,	,	PUNCT
aji-148	258	41	prospective	prospective	ADJ
aji-148	258	42	interventional	interventional	ADJ
aji-148	258	43	study	study	NOUN
aji-148	258	44	.	.	PUNCT
aji-148	259	1	transplant	transplant	NOUN
aji-148	259	2	cell	cell	NOUN
aji-148	259	3	ther	ther	ADV
aji-148	259	4	.	.	PUNCT
aji-148	260	1	2024;11	2024;11	NUM
aji-148	260	2	:	:	PUNCT
aji-148	260	3	s26666367(24)00692	s26666367(24)00692	VERB
aji-148	260	4	-	-	PUNCT
aji-148	260	5	4	4	NUM
aji-148	260	6	.	.	NOUN
aji-148	260	7	5	5	NUM
aji-148	260	8	.	.	NUM
aji-148	260	9	provencio	provencio	PROPN
aji-148	260	10	m	m	PROPN
aji-148	260	11	,	,	PUNCT
aji-148	260	12	nadal	nadal	PROPN
aji-148	260	13	e	e	PROPN
aji-148	260	14	,	,	PUNCT
aji-148	260	15	insa	insa	PROPN
aji-148	260	16	aa	aa	PROPN
aji-148	260	17	.	.	PUNCT
aji-148	261	1	perioperative	perioperative	ADJ
aji-148	261	2	chemotherapy	chemotherapy	NOUN
aji-148	261	3	and	and	CCONJ
aji-148	261	4	nivolumab	nivolumab	NOUN
aji-148	261	5	in	in	ADP
aji-148	261	6	non	non	ADJ
aji-148	261	7	-	-	ADJ
aji-148	261	8	small	small	ADJ
aji-148	261	9	-	-	PUNCT
aji-148	261	10	cell	cell	NOUN
aji-148	261	11	lung	lung	NOUN
aji-148	261	12	cancer	cancer	NOUN
aji-148	261	13	(	(	PUNCT
aji-148	261	14	nadim	nadim	PROPN
aji-148	261	15	):	):	PUNCT
aji-148	261	16	5	5	NUM
aji-148	261	17	-	-	PUNCT
aji-148	261	18	year	year	NOUN
aji-148	261	19	clinical	clinical	ADJ
aji-148	261	20	outcomes	outcome	NOUN
aji-148	261	21	from	from	ADP
aji-148	261	22	a	a	DET
aji-148	261	23	multicentre	multicentre	NOUN
aji-148	261	24	,	,	PUNCT
aji-148	261	25	single	single	ADJ
aji-148	261	26	-	-	PUNCT
aji-148	261	27	arm	arm	NOUN
aji-148	261	28	,	,	PUNCT
aji-148	261	29	phase	phase	NOUN
aji-148	261	30	2	2	NUM
aji-148	261	31	trial	trial	NOUN
aji-148	261	32	.	.	PUNCT
aji-148	262	1	lancet	lancet	PROPN
aji-148	262	2	oncol	oncol	PROPN
aji-148	262	3	.	.	PUNCT
aji-148	263	1	2024;14	2024;14	NUM
aji-148	263	2	:	:	PUNCT
aji-148	263	3	s14702045(24)00498	s14702045(24)00498	NOUN
aji-148	263	4	-	-	PUNCT
aji-148	263	5	4	4	NUM
aji-148	263	6	.	.	NOUN
aji-148	263	7	6	6	NUM
aji-148	263	8	.	.	X
aji-148	263	9	tang	tang	PROPN
aji-148	263	10	b	b	PROPN
aji-148	263	11	,	,	PUNCT
aji-148	263	12	xiao	xiao	PROPN
aji-148	263	13	j	j	PROPN
aji-148	263	14	,	,	PUNCT
aji-148	263	15	chi	chi	PROPN
aji-148	263	16	z.	z.	PROPN
aji-148	263	17	phase	phase	NOUN
aji-148	263	18	ib	ib	PROPN
aji-148	263	19	study	study	NOUN
aji-148	263	20	of	of	ADP
aji-148	263	21	anti	anti	ADJ
aji-148	263	22	-	-	ADJ
aji-148	263	23	pd	pd	ADJ
aji-148	263	24	-	-	PUNCT
aji-148	263	25	l1	l1	PROPN
aji-148	263	26	monoclonal	monoclonal	NOUN
aji-148	263	27	antibody	antibody	NOUN
aji-148	263	28	socazolimab	socazolimab	NOUN
aji-148	263	29	in	in	ADP
aji-148	263	30	combination	combination	NOUN
aji-148	263	31	with	with	ADP
aji-148	263	32	nabpaclitaxel	nabpaclitaxel	PROPN
aji-148	263	33	as	as	ADP
aji-148	263	34	first	first	ADJ
aji-148	263	35	-	-	PUNCT
aji-148	263	36	line	line	NOUN
aji-148	263	37	therapy	therapy	NOUN
aji-148	263	38	for	for	ADP
aji-148	263	39	advanced	advanced	ADJ
aji-148	263	40	urothelial	urothelial	ADJ
aji-148	263	41	carcinoma	carcinoma	NOUN
aji-148	263	42	.	.	PUNCT
aji-148	264	1	oncologist	oncologist	NOUN
aji-148	264	2	.	.	PUNCT
aji-148	265	1	2024;oyae260	2024;oyae260	NUM
aji-148	265	2	.	.	PUNCT
aji-148	266	1	7	7	NUM
aji-148	266	2	.	.	X
aji-148	266	3	li	li	PROPN
aji-148	266	4	b	b	PROPN
aji-148	266	5	,	,	PUNCT
aji-148	266	6	tong	tong	PROPN
aji-148	266	7	sq	sq	PROPN
aji-148	266	8	,	,	PUNCT
aji-148	266	9	zhang	zhang	PROPN
aji-148	266	10	xh	xh	PROPN
aji-148	266	11	,	,	PUNCT
aji-148	266	12	lu	lu	PROPN
aji-148	266	13	j	j	PROPN
aji-148	266	14	,	,	PUNCT
aji-148	266	15	gu	gu	X
aji-148	266	16	ql	ql	PROPN
aji-148	266	17	,	,	PUNCT
aji-148	266	18	lu	lu	PROPN
aji-148	266	19	dy	dy	NOUN
aji-148	266	20	.	.	PUNCT
aji-148	267	1	a	a	DET
aji-148	267	2	new	new	ADJ
aji-148	267	3	experimental	experimental	ADJ
aji-148	267	4	and	and	CCONJ
aji-148	267	5	clinical	clinical	ADJ
aji-148	267	6	approach	approach	NOUN
aji-148	267	7	of	of	ADP
aji-148	267	8	combining	combine	VERB
aji-148	267	9	usage	usage	NOUN
aji-148	267	10	of	of	ADP
aji-148	267	11	highly	highly	ADV
aji-148	267	12	active	active	ADJ
aji-148	267	13	tumor	tumor	NOUN
aji-148	267	14	-	-	PUNCT
aji-148	267	15	infiltrating	infiltrate	VERB
aji-148	267	16	lymphocytes	lymphocyte	NOUN
aji-148	267	17	and	and	CCONJ
aji-148	267	18	highly	highly	ADV
aji-148	267	19	sensitive	sensitive	ADJ
aji-148	267	20	antitumor	antitumor	NOUN
aji-148	267	21	drugs	drug	NOUN
aji-148	267	22	for	for	ADP
aji-148	267	23	the	the	DET
aji-148	267	24	advanced	advanced	ADJ
aji-148	267	25	malignant	malignant	ADJ
aji-148	267	26	tumor	tumor	NOUN
aji-148	267	27	.	.	PUNCT
aji-148	268	1	chin	chin	PROPN
aji-148	268	2	med	med	PROPN
aji-148	268	3	j	j	PROPN
aji-148	268	4	(	(	PUNCT
aji-148	268	5	english	english	PROPN
aji-148	268	6	)	)	PUNCT
aji-148	268	7	.	.	PUNCT
aji-148	269	1	1994;107(11):803	1994;107(11):803	NUM
aji-148	269	2	-	-	SYM
aji-148	269	3	7	7	NUM
aji-148	269	4	.	.	NOUN
aji-148	269	5	8	8	NUM
aji-148	269	6	.	.	PUNCT
aji-148	270	1	li	li	PROPN
aji-148	270	2	b	b	PROPN
aji-148	270	3	,	,	PUNCT
aji-148	270	4	tong	tong	PROPN
aji-148	270	5	sq	sq	PROPN
aji-148	270	6	,	,	PUNCT
aji-148	270	7	hu	hu	PROPN
aji-148	270	8	by	by	ADP
aji-148	270	9	,	,	PUNCT
aji-148	270	10	zhu	zhu	PROPN
aji-148	270	11	ym	ym	PROPN
aji-148	270	12	,	,	PUNCT
aji-148	270	13	zhang	zhang	PROPN
aji-148	270	14	xh	xh	PROPN
aji-148	270	15	,	,	PUNCT
aji-148	270	16	wu	wu	PROPN
aji-148	270	17	jh	jh	PROPN
aji-148	270	18	,	,	PUNCT
aji-148	270	19	lu	lu	PROPN
aji-148	270	20	j	j	PROPN
aji-148	270	21	,	,	PUNCT
aji-148	270	22	lu	lu	PROPN
aji-148	270	23	dy	dy	NOUN
aji-148	270	24	.	.	PUNCT
aji-148	271	1	study	study	NOUN
aji-148	271	2	on	on	ADP
aji-148	271	3	the	the	DET
aji-148	271	4	influence	influence	NOUN
aji-148	271	5	of	of	ADP
aji-148	271	6	enzymatic	enzymatic	ADJ
aji-148	271	7	digestion	digestion	NOUN
aji-148	271	8	upon	upon	SCONJ
aji-148	271	9	tumor	tumor	NOUN
aji-148	271	10	-	-	PUNCT
aji-148	271	11	infiltrating	infiltrate	VERB
aji-148	271	12	lymphocytes	lymphocyte	NOUN
aji-148	271	13	.	.	PUNCT
aji-148	272	1	acta	acta	PROPN
aji-148	272	2	biologiae	biologiae	PROPN
aji-148	272	3	experimentalis	experimentalis	PROPN
aji-148	272	4	sinica	sinica	PROPN
aji-148	272	5	(	(	PUNCT
aji-148	272	6	shi	shi	PROPN
aji-148	272	7	yan	yan	PROPN
aji-148	272	8	sheng	sheng	PROPN
aji-148	272	9	wu	wu	PROPN
aji-148	272	10	xue	xue	PROPN
aji-148	272	11	bao	bao	PROPN
aji-148	272	12	.	.	PUNCT
aji-148	273	1	chinese	chinese	ADJ
aji-148	273	2	)	)	PUNCT
aji-148	273	3	1994;27(1):103	1994;27(1):103	NUM
aji-148	273	4	-	-	SYM
aji-148	273	5	7	7	NUM
aji-148	273	6	.	.	NOUN
aji-148	273	7	9	9	NUM
aji-148	273	8	.	.	PUNCT
aji-148	273	9	li	li	PROPN
aji-148	273	10	b	b	PROPN
aji-148	273	11	,	,	PUNCT
aji-148	273	12	tong	tong	PROPN
aji-148	273	13	sq	sq	PROPN
aji-148	273	14	,	,	PUNCT
aji-148	273	15	zhang	zhang	PROPN
aji-148	273	16	xh	xh	PROPN
aji-148	273	17	,	,	PUNCT
aji-148	273	18	zhu	zhu	PROPN
aji-148	273	19	ym	ym	PROPN
aji-148	273	20	,	,	PUNCT
aji-148	273	21	hu	hu	PROPN
aji-148	273	22	bw	bw	PROPN
aji-148	273	23	,	,	PUNCT
aji-148	273	24	lu	lu	PROPN
aji-148	273	25	dy	dy	NOUN
aji-148	273	26	.	.	PUNCT
aji-148	274	1	research	research	NOUN
aji-148	274	2	on	on	ADP
aji-148	274	3	til	til	ADV
aji-148	274	4	proliferation	proliferation	NOUN
aji-148	274	5	,	,	PUNCT
aji-148	274	6	phenotype	phenotype	NOUN
aji-148	274	7	from	from	ADP
aji-148	274	8	human	human	ADJ
aji-148	274	9	malignant	malignant	ADJ
aji-148	274	10	solid	solid	ADJ
aji-148	274	11	tumors	tumor	NOUN
aji-148	274	12	;	;	PUNCT
aji-148	274	13	modern	modern	ADJ
aji-148	274	14	immunology	immunology	NOUN
aji-148	274	15	(	(	PUNCT
aji-148	274	16	chinese	chinese	PROPN
aji-148	274	17	)	)	PUNCT
aji-148	274	18	.	.	PUNCT
aji-148	275	1	1994;14(5):257	1994;14(5):257	NUM
aji-148	275	2	-	-	SYM
aji-148	275	3	260	260	NUM
aji-148	275	4	.	.	PUNCT
aji-148	275	5	10	10	NUM
aji-148	275	6	.	.	PUNCT
aji-148	276	1	li	li	PROPN
aji-148	276	2	b	b	PROPN
aji-148	276	3	,	,	PUNCT
aji-148	276	4	tong	tong	PROPN
aji-148	276	5	sq	sq	PROPN
aji-148	276	6	,	,	PUNCT
aji-148	276	7	zhu	zhu	PROPN
aji-148	276	8	ym	ym	PROPN
aji-148	276	9	,	,	PUNCT
aji-148	276	10	hu	hu	PROPN
aji-148	276	11	bw	bw	PROPN
aji-148	276	12	,	,	PUNCT
aji-148	276	13	zhang	zhang	PROPN
aji-148	276	14	xh	xh	PROPN
aji-148	276	15	,	,	PUNCT
aji-148	276	16	lu	lu	PROPN
aji-148	276	17	j	j	PROPN
aji-148	276	18	,	,	PUNCT
aji-148	276	19	wu	wu	PROPN
aji-148	276	20	jh	jh	PROPN
aji-148	276	21	,	,	PUNCT
aji-148	276	22	hu	hu	PROPN
aji-148	276	23	hl	hl	PROPN
aji-148	276	24	,	,	PUNCT
aji-148	276	25	shen	shen	PROPN
aji-148	277	1	dh	dh	NOUN
aji-148	277	2	and	and	CCONJ
aji-148	277	3	lu	lu	PROPN
aji-148	277	4	dy	dy	NOUN
aji-148	277	5	.	.	PUNCT
aji-148	278	1	establishment	establishment	NOUN
aji-148	278	2	of	of	ADP
aji-148	278	3	a	a	DET
aji-148	278	4	method	method	NOUN
aji-148	278	5	for	for	ADP
aji-148	278	6	separation	separation	NOUN
aji-148	278	7	of	of	ADP
aji-148	278	8	tumor	tumor	NOUN
aji-148	278	9	infiltrating	infiltrate	VERB
aji-148	278	10	lymphocytes	lymphocyte	NOUN
aji-148	278	11	with	with	ADP
aji-148	278	12	high	high	ADJ
aji-148	278	13	vitality	vitality	NOUN
aji-148	278	14	.	.	PUNCT
aji-148	279	1	journal	journal	NOUN
aji-148	279	2	of	of	ADP
aji-148	279	3	immunology	immunology	NOUN
aji-148	279	4	(	(	PUNCT
aji-148	279	5	chinese	chinese	PROPN
aji-148	279	6	)	)	PUNCT
aji-148	279	7	.	.	PUNCT
aji-148	280	1	1994;10(1):44	1994;10(1):44	NUM
aji-148	280	2	-	-	SYM
aji-148	280	3	47	47	NUM
aji-148	280	4	.	.	PUNCT
aji-148	281	1	11	11	NUM
aji-148	281	2	.	.	PUNCT
aji-148	282	1	li	li	PROPN
aji-148	282	2	hf	hf	PROPN
aji-148	282	3	,	,	PUNCT
aji-148	282	4	lu	lu	PROPN
aji-148	282	5	j	j	PROPN
aji-148	282	6	,	,	PUNCT
aji-148	282	7	hua	hua	PROPN
aji-148	282	8	zd	zd	PROPN
aji-148	282	9	;	;	PUNCT
aji-148	282	10	li	li	PROPN
aji-148	282	11	b	b	PROPN
aji-148	282	12	,	,	PUNCT
aji-148	282	13	tong	tong	PROPN
aji-148	282	14	sq	sq	PROPN
aji-148	282	15	,	,	PUNCT
aji-148	282	16	lu	lu	PROPN
aji-148	282	17	dy	dy	NOUN
aji-148	282	18	.	.	PUNCT
aji-148	283	1	study	study	NOUN
aji-148	283	2	on	on	ADP
aji-148	283	3	the	the	DET
aji-148	283	4	killing	kill	VERB
aji-148	283	5	activity	activity	NOUN
aji-148	283	6	of	of	ADP
aji-148	283	7	til	til	NOUN
aji-148	283	8	cells	cell	NOUN
aji-148	283	9	in	in	ADP
aji-148	283	10	ovarian	ovarian	ADJ
aji-148	283	11	cancer	cancer	NOUN
aji-148	283	12	.	.	PUNCT
aji-148	284	1	shanghai	shanghai	PROPN
aji-148	284	2	medical	medical	PROPN
aji-148	284	3	(	(	PUNCT
aji-148	284	4	chinese	chinese	ADJ
aji-148	284	5	)	)	PUNCT
aji-148	284	6	1995;18(5):268	1995;18(5):268	PROPN
aji-148	284	7	-	-	PUNCT
aji-148	284	8	270	270	NUM
aji-148	284	9	.	.	PUNCT
aji-148	284	10	12	12	NUM
aji-148	284	11	.	.	PUNCT
aji-148	285	1	lu	lu	PROPN
aji-148	285	2	j	j	PROPN
aji-148	285	3	,	,	PUNCT
aji-148	285	4	li	li	PROPN
aji-148	285	5	b	b	PROPN
aji-148	285	6	,	,	PUNCT
aji-148	285	7	hua	hua	PROPN
aji-148	285	8	zd	zd	PROPN
aji-148	285	9	,	,	PUNCT
aji-148	285	10	zhu	zhu	PROPN
aji-148	285	11	ym	ym	PROPN
aji-148	285	12	,	,	PUNCT
aji-148	285	13	tong	tong	PROPN
aji-148	285	14	sq	sq	PROPN
aji-148	285	15	.	.	PROPN
aji-148	285	16	research	research	NOUN
aji-148	285	17	on	on	ADP
aji-148	285	18	til	til	ADV
aji-148	285	19	yield	yield	NOUN
aji-148	285	20	and	and	CCONJ
aji-148	285	21	vitality	vitality	NOUN
aji-148	285	22	of	of	ADP
aji-148	285	23	different	different	ADJ
aji-148	285	24	materials	material	NOUN
aji-148	285	25	;	;	PUNCT
aji-148	285	26	immunological	immunological	ADJ
aji-148	285	27	journal	journal	NOUN
aji-148	285	28	(	(	PUNCT
aji-148	285	29	chinese	chinese	ADJ
aji-148	285	30	)	)	PUNCT
aji-148	285	31	1995;11(3):182	1995;11(3):182	PROPN
aji-148	285	32	-	-	SYM
aji-148	285	33	184	184	NUM
aji-148	285	34	.	.	NOUN
aji-148	285	35	13	13	NUM
aji-148	285	36	.	.	PUNCT
aji-148	286	1	taylor	taylor	PROPN
aji-148	286	2	s	s	PROPN
aji-148	286	3	,	,	PUNCT
aji-148	286	4	law	law	PROPN
aji-148	286	5	k	k	PROPN
aji-148	286	6	,	,	PUNCT
aji-148	286	7	coomber	coomber	PROPN
aji-148	286	8	-	-	PUNCT
aji-148	286	9	moore	moore	PROPN
aji-148	286	10	j.	j.	PROPN
aji-148	286	11	correction	correction	PROPN
aji-148	286	12	:	:	PUNCT
aji-148	286	13	patient	patient	NOUN
aji-148	286	14	-	-	PUNCT
aji-148	286	15	reported	report	VERB
aji-148	286	16	outcome	outcome	NOUN
aji-148	286	17	(	(	PUNCT
aji-148	286	18	pro	pro	ADJ
aji-148	286	19	)	)	PUNCT
aji-148	286	20	instruments	instrument	NOUN
aji-148	286	21	used	use	VERB
aji-148	286	22	in	in	ADP
aji-148	286	23	patients	patient	NOUN
aji-148	286	24	undergoing	undergo	VERB
aji-148	286	25	adoptive	adoptive	ADJ
aji-148	286	26	cell	cell	NOUN
aji-148	286	27	therapy	therapy	NOUN
aji-148	286	28	(	(	PUNCT
aji-148	286	29	act	act	PROPN
aji-148	286	30	)	)	PUNCT
aji-148	286	31	for	for	ADP
aji-148	286	32	the	the	DET
aji-148	286	33	treatment	treatment	NOUN
aji-148	286	34	of	of	ADP
aji-148	286	35	cancer	cancer	NOUN
aji-148	286	36	:	:	PUNCT
aji-148	286	37	a	a	DET
aji-148	286	38	systematic	systematic	ADJ
aji-148	286	39	review	review	NOUN
aji-148	286	40	.	.	PUNCT
aji-148	287	1	syst	syst	PROPN
aji-148	287	2	rev	rev	PROPN
aji-148	287	3	.	.	PUNCT
aji-148	288	1	2024;13(1):117	2024;13(1):117	NUM
aji-148	288	2	.	.	PUNCT
aji-148	289	1	14	14	NUM
aji-148	289	2	.	.	PUNCT
aji-148	290	1	xiong	xiong	PROPN
aji-148	291	1	d	d	PROPN
aji-148	291	2	,	,	PUNCT
aji-148	291	3	yu	yu	PROPN
aji-148	291	4	h	h	NOUN
aji-148	291	5	,	,	PUNCT
aji-148	291	6	sun	sun	PROPN
aji-148	291	7	zj	zj	PROPN
aji-148	291	8	.	.	PROPN
aji-148	291	9	unlocking	unlock	VERB
aji-148	291	10	t	t	PROPN
aji-148	291	11	cell	cell	NOUN
aji-148	291	12	exhaustion	exhaustion	NOUN
aji-148	291	13	:	:	PUNCT
aji-148	291	14	insights	insight	NOUN
aji-148	291	15	and	and	CCONJ
aji-148	291	16	implications	implication	NOUN
aji-148	291	17	for	for	ADP
aji-148	291	18	car	car	NOUN
aji-148	291	19	-	-	PUNCT
aji-148	291	20	t	t	NOUN
aji-148	291	21	cell	cell	NOUN
aji-148	291	22	therapy	therapy	NOUN
aji-148	291	23	.	.	PUNCT
aji-148	292	1	acta	acta	PROPN
aji-148	292	2	pharm	pharm	PROPN
aji-148	292	3	sin	sin	PROPN
aji-148	292	4	b.	b.	PROPN
aji-148	293	1	2024;14(8):3416	2024;14(8):3416	PROPN
aji-148	293	2	-	-	SYM
aji-148	293	3	3431	3431	NUM
aji-148	293	4	.	.	PUNCT
aji-148	294	1	15	15	NUM
aji-148	294	2	.	.	PUNCT
aji-148	294	3	yang	yang	PROPN
aji-148	294	4	jc	jc	PROPN
aji-148	294	5	,	,	PUNCT
aji-148	295	1	rosenberg	rosenberg	PROPN
aji-148	295	2	sa	sa	PROPN
aji-148	295	3	.	.	PROPN
aji-148	295	4	adoptive	adoptive	PROPN
aji-148	295	5	t	t	PROPN
aji-148	295	6	-	-	PUNCT
aji-148	295	7	cell	cell	NOUN
aji-148	295	8	therapy	therapy	NOUN
aji-148	295	9	for	for	ADP
aji-148	295	10	cancer	cancer	NOUN
aji-148	295	11	.	.	PUNCT
aji-148	296	1	adv	adv	PROPN
aji-148	296	2	immunol	immunol	NOUN
aji-148	296	3	.	.	PUNCT
aji-148	297	1	2016;130:279	2016;130:279	NUM
aji-148	297	2	-	-	SYM
aji-148	297	3	94	94	NUM
aji-148	297	4	.	.	PUNCT
aji-148	298	1	16	16	NUM
aji-148	298	2	.	.	PUNCT
aji-148	299	1	poncette	poncette	PROPN
aji-148	299	2	l	l	PROPN
aji-148	299	3	,	,	PUNCT
aji-148	299	4	bluhm	bluhm	PROPN
aji-148	299	5	j	j	PROPN
aji-148	299	6	,	,	PUNCT
aji-148	299	7	blankenstein	blankenstein	NOUN
aji-148	299	8	t.	t.	PROPN
aji-148	299	9	the	the	DET
aji-148	299	10	role	role	NOUN
aji-148	299	11	of	of	ADP
aji-148	299	12	cd4	cd4	PROPN
aji-148	299	13	t	t	PROPN
aji-148	299	14	cells	cell	NOUN
aji-148	299	15	in	in	ADP
aji-148	299	16	rejection	rejection	NOUN
aji-148	299	17	of	of	ADP
aji-148	299	18	solid	solid	ADJ
aji-148	299	19	tumors	tumor	NOUN
aji-148	299	20	.	.	PUNCT
aji-148	300	1	curr	curr	PROPN
aji-148	300	2	opin	opin	PROPN
aji-148	300	3	immunol	immunol	NOUN
aji-148	300	4	.	.	PUNCT
aji-148	301	1	2022;74:18	2022;74:18	NUM
aji-148	301	2	-	-	SYM
aji-148	301	3	24	24	NUM
aji-148	301	4	.	.	PUNCT
aji-148	301	5	17	17	NUM
aji-148	301	6	.	.	PUNCT
aji-148	302	1	kirtane	kirtane	PROPN
aji-148	302	2	k	k	PROPN
aji-148	302	3	,	,	PUNCT
aji-148	302	4	elmariah	elmariah	PROPN
aji-148	302	5	h	h	NOUN
aji-148	302	6	,	,	PUNCT
aji-148	302	7	chung	chung	PROPN
aji-148	302	8	ch	ch	PROPN
aji-148	302	9	,	,	PUNCT
aji-148	302	10	abatedaga	abatedaga	NOUN
aji-148	302	11	d.	d.	PROPN
aji-148	302	12	adoptive	adoptive	ADJ
aji-148	302	13	cellular	cellular	PROPN
aji-148	302	14	therapy	therapy	NOUN
aji-148	302	15	in	in	ADP
aji-148	302	16	solid	solid	ADJ
aji-148	302	17	tumor	tumor	NOUN
aji-148	302	18	malignancies	malignancy	NOUN
aji-148	302	19	:	:	PUNCT
aji-148	302	20	review	review	NOUN
aji-148	302	21	of	of	ADP
aji-148	302	22	the	the	DET
aji-148	302	23	literature	literature	NOUN
aji-148	302	24	and	and	CCONJ
aji-148	302	25	challenges	challenge	NOUN
aji-148	302	26	ahead	ahead	ADV
aji-148	302	27	.	.	PUNCT
aji-148	303	1	j	j	PROPN
aji-148	303	2	immunother	immunother	ADJ
aji-148	303	3	cancer	cancer	NOUN
aji-148	303	4	.	.	PUNCT
aji-148	304	1	2021;9(7):e002723	2021;9(7):e002723	PROPN
aji-148	304	2	.	.	PROPN
aji-148	304	3	https://www.ncbi.nlm.nih.gov/pubmed/?term=rosenberg%20sa%5bauthor%5d&cauthor=true&cauthor_uid=3489291	https://www.ncbi.nlm.nih.gov/pubmed/?term=rosenberg%20sa%5bauthor%5d&cauthor=true&cauthor_uid=3489291	PROPN
aji-148	304	4	https://www.ncbi.nlm.nih.gov/pubmed/?term=spiess%20p%5bauthor%5d&cauthor=true&cauthor_uid=3489291	https://www.ncbi.nlm.nih.gov/pubmed/?term=spiess%20p%5bauthor%5d&cauthor=true&cauthor_uid=3489291	PROPN
aji-148	304	5	https://www.ncbi.nlm.nih.gov/pubmed/?term=lafreniere%20r%5bauthor%5d&cauthor=true&cauthor_uid=3489291	https://www.ncbi.nlm.nih.gov/pubmed/?term=lafreniere%20r%5bauthor%5d&cauthor=true&cauthor_uid=3489291	PROPN
aji-148	304	6	https://www.ncbi.nlm.nih.gov/pubmed/3489291	https://www.ncbi.nlm.nih.gov/pubmed/3489291	PROPN
aji-148	304	7	https://www.ncbi.nlm.nih.gov/pubmed/?term=muul%20lm%5bauthor%5d&cauthor=true&cauthor_uid=3100623	https://www.ncbi.nlm.nih.gov/pubmed/?term=muul%20lm%5bauthor%5d&cauthor=true&cauthor_uid=3100623	PROPN
aji-148	304	8	https://www.ncbi.nlm.nih.gov/pubmed/?term=spiess%20pj%5bauthor%5d&cauthor=true&cauthor_uid=3100623	https://www.ncbi.nlm.nih.gov/pubmed/?term=spiess%20pj%5bauthor%5d&cauthor=true&cauthor_uid=3100623	PROPN
aji-148	304	9	https://www.ncbi.nlm.nih.gov/pubmed/?term=director%20ep%5bauthor%5d&cauthor=true&cauthor_uid=3100623	https://www.ncbi.nlm.nih.gov/pubmed/?term=director%20ep%5bauthor%5d&cauthor=true&cauthor_uid=3100623	NOUN
aji-148	304	10	https://www.ncbi.nlm.nih.gov/pubmed/?term=rosenberg%20sa%5bauthor%5d&cauthor=true&cauthor_uid=3100623	https://www.ncbi.nlm.nih.gov/pubmed/?term=rosenberg%20sa%5bauthor%5d&cauthor=true&cauthor_uid=3100623	X
aji-148	304	11	https://www.ncbi.nlm.nih.gov/pubmed/3100623	https://www.ncbi.nlm.nih.gov/pubmed/3100623	NUM
aji-148	304	12	https://www.ncbi.nlm.nih.gov/pubmed/?term=rosenberg%20sa%5bauthor%5d&cauthor=true&cauthor_uid=3264384	https://www.ncbi.nlm.nih.gov/pubmed/?term=rosenberg%20sa%5bauthor%5d&cauthor=true&cauthor_uid=3264384	PROPN
aji-148	304	13	https://www.ncbi.nlm.nih.gov/pubmed/?term=packard%20bs%5bauthor%5d&cauthor=true&cauthor_uid=3264384	https://www.ncbi.nlm.nih.gov/pubmed/?term=packard%20bs%5bauthor%5d&cauthor=true&cauthor_uid=3264384	PART
aji-148	304	14	https://www.ncbi.nlm.nih.gov/pubmed/?term=aebersold%20pm%5bauthor%5d&cauthor=true&cauthor_uid=3264384	https://www.ncbi.nlm.nih.gov/pubmed/?term=aebersold%20pm%5bauthor%5d&cauthor=true&cauthor_uid=3264384	PROPN
aji-148	304	15	https://www.ncbi.nlm.nih.gov/pubmed/?term=aebersold%20pm%5bauthor%5d&cauthor=true&cauthor_uid=3264384	https://www.ncbi.nlm.nih.gov/pubmed/?term=aebersold%20pm%5bauthor%5d&cauthor=true&cauthor_uid=3264384	X
aji-148	304	16	https://www.ncbi.nlm.nih.gov/pubmed/?term=solomon%20d%5bauthor%5d&cauthor=true&cauthor_uid=3264384	https://www.ncbi.nlm.nih.gov/pubmed/?term=solomon%20d%5bauthor%5d&cauthor=true&cauthor_uid=3264384	PROPN
aji-148	304	17	https://www.ncbi.nlm.nih.gov/pubmed/3264384	https://www.ncbi.nlm.nih.gov/pubmed/3264384	X
aji-148	304	18	https://www.ncbi.nlm.nih.gov/pubmed/3264384	https://www.ncbi.nlm.nih.gov/pubmed/3264384	PRON
aji-148	304	19	https://www.ncbi.nlm.nih.gov/pubmed/?term=tong%20sq%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=tong%20sq%5bauthor%5d&cauthor=true&cauthor_uid=8042406	ADJ
aji-148	304	20	https://www.ncbi.nlm.nih.gov/pubmed/?term=hu%20by%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=hu%20by%5bauthor%5d&cauthor=true&cauthor_uid=8042406	NOUN
aji-148	304	21	https://www.ncbi.nlm.nih.gov/pubmed/?term=zhu%20ym%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=zhu%20ym%5bauthor%5d&cauthor=true&cauthor_uid=8042406	PROPN
aji-148	304	22	https://www.ncbi.nlm.nih.gov/pubmed/?term=zhang%20xh%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=zhang%20xh%5bauthor%5d&cauthor=true&cauthor_uid=8042406	VERB
aji-148	304	23	https://www.ncbi.nlm.nih.gov/pubmed/?term=wu%20jh%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=wu%20jh%5bauthor%5d&cauthor=true&cauthor_uid=8042406	NOUN
aji-148	304	24	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20j%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20j%5bauthor%5d&cauthor=true&cauthor_uid=8042406	VERB
aji-148	304	25	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20dy%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20dy%5bauthor%5d&cauthor=true&cauthor_uid=8042406	VERB
aji-148	304	26	https://www.ncbi.nlm.nih.gov/pubmed/8042406	https://www.ncbi.nlm.nih.gov/pubmed/8042406	NUM
aji-148	304	27	https://www.ncbi.nlm.nih.gov/pubmed/8042406	https://www.ncbi.nlm.nih.gov/pubmed/8042406	NUM
aji-148	304	28	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20dy%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20dy%5bauthor%5d&cauthor=true&cauthor_uid=8042406	ADJ
aji-148	304	29	https://www.ncbi.nlm.nih.gov/pubmed/?term=wu%20jh%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=wu%20jh%5bauthor%5d&cauthor=true&cauthor_uid=8042406	NOUN
aji-148	304	30	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20dy%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20dy%5bauthor%5d&cauthor=true&cauthor_uid=8042406	VERB
aji-148	304	31	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20dy%5bauthor%5d&cauthor=true&cauthor_uid=8042406	https://www.ncbi.nlm.nih.gov/pubmed/?term=lu%20dy%5bauthor%5d&cauthor=true&cauthor_uid=8042406	ADJ
aji-148	304	32	li	li	PROPN
aji-148	304	33	and	and	CCONJ
aji-148	304	34	li	li	PROPN
aji-148	304	35	;	;	PUNCT
aji-148	304	36	asian	asian	PROPN
aji-148	304	37	j.	j.	PROPN
aji-148	304	38	immunol	immunol	PROPN
aji-148	304	39	.	.	PROPN
aji-148	304	40	,	,	PUNCT
aji-148	304	41	vol	vol	NOUN
aji-148	304	42	.	.	PROPN
aji-148	305	1	7	7	NUM
aji-148	305	2	,	,	PUNCT
aji-148	305	3	no	no	INTJ
aji-148	305	4	.	.	NOUN
aji-148	305	5	1	1	NUM
aji-148	305	6	,	,	PUNCT
aji-148	305	7	pp	pp	ADJ
aji-148	305	8	.	.	PUNCT
aji-148	306	1	247	247	NUM
aji-148	306	2	-	-	SYM
aji-148	306	3	257	257	NUM
aji-148	306	4	,	,	PUNCT
aji-148	306	5	2024	2024	NUM
aji-148	306	6	;	;	PUNCT
aji-148	306	7	article	article	NOUN
aji-148	306	8	no.aji.126682	no.aji.126682	ADP
aji-148	306	9	255	255	NUM
aji-148	306	10	18	18	NUM
aji-148	306	11	.	.	PUNCT
aji-148	306	12	kochenderfer	kochenderfer	PROPN
aji-148	306	13	jn	jn	PROPN
aji-148	306	14	,	,	PUNCT
aji-148	306	15	rosenberg	rosenberg	PROPN
aji-148	306	16	sa	sa	PROPN
aji-148	306	17	.	.	PUNCT
aji-148	307	1	treating	treat	VERB
aji-148	307	2	b	b	NOUN
aji-148	307	3	-	-	PUNCT
aji-148	307	4	cell	cell	NOUN
aji-148	307	5	cancer	cancer	NOUN
aji-148	307	6	with	with	ADP
aji-148	307	7	t	t	PROPN
aji-148	307	8	cells	cell	NOUN
aji-148	307	9	expressing	express	VERB
aji-148	307	10	anticd19	anticd19	NOUN
aji-148	307	11	chimeric	chimeric	ADJ
aji-148	307	12	antigen	antigen	ADJ
aji-148	307	13	receptors	receptor	NOUN
aji-148	307	14	.	.	PUNCT
aji-148	308	1	nat	nat	PROPN
aji-148	308	2	.	.	PUNCT
aji-148	309	1	rev	rev	PROPN
aji-148	309	2	.	.	PROPN
aji-148	310	1	clin	clin	PROPN
aji-148	310	2	.	.	PUNCT
aji-148	311	1	oncol	oncol	ADJ
aji-148	311	2	.	.	PUNCT
aji-148	312	1	2013;10:267–276	2013;10:267–276	X
aji-148	312	2	.	.	PUNCT
aji-148	313	1	19	19	NUM
aji-148	313	2	.	.	PROPN
aji-148	313	3	june	june	PROPN
aji-148	313	4	ch	ch	PROPN
aji-148	313	5	,	,	PUNCT
aji-148	313	6	sadelain	sadelain	NOUN
aji-148	313	7	m.	m.	NOUN
aji-148	313	8	chimeric	chimeric	ADJ
aji-148	313	9	antigen	antigen	ADJ
aji-148	313	10	receptor	receptor	NOUN
aji-148	313	11	therapy	therapy	NOUN
aji-148	313	12	.	.	PUNCT
aji-148	314	1	n.	n.	PROPN
aji-148	314	2	engl	engl	PROPN
aji-148	314	3	.	.	PUNCT
aji-148	315	1	j.	j.	PROPN
aji-148	315	2	med	med	PROPN
aji-148	315	3	.	.	PUNCT
aji-148	316	1	2018;379:64–73	2018;379:64–73	NUM
aji-148	316	2	.	.	NOUN
aji-148	316	3	20	20	NUM
aji-148	316	4	.	.	PUNCT
aji-148	316	5	kochenderfer	kochenderfer	PROPN
aji-148	316	6	jn	jn	PROPN
aji-148	316	7	.	.	PROPN
aji-148	317	1	b	b	X
aji-148	317	2	-	-	PUNCT
aji-148	317	3	cell	cell	NOUN
aji-148	317	4	depletion	depletion	NOUN
aji-148	317	5	and	and	CCONJ
aji-148	317	6	remissions	remission	NOUN
aji-148	317	7	of	of	ADP
aji-148	317	8	malignancy	malignancy	NOUN
aji-148	317	9	along	along	ADP
aji-148	317	10	with	with	ADP
aji-148	317	11	cytokine	cytokine	NOUN
aji-148	317	12	-	-	PUNCT
aji-148	317	13	associated	associate	VERB
aji-148	317	14	toxicity	toxicity	NOUN
aji-148	317	15	in	in	ADP
aji-148	317	16	a	a	DET
aji-148	317	17	clinical	clinical	ADJ
aji-148	317	18	trial	trial	NOUN
aji-148	317	19	of	of	ADP
aji-148	317	20	anti	anti	ADJ
aji-148	317	21	-	-	ADJ
aji-148	317	22	cd19	cd19	ADJ
aji-148	317	23	chimeric	chimeric	ADJ
aji-148	317	24	-	-	PUNCT
aji-148	317	25	antigenreceptor	antigenreceptor	NOUN
aji-148	317	26	-	-	PUNCT
aji-148	317	27	transduced	transduce	VERB
aji-148	317	28	t	t	NOUN
aji-148	317	29	cells	cell	NOUN
aji-148	317	30	.	.	PUNCT
aji-148	318	1	blood	blood	NOUN
aji-148	318	2	.	.	PUNCT
aji-148	319	1	2012;119:2709–2720	2012;119:2709–2720	X
aji-148	319	2	.	.	PUNCT
aji-148	319	3	21	21	NUM
aji-148	319	4	.	.	PUNCT
aji-148	319	5	kochenderfer	kochenderfer	PROPN
aji-148	319	6	jn	jn	PROPN
aji-148	319	7	,	,	PUNCT
aji-148	319	8	et	et	PROPN
aji-148	319	9	al	al	PROPN
aji-148	319	10	.	.	PUNCT
aji-148	320	1	eradication	eradication	NOUN
aji-148	320	2	of	of	ADP
aji-148	320	3	blineage	blineage	NOUN
aji-148	320	4	cells	cell	NOUN
aji-148	320	5	and	and	CCONJ
aji-148	320	6	regression	regression	NOUN
aji-148	320	7	of	of	ADP
aji-148	320	8	lymphoma	lymphoma	NOUN
aji-148	320	9	in	in	ADP
aji-148	320	10	a	a	DET
aji-148	320	11	patient	patient	NOUN
aji-148	320	12	treated	treat	VERB
aji-148	320	13	with	with	ADP
aji-148	320	14	autologous	autologous	ADJ
aji-148	320	15	t	t	NOUN
aji-148	320	16	cells	cell	NOUN
aji-148	320	17	genetically	genetically	ADV
aji-148	320	18	engineered	engineer	VERB
aji-148	320	19	to	to	PART
aji-148	320	20	recognize	recognize	VERB
aji-148	320	21	cd19	cd19	PROPN
aji-148	320	22	.	.	PUNCT
aji-148	320	23	blood	blood	NOUN
aji-148	320	24	.	.	PUNCT
aji-148	321	1	2010;116:4099–4102	2010;116:4099–4102	X
aji-148	321	2	.	.	PUNCT
aji-148	322	1	22	22	NUM
aji-148	322	2	.	.	PUNCT
aji-148	323	1	brentjens	brentjens	PROPN
aji-148	323	2	rj	rj	PROPN
aji-148	323	3	,	,	PUNCT
aji-148	323	4	et	et	PROPN
aji-148	323	5	al	al	PROPN
aji-148	323	6	.	.	PROPN
aji-148	323	7	safety	safety	NOUN
aji-148	323	8	and	and	CCONJ
aji-148	323	9	persistence	persistence	NOUN
aji-148	323	10	of	of	ADP
aji-148	323	11	adoptively	adoptively	ADV
aji-148	323	12	transferred	transfer	VERB
aji-148	323	13	autologous	autologous	ADJ
aji-148	323	14	cd19targeted	cd19targete	VERB
aji-148	323	15	t	t	NOUN
aji-148	323	16	cells	cell	NOUN
aji-148	323	17	in	in	ADP
aji-148	323	18	patients	patient	NOUN
aji-148	323	19	with	with	ADP
aji-148	323	20	relapsed	relapse	VERB
aji-148	323	21	or	or	CCONJ
aji-148	323	22	chemotherapy	chemotherapy	NOUN
aji-148	323	23	refractory	refractory	NOUN
aji-148	323	24	b	b	NOUN
aji-148	323	25	-	-	PUNCT
aji-148	323	26	cell	cell	NOUN
aji-148	323	27	leukemias	leukemia	NOUN
aji-148	323	28	.	.	PUNCT
aji-148	324	1	blood	blood	NOUN
aji-148	324	2	.	.	PUNCT
aji-148	325	1	2011;118:4817–4828	2011;118:4817–4828	NOUN
aji-148	325	2	.	.	PUNCT
aji-148	326	1	23	23	NUM
aji-148	326	2	.	.	PUNCT
aji-148	327	1	kalos	kalos	PROPN
aji-148	327	2	m.	m.	PROPN
aji-148	327	3	t	t	PROPN
aji-148	327	4	cells	cell	NOUN
aji-148	327	5	with	with	ADP
aji-148	327	6	chimeric	chimeric	ADJ
aji-148	327	7	antigen	antigen	ADJ
aji-148	327	8	receptors	receptor	NOUN
aji-148	327	9	have	have	AUX
aji-148	327	10	potent	potent	VERB
aji-148	327	11	antitumor	antitumor	NOUN
aji-148	327	12	effects	effect	NOUN
aji-148	327	13	and	and	CCONJ
aji-148	327	14	can	can	AUX
aji-148	327	15	establish	establish	VERB
aji-148	327	16	memory	memory	NOUN
aji-148	327	17	in	in	ADP
aji-148	327	18	patients	patient	NOUN
aji-148	327	19	with	with	ADP
aji-148	327	20	advanced	advanced	ADJ
aji-148	327	21	leukemia	leukemia	NOUN
aji-148	327	22	.	.	PUNCT
aji-148	328	1	sci	sci	PROPN
aji-148	328	2	.	.	PROPN
aji-148	328	3	transl	transl	PROPN
aji-148	328	4	.	.	PUNCT
aji-148	329	1	med	med	PROPN
aji-148	329	2	.	.	PUNCT
aji-148	330	1	2011;3:95ra73	2011;3:95ra73	NUM
aji-148	330	2	24	24	NUM
aji-148	330	3	.	.	PUNCT
aji-148	331	1	porter	porter	PROPN
aji-148	331	2	dl	dl	PROPN
aji-148	331	3	,	,	PUNCT
aji-148	331	4	levine	levine	PROPN
aji-148	331	5	bl	bl	PROPN
aji-148	331	6	,	,	PUNCT
aji-148	331	7	kalos	kalos	PROPN
aji-148	331	8	m	m	PROPN
aji-148	331	9	,	,	PUNCT
aji-148	331	10	bagg	bagg	PROPN
aji-148	331	11	a	a	PROPN
aji-148	331	12	,	,	PUNCT
aji-148	331	13	june	june	PROPN
aji-148	331	14	ch	ch	PROPN
aji-148	331	15	.	.	PROPN
aji-148	331	16	chimeric	chimeric	ADJ
aji-148	331	17	antigen	antigen	NOUN
aji-148	331	18	receptormodified	receptormodifie	VERB
aji-148	331	19	t	t	NOUN
aji-148	331	20	cells	cell	NOUN
aji-148	331	21	in	in	ADP
aji-148	331	22	chronic	chronic	ADJ
aji-148	331	23	lymphoid	lymphoid	NOUN
aji-148	331	24	leukemia	leukemia	NOUN
aji-148	331	25	.	.	PUNCT
aji-148	332	1	n.	n.	PROPN
aji-148	332	2	engl	engl	PROPN
aji-148	332	3	.	.	PUNCT
aji-148	333	1	j.	j.	PROPN
aji-148	333	2	med	med	PROPN
aji-148	333	3	.	.	PUNCT
aji-148	334	1	2011;365:725	2011;365:725	NUM
aji-148	334	2	–	–	PUNCT
aji-148	334	3	733	733	NUM
aji-148	334	4	.	.	X
aji-148	335	1	25	25	NUM
aji-148	335	2	.	.	PUNCT
aji-148	336	1	neelapu	neelapu	PROPN
aji-148	336	2	ss	ss	PROPN
aji-148	336	3	.	.	PROPN
aji-148	336	4	axicabtagene	axicabtagene	PROPN
aji-148	336	5	ciloleucel	ciloleucel	PROPN
aji-148	336	6	car	car	PROPN
aji-148	336	7	t	t	NOUN
aji-148	336	8	-	-	PUNCT
aji-148	336	9	cell	cell	NOUN
aji-148	336	10	therapy	therapy	NOUN
aji-148	336	11	in	in	ADP
aji-148	336	12	refractory	refractory	NOUN
aji-148	336	13	large	large	ADJ
aji-148	336	14	b	b	NOUN
aji-148	336	15	-	-	PUNCT
aji-148	336	16	cell	cell	NOUN
aji-148	336	17	lymphoma	lymphoma	NOUN
aji-148	336	18	.	.	PUNCT
aji-148	337	1	n.	n.	PROPN
aji-148	337	2	engl	engl	PROPN
aji-148	337	3	.	.	PUNCT
aji-148	338	1	j.	j.	PROPN
aji-148	338	2	med	med	PROPN
aji-148	338	3	.	.	PUNCT
aji-148	339	1	2017;377:2531–2544	2017;377:2531–2544	NUM
aji-148	339	2	.	.	X
aji-148	340	1	26	26	NUM
aji-148	340	2	.	.	PUNCT
aji-148	341	1	abramson	abramson	PROPN
aji-148	341	2	js	js	PROPN
aji-148	341	3	,	,	PUNCT
aji-148	341	4	et	et	PROPN
aji-148	341	5	al	al	PROPN
aji-148	341	6	.	.	PROPN
aji-148	342	1	lisocabtagene	lisocabtagene	PROPN
aji-148	342	2	maraleucel	maraleucel	PROPN
aji-148	342	3	for	for	ADP
aji-148	342	4	patients	patient	NOUN
aji-148	342	5	with	with	ADP
aji-148	342	6	relapsed	relapse	VERB
aji-148	342	7	or	or	CCONJ
aji-148	342	8	refractory	refractory	NOUN
aji-148	342	9	large	large	ADJ
aji-148	342	10	b	b	NOUN
aji-148	342	11	-	-	PUNCT
aji-148	342	12	cell	cell	NOUN
aji-148	342	13	lymphomas	lymphoma	NOUN
aji-148	342	14	(	(	PUNCT
aji-148	342	15	transcend	transcend	VERB
aji-148	342	16	nhl	nhl	PROPN
aji-148	342	17	001	001	NUM
aji-148	342	18	):	):	PUNCT
aji-148	342	19	a	a	DET
aji-148	342	20	multicentre	multicentre	NOUN
aji-148	342	21	seamless	seamless	ADJ
aji-148	342	22	design	design	NOUN
aji-148	342	23	study	study	NOUN
aji-148	342	24	.	.	PUNCT
aji-148	343	1	lancet	lancet	PROPN
aji-148	343	2	.	.	PUNCT
aji-148	344	1	2020	2020	NUM
aji-148	344	2	;	;	PUNCT
aji-148	344	3	396:839–852	396:839–852	NUM
aji-148	344	4	.	.	PUNCT
aji-148	345	1	27	27	NUM
aji-148	345	2	.	.	PUNCT
aji-148	346	1	schuster	schuster	PROPN
aji-148	346	2	sj	sj	PROPN
aji-148	346	3	.	.	PROPN
aji-148	347	1	tisagenlecleucel	tisagenlecleucel	PROPN
aji-148	347	2	in	in	ADP
aji-148	347	3	adult	adult	NOUN
aji-148	347	4	relapsed	relapse	VERB
aji-148	347	5	or	or	CCONJ
aji-148	347	6	refractory	refractory	NOUN
aji-148	347	7	diffuse	diffuse	VERB
aji-148	347	8	large	large	ADJ
aji-148	347	9	b	b	NOUN
aji-148	347	10	-	-	PUNCT
aji-148	347	11	cell	cell	NOUN
aji-148	347	12	lymphoma	lymphoma	NOUN
aji-148	347	13	.	.	PUNCT
aji-148	348	1	n.	n.	PROPN
aji-148	348	2	engl	engl	PROPN
aji-148	348	3	.	.	PUNCT
aji-148	349	1	j.	j.	PROPN
aji-148	349	2	med	med	PROPN
aji-148	349	3	.	.	PROPN
aji-148	349	4	2019	2019	NUM
aji-148	349	5	;	;	PUNCT
aji-148	349	6	380:45	380:45	NUM
aji-148	349	7	–	–	PUNCT
aji-148	349	8	56	56	NUM
aji-148	349	9	.	.	NOUN
aji-148	349	10	28	28	NUM
aji-148	349	11	.	.	PUNCT
aji-148	350	1	wang	wang	PROPN
aji-148	350	2	m.	m.	PROPN
aji-148	350	3	kte	kte	PROPN
aji-148	350	4	-	-	PROPN
aji-148	350	5	x19	x19	PROPN
aji-148	350	6	car	car	NOUN
aji-148	350	7	t	t	NOUN
aji-148	350	8	-	-	PUNCT
aji-148	350	9	cell	cell	NOUN
aji-148	350	10	therapy	therapy	NOUN
aji-148	350	11	in	in	ADP
aji-148	350	12	relapsed	relapse	VERB
aji-148	350	13	or	or	CCONJ
aji-148	350	14	refractory	refractory	NOUN
aji-148	350	15	mantle	mantle	NOUN
aji-148	350	16	-	-	PUNCT
aji-148	350	17	cell	cell	NOUN
aji-148	350	18	lymphoma	lymphoma	NOUN
aji-148	350	19	.	.	PUNCT
aji-148	351	1	n.	n.	PROPN
aji-148	351	2	engl	engl	PROPN
aji-148	351	3	.	.	PUNCT
aji-148	352	1	j.	j.	PROPN
aji-148	352	2	med	med	PROPN
aji-148	352	3	.	.	PUNCT
aji-148	353	1	2020;382	2020;382	NUM
aji-148	353	2	:	:	PUNCT
aji-148	353	3	1331–1342	1331–1342	NUM
aji-148	353	4	.	.	PUNCT
aji-148	354	1	29	29	NUM
aji-148	354	2	.	.	PUNCT
aji-148	355	1	teomete	teomete	PROPN
aji-148	355	2	m	m	PROPN
aji-148	355	3	,	,	PUNCT
aji-148	355	4	cabuk	cabuk	VERB
aji-148	355	5	d	d	PROPN
aji-148	355	6	,	,	PUNCT
aji-148	355	7	korkmaz	korkmaz	NOUN
aji-148	355	8	t.	t.	NOUN
aji-148	355	9	recommendations	recommendation	NOUN
aji-148	355	10	for	for	ADP
aji-148	355	11	cyclin‑dependent	cyclin‑dependent	ADJ
aji-148	355	12	kinase	kinase	PROPN
aji-148	355	13	4/6	4/6	NUM
aji-148	355	14	inhibitor	inhibitor	NOUN
aji-148	355	15	treatments	treatment	NOUN
aji-148	355	16	in	in	ADP
aji-148	355	17	the	the	DET
aji-148	355	18	context	context	NOUN
aji-148	355	19	of	of	ADP
aji-148	355	20	co‑morbidity	co‑morbidity	NOUN
aji-148	355	21	and	and	CCONJ
aji-148	355	22	drug	drug	NOUN
aji-148	355	23	interactions	interaction	NOUN
aji-148	355	24	(	(	PUNCT
aji-148	355	25	review	review	NOUN
aji-148	355	26	)	)	PUNCT
aji-148	355	27	.	.	PUNCT
aji-148	356	1	oncol	oncol	ADJ
aji-148	356	2	lett	lett	PROPN
aji-148	356	3	.	.	PUNCT
aji-148	357	1	2024	2024	NUM
aji-148	357	2	;	;	PUNCT
aji-148	358	1	27(4):145	27(4):145	NUM
aji-148	358	2	.	.	PUNCT
aji-148	359	1	30	30	NUM
aji-148	359	2	.	.	PUNCT
aji-148	359	3	lieschke	lieschke	PROPN
aji-148	359	4	gj	gj	PROPN
aji-148	359	5	,	,	PUNCT
aji-148	359	6	morstyn	morstyn	ADJ
aji-148	359	7	g.	g.	PROPN
aji-148	359	8	clinical	clinical	ADJ
aji-148	359	9	trials	trial	NOUN
aji-148	359	10	of	of	ADP
aji-148	359	11	granulocyte	granulocyte	ADJ
aji-148	359	12	colony	colony	NOUN
aji-148	359	13	-	-	PUNCT
aji-148	359	14	stimulating	stimulate	VERB
aji-148	359	15	factors	factor	NOUN
aji-148	359	16	for	for	ADP
aji-148	359	17	treatment	treatment	NOUN
aji-148	359	18	of	of	ADP
aji-148	359	19	bone	bone	NOUN
aji-148	359	20	marrow	marrow	NOUN
aji-148	359	21	depression	depression	NOUN
aji-148	359	22	associated	associate	VERB
aji-148	359	23	with	with	ADP
aji-148	359	24	cancer	cancer	NOUN
aji-148	359	25	chemotherapy	chemotherapy	NOUN
aji-148	359	26	.	.	PUNCT
aji-148	360	1	immunol	immunol	NOUN
aji-148	360	2	ser	ser	PROPN
aji-148	360	3	.	.	PUNCT
aji-148	361	1	1992;57:671	1992;57:671	NUM
aji-148	361	2	-	-	SYM
aji-148	361	3	93	93	NUM
aji-148	361	4	.	.	PUNCT
aji-148	362	1	31	31	NUM
aji-148	362	2	.	.	PUNCT
aji-148	363	1	lu	lu	PROPN
aji-148	363	2	j	j	PROPN
aji-148	363	3	,	,	PUNCT
aji-148	363	4	hu	hu	PROPN
aji-148	364	1	l	l	PROPN
aji-148	364	2	lw	lw	PROPN
aji-148	364	3	,	,	PUNCT
aji-148	364	4	hua	hua	PROPN
aji-148	364	5	zd	zd	PROPN
aji-148	364	6	,	,	PUNCT
aji-148	364	7	li	li	PROPN
aji-148	364	8	b	b	PROPN
aji-148	364	9	,	,	PUNCT
aji-148	364	10	tong	tong	PROPN
aji-148	364	11	sq	sq	PROPN
aji-148	364	12	;	;	PUNCT
aji-148	364	13	analysis	analysis	NOUN
aji-148	364	14	of	of	ADP
aji-148	364	15	the	the	DET
aji-148	364	16	therapeutic	therapeutic	ADJ
aji-148	364	17	effects	effect	NOUN
aji-148	364	18	of	of	ADP
aji-148	364	19	different	different	ADJ
aji-148	364	20	therapeutic	therapeutic	ADJ
aji-148	364	21	approaches	approach	NOUN
aji-148	364	22	for	for	ADP
aji-148	364	23	til	til	PROPN
aji-148	364	24	.	.	PUNCT
aji-148	365	1	chinese	chinese	PROPN
aji-148	365	2	journal	journal	PROPN
aji-148	365	3	cancer	cancer	NOUN
aji-148	365	4	biotherapy	biotherapy	NOUN
aji-148	365	5	(	(	PUNCT
aji-148	365	6	chinese	chinese	ADJ
aji-148	365	7	)	)	PUNCT
aji-148	365	8	1996;3(2):127	1996;3(2):127	NUM
aji-148	365	9	-	-	SYM
aji-148	365	10	129	129	NUM
aji-148	365	11	.	.	PUNCT
aji-148	366	1	32	32	NUM
aji-148	366	2	.	.	PUNCT
aji-148	367	1	gu	gu	NOUN
aji-148	367	2	ql	ql	PROPN
aji-148	367	3	,	,	PUNCT
aji-148	367	4	lin	lin	PROPN
aji-148	367	5	yz	yz	PROPN
aji-148	367	6	,	,	PUNCT
aji-148	367	7	yin	yin	PROPN
aji-148	367	8	hr	hr	PROPN
aji-148	367	9	,	,	PUNCT
aji-148	367	10	li	li	PROPN
aji-148	367	11	b	b	PROPN
aji-148	367	12	,	,	PUNCT
aji-148	367	13	zhu	zhu	PROPN
aji-148	367	14	ym	ym	PROPN
aji-148	367	15	,	,	PUNCT
aji-148	367	16	hu	hu	PROPN
aji-148	367	17	by	by	ADP
aji-148	367	18	.	.	PUNCT
aji-148	368	1	preliminary	preliminary	ADJ
aji-148	368	2	study	study	NOUN
aji-148	368	3	on	on	ADP
aji-148	368	4	cryopreservation	cryopreservation	NOUN
aji-148	368	5	of	of	ADP
aji-148	368	6	tumor	tumor	NOUN
aji-148	368	7	infiltrating	infiltrate	VERB
aji-148	368	8	lymphocytes	lymphocyte	NOUN
aji-148	368	9	.	.	PUNCT
aji-148	369	1	journal	journal	NOUN
aji-148	369	2	of	of	ADP
aji-148	369	3	immunology	immunology	NOUN
aji-148	369	4	(	(	PUNCT
aji-148	369	5	chinese	chinese	PROPN
aji-148	369	6	)	)	PUNCT
aji-148	369	7	,	,	PUNCT
aji-148	369	8	1995;04:251	1995;04:251	NUM
aji-148	369	9	-	-	SYM
aji-148	369	10	252	252	NUM
aji-148	369	11	.	.	PUNCT
aji-148	370	1	33	33	NUM
aji-148	370	2	.	.	PUNCT
aji-148	371	1	hua	hua	PROPN
aji-148	371	2	zd	zd	PROPN
aji-148	371	3	;	;	PUNCT
aji-148	371	4	lu	lu	PROPN
aji-148	371	5	j	j	PROPN
aji-148	371	6	,	,	PUNCT
aji-148	371	7	li	li	PROPN
aji-148	371	8	hf	hf	PROPN
aji-148	371	9	,	,	PUNCT
aji-148	371	10	li	li	PROPN
aji-148	371	11	b	b	PROPN
aji-148	371	12	,	,	PUNCT
aji-148	371	13	zhu	zhu	PROPN
aji-148	371	14	ym	ym	PROPN
aji-148	371	15	,	,	PUNCT
aji-148	371	16	tong	tong	PROPN
aji-148	371	17	sq	sq	PROPN
aji-148	371	18	.	.	PROPN
aji-148	371	19	clinical	clinical	ADJ
aji-148	371	20	study	study	NOUN
aji-148	371	21	of	of	ADP
aji-148	371	22	tumor	tumor	NOUN
aji-148	371	23	infiltrating	infiltrate	VERB
aji-148	371	24	lymphocytes	lymphocyte	NOUN
aji-148	371	25	in	in	ADP
aji-148	371	26	ovarian	ovarian	ADJ
aji-148	371	27	cancer	cancer	NOUN
aji-148	371	28	.	.	PUNCT
aji-148	372	1	chinese	chinese	ADJ
aji-148	372	2	journal	journal	NOUN
aji-148	372	3	of	of	ADP
aji-148	372	4	obstetrics	obstetric	NOUN
aji-148	372	5	and	and	CCONJ
aji-148	372	6	gynecology	gynecology	NOUN
aji-148	372	7	(	(	PUNCT
aji-148	372	8	chinese	chinese	ADJ
aji-148	372	9	)	)	PUNCT
aji-148	372	10	1996;31(9):55	1996;31(9):55	PROPN
aji-148	372	11	-	-	SYM
aji-148	372	12	57	57	NUM
aji-148	372	13	.	.	PUNCT
aji-148	373	1	34	34	NUM
aji-148	373	2	.	.	PUNCT
aji-148	374	1	lu	lu	PROPN
aji-148	374	2	j	j	PROPN
aji-148	374	3	,	,	PUNCT
aji-148	374	4	li	li	PROPN
aji-148	374	5	b	b	PROPN
aji-148	374	6	,	,	PUNCT
aji-148	374	7	hua	hua	PROPN
aji-148	374	8	zd	zd	PROPN
aji-148	374	9	,	,	PUNCT
aji-148	374	10	zhu	zhu	PROPN
aji-148	374	11	ym	ym	PROPN
aji-148	374	12	,	,	PUNCT
aji-148	374	13	tong	tong	PROPN
aji-148	374	14	sq	sq	PROPN
aji-148	374	15	.	.	PROPN
aji-148	374	16	research	research	NOUN
aji-148	374	17	on	on	ADP
aji-148	374	18	til	til	ADV
aji-148	374	19	yield	yield	NOUN
aji-148	374	20	and	and	CCONJ
aji-148	374	21	vitality	vitality	NOUN
aji-148	374	22	of	of	ADP
aji-148	374	23	different	different	ADJ
aji-148	374	24	materials	material	NOUN
aji-148	374	25	.	.	PUNCT
aji-148	375	1	journal	journal	NOUN
aji-148	375	2	of	of	ADP
aji-148	375	3	immunology	immunology	NOUN
aji-148	375	4	(	(	PUNCT
aji-148	375	5	chinese	chinese	ADJ
aji-148	375	6	)	)	PUNCT
aji-148	375	7	1995;11(3):182	1995;11(3):182	NUM
aji-148	375	8	-	-	SYM
aji-148	375	9	185	185	NUM
aji-148	375	10	.	.	PUNCT
aji-148	376	1	35	35	NUM
aji-148	376	2	.	.	PUNCT
aji-148	377	1	lu	lu	PROPN
aji-148	377	2	j	j	PROPN
aji-148	377	3	,	,	PUNCT
aji-148	377	4	hua	hua	PROPN
aji-148	377	5	zd	zd	PROPN
aji-148	377	6	,	,	PUNCT
aji-148	377	7	li	li	PROPN
aji-148	377	8	hf	hf	PROPN
aji-148	377	9	,	,	PUNCT
aji-148	377	10	li	li	PROPN
aji-148	377	11	b	b	PROPN
aji-148	377	12	,	,	PUNCT
aji-148	377	13	zhu	zhu	PROPN
aji-148	377	14	ym	ym	PROPN
aji-148	377	15	,	,	PUNCT
aji-148	377	16	tong	tong	PROPN
aji-148	377	17	sq	sq	PROPN
aji-148	377	18	.	.	PROPN
aji-148	378	1	in	in	ADP
aji-148	378	2	vitro	vitro	X
aji-148	378	3	study	study	NOUN
aji-148	378	4	of	of	ADP
aji-148	378	5	ovarian	ovarian	ADJ
aji-148	378	6	cancer	cancer	NOUN
aji-148	378	7	til	til	PROPN
aji-148	378	8	shanghai	shanghai	PROPN
aji-148	378	9	medical	medical	PROPN
aji-148	378	10	journal	journal	PROPN
aji-148	378	11	.	.	PUNCT
aji-148	379	1	(	(	PUNCT
aji-148	379	2	chinese	chinese	ADJ
aji-148	379	3	)	)	PUNCT
aji-148	379	4	1995;18(6):325	1995;18(6):325	PROPN
aji-148	379	5	-	-	PROPN
aji-148	379	6	327	327	NUM
aji-148	379	7	.	.	PUNCT
aji-148	380	1	36	36	NUM
aji-148	380	2	.	.	PUNCT
aji-148	381	1	ito	ito	PROPN
aji-148	381	2	t	t	PROPN
aji-148	381	3	,	,	PUNCT
aji-148	381	4	ando	ando	PROPN
aji-148	381	5	h	h	PROPN
aji-148	381	6	,	,	PUNCT
aji-148	381	7	suzuki	suzuki	PROPN
aji-148	381	8	t	t	PROPN
aji-148	381	9	,	,	PUNCT
aji-148	381	10	et	et	PROPN
aji-148	381	11	al	al	PROPN
aji-148	381	12	.	.	PUNCT
aji-148	381	13	identification	identification	NOUN
aji-148	381	14	of	of	ADP
aji-148	381	15	a	a	DET
aji-148	381	16	primary	primary	ADJ
aji-148	381	17	target	target	NOUN
aji-148	381	18	of	of	ADP
aji-148	381	19	thalidomide	thalidomide	NOUN
aji-148	381	20	teratogenicity	teratogenicity	NOUN
aji-148	381	21	.	.	PUNCT
aji-148	382	1	science	science	NOUN
aji-148	382	2	.	.	PUNCT
aji-148	383	1	2010;327:1345	2010;327:1345	NUM
aji-148	383	2	–	–	PUNCT
aji-148	383	3	1350	1350	NUM
aji-148	383	4	.	.	PUNCT
aji-148	384	1	37	37	NUM
aji-148	384	2	.	.	PUNCT
aji-148	385	1	lopez	lopez	PROPN
aji-148	385	2	-	-	PUNCT
aji-148	385	3	girona	girona	PROPN
aji-148	385	4	a	a	X
aji-148	385	5	,	,	PUNCT
aji-148	385	6	mendy	mendy	PROPN
aji-148	385	7	d	d	PROPN
aji-148	385	8	,	,	PUNCT
aji-148	385	9	ito	ito	PROPN
aji-148	385	10	t.	t.	PROPN
aji-148	385	11	cereblon	cereblon	PROPN
aji-148	385	12	is	be	AUX
aji-148	385	13	a	a	DET
aji-148	385	14	direct	direct	ADJ
aji-148	385	15	protein	protein	NOUN
aji-148	385	16	target	target	NOUN
aji-148	385	17	for	for	ADP
aji-148	385	18	immunomodulatory	immunomodulatory	ADJ
aji-148	385	19	and	and	CCONJ
aji-148	385	20	antiproliferative	antiproliferative	ADJ
aji-148	385	21	activities	activity	NOUN
aji-148	385	22	of	of	ADP
aji-148	385	23	lenalidomide	lenalidomide	NOUN
aji-148	385	24	and	and	CCONJ
aji-148	385	25	pomalidomide	pomalidomide	NOUN
aji-148	385	26	.	.	PUNCT
aji-148	386	1	leukemia	leukemia	NOUN
aji-148	386	2	.	.	PUNCT
aji-148	387	1	2012;26:2326	2012;26:2326	NUM
aji-148	387	2	–	–	PUNCT
aji-148	387	3	2335	2335	NUM
aji-148	387	4	.	.	PUNCT
aji-148	388	1	38	38	NUM
aji-148	388	2	.	.	PUNCT
aji-148	389	1	gandhi	gandhi	PROPN
aji-148	389	2	ak	ak	PROPN
aji-148	389	3	,	,	PUNCT
aji-148	389	4	kang	kang	PROPN
aji-148	389	5	j	j	PROPN
aji-148	389	6	,	,	PUNCT
aji-148	389	7	havens	haven	NOUN
aji-148	389	8	cg	cg	VERB
aji-148	389	9	.	.	PUNCT
aji-148	389	10	immunomodulatory	immunomodulatory	PROPN
aji-148	389	11	agents	agent	NOUN
aji-148	389	12	lenalidomide	lenalidomide	VERB
aji-148	389	13	and	and	CCONJ
aji-148	389	14	pomalidomide	pomalidomide	VERB
aji-148	389	15	co	co	VERB
aji-148	389	16	-	-	VERB
aji-148	389	17	stimulate	stimulate	ADJ
aji-148	389	18	t	t	NOUN
aji-148	389	19	cells	cell	NOUN
aji-148	389	20	by	by	ADP
aji-148	389	21	inducing	induce	VERB
aji-148	389	22	degradation	degradation	NOUN
aji-148	389	23	of	of	ADP
aji-148	389	24	t	t	NOUN
aji-148	389	25	cell	cell	NOUN
aji-148	389	26	repressors	repressor	VERB
aji-148	389	27	ikaros	ikaro	NOUN
aji-148	389	28	and	and	CCONJ
aji-148	389	29	aiolos	aiolo	NOUN
aji-148	389	30	via	via	ADP
aji-148	389	31	modulation	modulation	NOUN
aji-148	389	32	of	of	ADP
aji-148	389	33	the	the	DET
aji-148	389	34	e3	e3	NOUN
aji-148	389	35	ubiquitin	ubiquitin	ADJ
aji-148	389	36	ligase	ligase	NOUN
aji-148	389	37	complex	complex	PROPN
aji-148	389	38	crl4(crbn	crl4(crbn	PUNCT
aji-148	389	39	.	.	PUNCT
aji-148	389	40	)	)	PUNCT
aji-148	390	1	br	br	NOUN
aji-148	391	1	j	j	PROPN
aji-148	391	2	haematol	haematol	NOUN
aji-148	391	3	.	.	PUNCT
aji-148	392	1	2014;164:811–821	2014;164:811–821	NUM
aji-148	392	2	39	39	NUM
aji-148	392	3	.	.	PUNCT
aji-148	393	1	mansour	mansour	PROPN
aji-148	393	2	ama	ama	PROPN
aji-148	393	3	,	,	PUNCT
aji-148	393	4	khattab	khattab	PROPN
aji-148	393	5	mm	mm	PROPN
aji-148	393	6	,	,	PUNCT
aji-148	393	7	el	el	PROPN
aji-148	393	8	-	-	PROPN
aji-148	393	9	khatib	khatib	PROPN
aji-148	393	10	as	as	ADP
aji-148	393	11	.	.	PROPN
aji-148	393	12	valsartan	valsartan	PROPN
aji-148	393	13	as	as	ADP
aji-148	393	14	a	a	DET
aji-148	393	15	prophylactic	prophylactic	ADJ
aji-148	393	16	treatment	treatment	NOUN
aji-148	393	17	against	against	ADP
aji-148	393	18	breast	breast	NOUN
aji-148	393	19	cancer	cancer	NOUN
aji-148	393	20	development	development	NOUN
aji-148	393	21	and	and	CCONJ
aji-148	393	22	niche	niche	NOUN
aji-148	393	23	activation	activation	NOUN
aji-148	393	24	:	:	PUNCT
aji-148	393	25	what	what	PRON
aji-148	393	26	molecular	molecular	ADJ
aji-148	393	27	sequels	sequel	NOUN
aji-148	393	28	follow	follow	VERB
aji-148	393	29	chronic	chronic	ADJ
aji-148	393	30	at-1r	at-1r	PROPN
aji-148	393	31	blockade	blockade	NOUN
aji-148	393	32	?	?	PUNCT
aji-148	394	1	life	life	NOUN
aji-148	394	2	sci	sci	PROPN
aji-148	394	3	.	.	PUNCT
aji-148	395	1	2024;353:122939	2024;353:122939	NUM
aji-148	395	2	.	.	PUNCT
aji-148	396	1	40	40	NUM
aji-148	396	2	.	.	PUNCT
aji-148	397	1	zhang	zhang	PROPN
aji-148	397	2	j	j	PROPN
aji-148	397	3	,	,	PUNCT
aji-148	397	4	wang	wang	PROPN
aji-148	397	5	l	l	PROPN
aji-148	397	6	,	,	PUNCT
aji-148	397	7	guo	guo	PROPN
aji-148	397	8	h.	h.	PROPN
aji-148	398	1	the	the	DET
aji-148	398	2	role	role	NOUN
aji-148	398	3	of	of	ADP
aji-148	398	4	tim3	tim3	PROPN
aji-148	398	5	blockade	blockade	NOUN
aji-148	398	6	in	in	ADP
aji-148	398	7	the	the	DET
aji-148	398	8	tumor	tumor	NOUN
aji-148	398	9	immune	immune	ADJ
aji-148	398	10	microenvironment	microenvironment	NOUN
aji-148	398	11	beyond	beyond	ADP
aji-148	398	12	t	t	NOUN
aji-148	398	13	cells	cell	NOUN
aji-148	398	14	.	.	PUNCT
aji-148	399	1	pharmacol	pharmacol	NOUN
aji-148	399	2	res	re	NOUN
aji-148	399	3	.	.	PUNCT
aji-148	400	1	2024;209:107458	2024;209:107458	NUM
aji-148	400	2	.	.	PUNCT
aji-148	401	1	41	41	NUM
aji-148	401	2	.	.	PUNCT
aji-148	402	1	walsh	walsh	PROPN
aji-148	402	2	rj	rj	PROPN
aji-148	402	3	,	,	PUNCT
aji-148	402	4	sundar	sundar	NOUN
aji-148	402	5	r	r	PROPN
aji-148	402	6	,	,	PUNCT
aji-148	402	7	lim	lim	PROPN
aji-148	402	8	jsj	jsj	PROPN
aji-148	402	9	.	.	PROPN
aji-148	402	10	immune	immune	ADJ
aji-148	402	11	checkpoint	checkpoint	NOUN
aji-148	402	12	inhibitor	inhibitor	NOUN
aji-148	402	13	combinations	combination	NOUN
aji-148	402	14	-	-	PUNCT
aji-148	402	15	current	current	ADJ
aji-148	402	16	li	li	PROPN
aji-148	402	17	and	and	CCONJ
aji-148	402	18	li	li	PROPN
aji-148	402	19	;	;	PUNCT
aji-148	402	20	asian	asian	PROPN
aji-148	402	21	j.	j.	PROPN
aji-148	402	22	immunol	immunol	PROPN
aji-148	402	23	.	.	PROPN
aji-148	402	24	,	,	PUNCT
aji-148	402	25	vol	vol	NOUN
aji-148	402	26	.	.	PROPN
aji-148	402	27	7	7	NUM
aji-148	402	28	,	,	PUNCT
aji-148	402	29	no	no	INTJ
aji-148	402	30	.	.	NOUN
aji-148	402	31	1	1	NUM
aji-148	402	32	,	,	PUNCT
aji-148	402	33	pp	pp	ADJ
aji-148	402	34	.	.	PUNCT
aji-148	403	1	247	247	NUM
aji-148	403	2	-	-	SYM
aji-148	403	3	257	257	NUM
aji-148	403	4	,	,	PUNCT
aji-148	403	5	2024	2024	NUM
aji-148	403	6	;	;	PUNCT
aji-148	404	1	article	article	NOUN
aji-148	404	2	no.aji.126682	no.aji.126682	ADP
aji-148	404	3	256	256	NUM
aji-148	404	4	and	and	CCONJ
aji-148	404	5	emerging	emerge	VERB
aji-148	404	6	strategies	strategy	NOUN
aji-148	404	7	.	.	PUNCT
aji-148	405	1	br	br	PROPN
aji-148	405	2	j	j	PROPN
aji-148	405	3	cancer	cancer	NOUN
aji-148	405	4	.	.	PUNCT
aji-148	406	1	2023;128(8):1415	2023;128(8):1415	NUM
aji-148	406	2	-	-	SYM
aji-148	406	3	1417	1417	NUM
aji-148	406	4	.	.	PUNCT
aji-148	407	1	42	42	NUM
aji-148	407	2	.	.	PUNCT
aji-148	408	1	ivanova	ivanova	PROPN
aji-148	408	2	e	e	PROPN
aji-148	408	3	,	,	PUNCT
aji-148	408	4	ward	ward	VERB
aji-148	408	5	a	a	PRON
aji-148	408	6	,	,	PUNCT
aji-148	408	7	wiegmans	wiegman	NOUN
aji-148	408	8	ap	ap	PROPN
aji-148	408	9	,	,	PUNCT
aji-148	408	10	richard	richard	PROPN
aji-148	408	11	dj	dj	PROPN
aji-148	408	12	.	.	PUNCT
aji-148	409	1	circulating	circulate	VERB
aji-148	409	2	tumor	tumor	NOUN
aji-148	409	3	cells	cell	NOUN
aji-148	409	4	in	in	ADP
aji-148	409	5	metastatic	metastatic	ADJ
aji-148	409	6	breast	breast	NOUN
aji-148	409	7	cancer	cancer	NOUN
aji-148	409	8	:	:	PUNCT
aji-148	409	9	from	from	ADP
aji-148	409	10	genome	genome	NOUN
aji-148	409	11	instability	instability	NOUN
aji-148	409	12	to	to	ADP
aji-148	409	13	metastasis	metastasis	NOUN
aji-148	409	14	.	.	PUNCT
aji-148	410	1	front	front	NOUN
aji-148	410	2	mol	mol	ADP
aji-148	410	3	biosci	biosci	PROPN
aji-148	410	4	.	.	PUNCT
aji-148	411	1	2020;7:134	2020;7:134	NUM
aji-148	411	2	.	.	PUNCT
aji-148	412	1	43	43	NUM
aji-148	412	2	.	.	PUNCT
aji-148	413	1	schuster	schuster	PROPN
aji-148	413	2	e	e	PROPN
aji-148	413	3	,	,	PUNCT
aji-148	413	4	taftaf	taftaf	NOUN
aji-148	413	5	r	r	NOUN
aji-148	413	6	,	,	PUNCT
aji-148	413	7	reduzzi	reduzzi	NOUN
aji-148	413	8	c.	c.	PROPN
aji-148	413	9	better	well	ADV
aji-148	413	10	together	together	ADV
aji-148	413	11	:	:	PUNCT
aji-148	413	12	circulating	circulate	VERB
aji-148	413	13	tumor	tumor	NOUN
aji-148	413	14	cell	cell	NOUN
aji-148	413	15	clustering	cluster	VERB
aji-148	413	16	in	in	ADP
aji-148	413	17	metastatic	metastatic	ADJ
aji-148	413	18	cancer	cancer	NOUN
aji-148	413	19	.	.	PUNCT
aji-148	414	1	trends	trend	NOUN
aji-148	414	2	cancer	cancer	NOUN
aji-148	414	3	.	.	PUNCT
aji-148	415	1	2021;7:1020–1032	2021;7:1020–1032	X
aji-148	415	2	.	.	PROPN
aji-148	416	1	44	44	NUM
aji-148	416	2	.	.	PUNCT
aji-148	417	1	liu	liu	PROPN
aji-148	417	2	mc	mc	PROPN
aji-148	417	3	,	,	PUNCT
aji-148	417	4	shields	shield	VERB
aji-148	417	5	pg	pg	PROPN
aji-148	417	6	,	,	PUNCT
aji-148	417	7	warren	warren	PROPN
aji-148	417	8	rd	rd	PROPN
aji-148	417	9	.	.	PUNCT
aji-148	417	10	circulating	circulate	VERB
aji-148	417	11	tumor	tumor	NOUN
aji-148	417	12	cells	cell	NOUN
aji-148	417	13	:	:	PUNCT
aji-148	417	14	a	a	DET
aji-148	417	15	useful	useful	ADJ
aji-148	417	16	predictor	predictor	NOUN
aji-148	417	17	of	of	ADP
aji-148	417	18	treatment	treatment	NOUN
aji-148	417	19	efficacy	efficacy	NOUN
aji-148	417	20	in	in	ADP
aji-148	417	21	metastatic	metastatic	ADJ
aji-148	417	22	breast	breast	NOUN
aji-148	417	23	cancer	cancer	NOUN
aji-148	417	24	.	.	PUNCT
aji-148	418	1	j	j	PROPN
aji-148	418	2	clin	clin	PROPN
aji-148	418	3	oncol	oncol	PROPN
aji-148	418	4	.	.	PUNCT
aji-148	419	1	2009;27:5153–5159	2009;27:5153–5159	NUM
aji-148	419	2	.	.	PUNCT
aji-148	420	1	45	45	NUM
aji-148	420	2	.	.	PUNCT
aji-148	420	3	li	li	PROPN
aji-148	420	4	b.	b.	PROPN
aji-148	420	5	biobank	biobank	PROPN
aji-148	420	6	for	for	ADP
aji-148	420	7	personalized	personalized	ADJ
aji-148	420	8	immunotherapy	immunotherapy	NOUN
aji-148	420	9	.	.	PUNCT
aji-148	421	1	chapter	chapter	NOUN
aji-148	421	2	13	13	NUM
aji-148	421	3	.	.	PUNCT
aji-148	422	1	in	in	ADP
aji-148	422	2	:	:	PUNCT
aji-148	422	3	li	li	PROPN
aji-148	422	4	b	b	PROPN
aji-148	422	5	,	,	PUNCT
aji-148	422	6	li	li	PROPN
aji-148	422	7	s	s	PROPN
aji-148	422	8	,	,	PUNCT
aji-148	422	9	larson	larson	PROPN
aji-148	422	10	a	a	NOUN
aji-148	422	11	,	,	PUNCT
aji-148	422	12	editors	editor	NOUN
aji-148	422	13	.	.	PUNCT
aji-148	423	1	personalized	personalize	VERB
aji-148	423	2	immunotherapy	immunotherapy	NOUN
aji-148	423	3	for	for	ADP
aji-148	423	4	tumor	tumor	NOUN
aji-148	423	5	diseases	disease	NOUN
aji-148	423	6	and	and	CCONJ
aji-148	423	7	beyond	beyond	ADP
aji-148	423	8	.	.	PUNCT
aji-148	424	1	(	(	PUNCT
aji-148	424	2	singapore	singapore	PROPN
aji-148	424	3	:	:	PUNCT
aji-148	424	4	bentham	bentham	PROPN
aji-148	424	5	science	science	PROPN
aji-148	424	6	publishers	publisher	NOUN
aji-148	424	7	;)	;)	PUNCT
aji-148	424	8	.	.	PUNCT
aji-148	424	9	2020;224–54	2020;224–54	NUM
aji-148	424	10	.	.	X
aji-148	425	1	46	46	NUM
aji-148	425	2	.	.	PUNCT
aji-148	426	1	li	li	PROPN
aji-148	426	2	b	b	PROPN
aji-148	426	3	,	,	PUNCT
aji-148	426	4	ding	ding	PROPN
aji-148	426	5	jq	jq	PROPN
aji-148	426	6	,	,	PUNCT
aji-148	426	7	larson	larson	PROPN
aji-148	426	8	a	a	PROPN
aji-148	426	9	,	,	PUNCT
aji-148	426	10	song	song	PROPN
aji-148	426	11	sw	sw	PROPN
aji-148	426	12	.	.	PUNCT
aji-148	426	13	tissue	tissue	NOUN
aji-148	426	14	recycling	recycling	NOUN
aji-148	426	15	-	-	PUNCT
aji-148	426	16	a	a	DET
aji-148	426	17	new	new	ADJ
aji-148	426	18	combination	combination	NOUN
aji-148	426	19	therapy	therapy	NOUN
aji-148	426	20	for	for	ADP
aji-148	426	21	solid	solid	ADJ
aji-148	426	22	tumor	tumor	NOUN
aji-148	426	23	:	:	PUNCT
aji-148	426	24	experimental	experimental	ADJ
aji-148	426	25	and	and	CCONJ
aji-148	426	26	preliminarily	preliminarily	ADV
aji-148	426	27	clinical	clinical	ADJ
aji-148	426	28	research	research	NOUN
aji-148	426	29	.	.	PUNCT
aji-148	427	1	anticancer	anticancer	NOUN
aji-148	427	2	.	.	PUNCT
aji-148	428	1	in	in	ADP
aji-148	428	2	vivo	vivo	NOUN
aji-148	428	3	.	.	PUNCT
aji-148	429	1	1999;13(5):1–6	1999;13(5):1–6	NUM
aji-148	429	2	.	.	PUNCT
aji-148	430	1	47	47	NUM
aji-148	430	2	.	.	PUNCT
aji-148	431	1	li	li	PROPN
aji-148	431	2	b.	b.	PROPN
aji-148	431	3	identification	identification	PROPN
aji-148	431	4	of	of	ADP
aji-148	431	5	mrnas	mrna	NOUN
aji-148	431	6	expressed	express	VERB
aji-148	431	7	in	in	ADP
aji-148	431	8	tumor	tumor	NOUN
aji-148	431	9	-	-	PUNCT
aji-148	431	10	infiltrating	infiltrate	VERB
aji-148	431	11	lymphocytes	lymphocyte	NOUN
aji-148	431	12	by	by	ADP
aji-148	431	13	a	a	DET
aji-148	431	14	strategy	strategy	NOUN
aji-148	431	15	for	for	ADP
aji-148	431	16	rapid	rapid	ADJ
aji-148	431	17	and	and	CCONJ
aji-148	431	18	high	high	ADJ
aji-148	431	19	throughput	throughput	NOUN
aji-148	431	20	screening	screening	NOUN
aji-148	431	21	.	.	PUNCT
aji-148	432	1	gene	gene	NOUN
aji-148	432	2	.	.	PUNCT
aji-148	433	1	2000;255:273–9	2000;255:273–9	NUM
aji-148	433	2	.	.	PUNCT
aji-148	434	1	48	48	NUM
aji-148	434	2	.	.	PUNCT
aji-148	435	1	li	li	PROPN
aji-148	435	2	b.	b.	PROPN
aji-148	435	3	a	a	DET
aji-148	435	4	strategy	strategy	NOUN
aji-148	435	5	to	to	PART
aji-148	435	6	identify	identify	VERB
aji-148	435	7	genomic	genomic	ADJ
aji-148	435	8	expression	expression	NOUN
aji-148	435	9	profiles	profile	NOUN
aji-148	435	10	at	at	ADP
aji-148	435	11	single	single	ADJ
aji-148	435	12	-	-	PUNCT
aji-148	435	13	t	t	NOUN
aji-148	435	14	-	-	PUNCT
aji-148	435	15	cell	cell	NOUN
aji-148	435	16	level	level	NOUN
aji-148	435	17	and	and	CCONJ
aji-148	435	18	a	a	DET
aji-148	435	19	small	small	ADJ
aji-148	435	20	number	number	NOUN
aji-148	435	21	of	of	ADP
aji-148	435	22	cells	cell	NOUN
aji-148	435	23	(	(	PUNCT
aji-148	435	24	review	review	NOUN
aji-148	435	25	paper	paper	NOUN
aji-148	435	26	)	)	PUNCT
aji-148	435	27	.	.	PUNCT
aji-148	436	1	j	j	PROPN
aji-148	436	2	biotechnol	biotechnol	PROPN
aji-148	436	3	.	.	PUNCT
aji-148	437	1	2005;8(1)71–82	2005;8(1)71–82	X
aji-148	437	2	.	.	X
aji-148	438	1	49	49	NUM
aji-148	438	2	.	.	PUNCT
aji-148	439	1	li	li	PROPN
aji-148	439	2	b	b	PROPN
aji-148	439	3	,	,	PUNCT
aji-148	439	4	perabekam	perabekam	PROPN
aji-148	439	5	s	s	PROPN
aji-148	439	6	,	,	PUNCT
aji-148	439	7	liu	liu	PROPN
aji-148	439	8	g	g	PROPN
aji-148	439	9	,	,	PUNCT
aji-148	439	10	yin	yin	PROPN
aji-148	439	11	m	m	PROPN
aji-148	439	12	,	,	PUNCT
aji-148	439	13	song	song	PROPN
aji-148	439	14	s	s	PROPN
aji-148	439	15	,	,	PUNCT
aji-148	439	16	larson	larson	PROPN
aji-148	439	17	a.	a.	PROPN
aji-148	439	18	experimental	experimental	PROPN
aji-148	439	19	and	and	CCONJ
aji-148	439	20	bioinformatics	bioinformatics	NOUN
aji-148	439	21	comparison	comparison	NOUN
aji-148	439	22	of	of	ADP
aji-148	439	23	gene	gene	NOUN
aji-148	439	24	expression	expression	NOUN
aji-148	439	25	between	between	ADP
aji-148	439	26	t	t	NOUN
aji-148	439	27	cells	cell	NOUN
aji-148	439	28	from	from	ADP
aji-148	439	29	til	til	SCONJ
aji-148	439	30	of	of	ADP
aji-148	439	31	liver	liver	NOUN
aji-148	439	32	cancer	cancer	NOUN
aji-148	439	33	and	and	CCONJ
aji-148	439	34	t	t	NOUN
aji-148	439	35	cells	cell	NOUN
aji-148	439	36	from	from	ADP
aji-148	439	37	unigene	unigene	NOUN
aji-148	439	38	.	.	PUNCT
aji-148	440	1	j	j	PROPN
aji-148	440	2	gastroenterol	gastroenterol	NOUN
aji-148	440	3	.	.	PUNCT
aji-148	441	1	2002;37(4):275–82	2002;37(4):275–82	X
aji-148	441	2	.	.	PROPN
aji-148	441	3	50	50	NUM
aji-148	441	4	.	.	PUNCT
aji-148	442	1	li	li	PROPN
aji-148	442	2	b	b	PROPN
aji-148	442	3	,	,	PUNCT
aji-148	442	4	liu	liu	PROPN
aji-148	442	5	g	g	PROPN
aji-148	442	6	,	,	PUNCT
aji-148	442	7	hu	hu	PROPN
aji-148	442	8	hl	hl	PROPN
aji-148	442	9	,	,	PUNCT
aji-148	442	10	ding	ding	PROPN
aji-148	442	11	jq	jq	PROPN
aji-148	442	12	,	,	PUNCT
aji-148	442	13	zheng	zheng	PROPN
aji-148	442	14	j	j	PROPN
aji-148	442	15	,	,	PUNCT
aji-148	442	16	tong	tong	PROPN
aji-148	442	17	a.	a.	NOUN
aji-148	442	18	biomarkers	biomarker	NOUN
aji-148	442	19	analysis	analysis	NOUN
aji-148	442	20	for	for	ADP
aji-148	442	21	heterogeneous	heterogeneous	ADJ
aji-148	442	22	immune	immune	ADJ
aji-148	442	23	responses	response	NOUN
aji-148	442	24	of	of	ADP
aji-148	442	25	quiescent	quiescent	ADJ
aji-148	442	26	cd8+cells	cd8+cell	NOUN
aji-148	442	27	-a	-a	X
aji-148	442	28	clue	clue	NOUN
aji-148	442	29	for	for	ADP
aji-148	442	30	personalized	personalized	ADJ
aji-148	442	31	immunotherapy	immunotherapy	NOUN
aji-148	442	32	.	.	PUNCT
aji-148	443	1	imedpub	imedpub	PROPN
aji-148	443	2	journals	journal	NOUN
aji-148	443	3	.	.	PUNCT
aji-148	444	1	2015;1(3):1–12	2015;1(3):1–12	NUM
aji-148	444	2	.	.	X
aji-148	445	1	51	51	NUM
aji-148	445	2	.	.	PUNCT
aji-148	446	1	huang	huang	PROPN
aji-148	446	2	xh	xh	PROPN
aji-148	446	3	,	,	PUNCT
aji-148	446	4	lu	lu	PROPN
aji-148	446	5	j	j	PROPN
aji-148	446	6	,	,	PUNCT
aji-148	446	7	zhang	zhang	PROPN
aji-148	446	8	yf	yf	PROPN
aji-148	446	9	,	,	PUNCT
aji-148	446	10	qiu	qiu	PROPN
aji-148	446	11	j	j	PROPN
aji-148	446	12	,	,	PUNCT
aji-148	446	13	yao	yao	PROPN
aji-148	446	14	gr	gr	NOUN
aji-148	446	15	,	,	PUNCT
aji-148	446	16	song	song	NOUN
aji-148	446	17	pt	pt	PROPN
aji-148	446	18	,	,	PUNCT
aji-148	446	19	li	li	PROPN
aji-148	446	20	b.	b.	PROPN
aji-148	446	21	prediction	prediction	PROPN
aji-148	446	22	,	,	PUNCT
aji-148	446	23	prevention	prevention	NOUN
aji-148	446	24	,	,	PUNCT
aji-148	446	25	prognostic	prognostic	ADJ
aji-148	446	26	and	and	CCONJ
aji-148	446	27	personalized	personalized	ADJ
aji-148	446	28	therapy	therapy	NOUN
aji-148	446	29	of	of	ADP
aji-148	446	30	ovarian	ovarian	ADJ
aji-148	446	31	cancerbiomarkers	cancerbiomarker	NOUN
aji-148	446	32	and	and	CCONJ
aji-148	446	33	precision	precision	NOUN
aji-148	446	34	medicine	medicine	NOUN
aji-148	446	35	.	.	PUNCT
aji-148	447	1	journal	journal	PROPN
aji-148	447	2	of	of	ADP
aji-148	447	3	cancer	cancer	NOUN
aji-148	447	4	science	science	NOUN
aji-148	447	5	and	and	CCONJ
aji-148	447	6	clinical	clinical	ADJ
aji-148	447	7	therapeutics	therapeutic	NOUN
aji-148	447	8	.	.	PUNCT
aji-148	448	1	2024;8(3):223	2024;8(3):223	NUM
aji-148	448	2	.	.	NOUN
aji-148	449	1	52	52	NUM
aji-148	449	2	.	.	PUNCT
aji-148	450	1	zhang	zhang	PROPN
aji-148	450	2	w	w	PROPN
aji-148	450	3	,	,	PUNCT
aji-148	450	4	ding	ding	PROPN
aji-148	450	5	jq	jq	PROPN
aji-148	450	6	,	,	PUNCT
aji-148	450	7	qu	qu	PROPN
aji-148	450	8	y.	y.	NOUN
aji-148	450	9	genomic	genomic	ADJ
aji-148	450	10	expression	expression	NOUN
aji-148	450	11	analysis	analysis	NOUN
aji-148	450	12	of	of	ADP
aji-148	450	13	quiescent	quiescent	ADJ
aji-148	450	14	cd8	cd8	PROPN
aji-148	450	15	tcells	tcell	NOUN
aji-148	450	16	from	from	ADP
aji-148	450	17	tumor	tumor	NOUN
aji-148	450	18	-	-	PUNCT
aji-148	450	19	infiltrating	infiltrate	VERB
aji-148	450	20	lymphocytes	lymphocyte	NOUN
aji-148	450	21	of	of	ADP
aji-148	450	22	in	in	ADP
aji-148	450	23	vivo	vivo	ADJ
aji-148	450	24	liver	liver	NOUN
aji-148	450	25	tumor	tumor	NOUN
aji-148	450	26	by	by	ADP
aji-148	450	27	single	single	ADJ
aji-148	450	28	-	-	PUNCT
aji-148	450	29	cell	cell	NOUN
aji-148	450	30	mrna	mrna	NOUN
aji-148	450	31	differential	differential	PROPN
aji-148	450	32	display	display	NOUN
aji-148	450	33	.	.	PUNCT
aji-148	451	1	immunology	immunology	NOUN
aji-148	451	2	.	.	PUNCT
aji-148	452	1	2009;127(1):83–90	2009;127(1):83–90	NUM
aji-148	452	2	.	.	PUNCT
aji-148	453	1	53	53	NUM
aji-148	453	2	.	.	PUNCT
aji-148	453	3	li	li	PROPN
aji-148	453	4	b.	b.	PROPN
aji-148	453	5	breakthrough	breakthrough	NOUN
aji-148	453	6	of	of	ADP
aji-148	453	7	2015	2015	NUM
aji-148	453	8	-	-	PUNCT
aji-148	453	9	personalized	personalize	VERB
aji-148	453	10	immunotherapy	immunotherapy	NOUN
aji-148	453	11	.	.	PUNCT
aji-148	454	1	imedpub	imedpub	NOUN
aji-148	454	2	journals	journal	NOUN
aji-148	454	3	.	.	PUNCT
aji-148	455	1	2015;1(4):1–2	2015;1(4):1–2	X
aji-148	455	2	.	.	PUNCT
aji-148	456	1	54	54	NUM
aji-148	456	2	.	.	PUNCT
aji-148	457	1	li	li	PROPN
aji-148	457	2	b	b	PROPN
aji-148	457	3	,	,	PUNCT
aji-148	457	4	liu	liu	PROPN
aji-148	457	5	g	g	PROPN
aji-148	457	6	,	,	PUNCT
aji-148	457	7	hu	hu	PROPN
aji-148	457	8	hl	hl	PROPN
aji-148	457	9	,	,	PUNCT
aji-148	457	10	ding	ding	PROPN
aji-148	457	11	jq	jq	PROPN
aji-148	457	12	,	,	PUNCT
aji-148	457	13	zheng	zheng	PROPN
aji-148	457	14	j	j	PROPN
aji-148	457	15	,	,	PUNCT
aji-148	457	16	tong	tong	PROPN
aji-148	457	17	a.	a.	NOUN
aji-148	457	18	biomarkers	biomarker	NOUN
aji-148	457	19	analysis	analysis	NOUN
aji-148	457	20	for	for	ADP
aji-148	457	21	heterogeneous	heterogeneous	ADJ
aji-148	457	22	immune	immune	ADJ
aji-148	457	23	responses	response	NOUN
aji-148	457	24	of	of	ADP
aji-148	457	25	quiescent	quiescent	ADJ
aji-148	457	26	cd8+cells	cd8+cell	NOUN
aji-148	457	27	-a	-a	X
aji-148	457	28	clue	clue	NOUN
aji-148	457	29	for	for	ADP
aji-148	457	30	personalized	personalized	ADJ
aji-148	457	31	immunotherapy	immunotherapy	NOUN
aji-148	457	32	.	.	PUNCT
aji-148	458	1	imedpub	imedpub	PROPN
aji-148	458	2	journals	journal	NOUN
aji-148	458	3	.	.	PUNCT
aji-148	459	1	2015;1(3):1–12	2015;1(3):1–12	NUM
aji-148	459	2	.	.	X
aji-148	460	1	55	55	NUM
aji-148	460	2	.	.	PUNCT
aji-148	461	1	konrad	konrad	PROPN
aji-148	461	2	ma	ma	PROPN
aji-148	461	3	,	,	PUNCT
aji-148	461	4	zúñiga	zúñiga	PROPN
aji-148	461	5	-	-	PUNCT
aji-148	461	6	pflücker	pflücker	PROPN
aji-148	461	7	jc	jc	PROPN
aji-148	461	8	.	.	PUNCT
aji-148	462	1	the	the	DET
aji-148	462	2	btg	btg	PROPN
aji-148	462	3	/	/	SYM
aji-148	462	4	tob	tob	NOUN
aji-148	462	5	family	family	NOUN
aji-148	462	6	protein	protein	NOUN
aji-148	462	7	tis21	tis21	NOUN
aji-148	462	8	regulates	regulate	VERB
aji-148	462	9	stage	stage	NOUN
aji-148	462	10	-	-	PUNCT
aji-148	462	11	specific	specific	ADJ
aji-148	462	12	proliferation	proliferation	NOUN
aji-148	462	13	of	of	ADP
aji-148	462	14	developing	develop	VERB
aji-148	462	15	thymocytes	thymocyte	NOUN
aji-148	462	16	.	.	PUNCT
aji-148	463	1	eur	eur	PROPN
aji-148	463	2	j	j	PROPN
aji-148	463	3	immunol	immunol	NOUN
aji-148	463	4	.	.	PUNCT
aji-148	464	1	2005;35(10):3030–42	2005;35(10):3030–42	NUM
aji-148	464	2	.	.	PROPN
aji-148	465	1	56	56	NUM
aji-148	465	2	.	.	PUNCT
aji-148	465	3	garcía	garcía	ADJ
aji-148	465	4	-	-	PUNCT
aji-148	465	5	palma	palma	NOUN
aji-148	465	6	l	l	NOUN
aji-148	465	7	,	,	PUNCT
aji-148	465	8	horn	horn	PROPN
aji-148	465	9	s	s	PROPN
aji-148	465	10	,	,	PUNCT
aji-148	465	11	haag	haag	PROPN
aji-148	465	12	f	f	PROPN
aji-148	465	13	,	,	PUNCT
aji-148	465	14	diessenbacher	diessenbacher	PROPN
aji-148	465	15	p	p	NOUN
aji-148	465	16	,	,	PUNCT
aji-148	465	17	streichert	streichert	PROPN
aji-148	465	18	t	t	PROPN
aji-148	465	19	,	,	PUNCT
aji-148	465	20	mayr	mayr	PROPN
aji-148	465	21	gw	gw	PROPN
aji-148	465	22	.	.	PUNCT
aji-148	466	1	up	up	ADP
aji-148	466	2	-	-	PUNCT
aji-148	466	3	regulation	regulation	NOUN
aji-148	466	4	of	of	ADP
aji-148	466	5	the	the	DET
aji-148	466	6	t	t	PROPN
aji-148	466	7	cell	cell	NOUN
aji-148	466	8	quiescence	quiescence	NOUN
aji-148	466	9	factor	factor	NOUN
aji-148	466	10	klf2	klf2	ADV
aji-148	466	11	in	in	ADP
aji-148	466	12	a	a	DET
aji-148	466	13	leukaemic	leukaemic	ADJ
aji-148	466	14	t	t	NOUN
aji-148	466	15	-	-	PUNCT
aji-148	466	16	cell	cell	NOUN
aji-148	466	17	line	line	NOUN
aji-148	466	18	after	after	ADP
aji-148	466	19	expression	expression	NOUN
aji-148	466	20	of	of	ADP
aji-148	466	21	the	the	DET
aji-148	466	22	inositol	inositol	NOUN
aji-148	466	23	5'-phosphatase	5'-phosphatase	NUM
aji-148	466	24	ship-1	ship-1	NOUN
aji-148	466	25	.	.	PUNCT
aji-148	467	1	br	br	PROPN
aji-148	467	2	j	j	PROPN
aji-148	467	3	haematol	haematol	NOUN
aji-148	467	4	.	.	PUNCT
aji-148	468	1	2005;131(5):628	2005;131(5):628	NUM
aji-148	468	2	–	–	PUNCT
aji-148	468	3	31	31	NUM
aji-148	468	4	.	.	PUNCT
aji-148	469	1	57	57	NUM
aji-148	469	2	.	.	PUNCT
aji-148	469	3	batlle	batlle	PROPN
aji-148	469	4	e	e	NOUN
aji-148	469	5	,	,	PUNCT
aji-148	469	6	massagué	massagué	X
aji-148	469	7	j.	j.	PROPN
aji-148	469	8	transforming	transform	VERB
aji-148	469	9	growth	growth	NOUN
aji-148	469	10	factor	factor	NOUN
aji-148	469	11	-	-	PUNCT
aji-148	469	12	beta	beta	NOUN
aji-148	469	13	signaling	signal	VERB
aji-148	469	14	in	in	ADP
aji-148	469	15	immunity	immunity	NOUN
aji-148	469	16	and	and	CCONJ
aji-148	469	17	cancer	cancer	NOUN
aji-148	469	18	.	.	PUNCT
aji-148	470	1	immunity	immunity	NOUN
aji-148	470	2	.	.	PUNCT
aji-148	471	1	immunity	immunity	NOUN
aji-148	471	2	.	.	PUNCT
aji-148	472	1	2019;50(4):924–40	2019;50(4):924–40	NUM
aji-148	472	2	.	.	PUNCT
aji-148	473	1	58	58	NUM
aji-148	473	2	.	.	PUNCT
aji-148	474	1	zhang	zhang	PROPN
aji-148	474	2	s	s	PROPN
aji-148	474	3	,	,	PUNCT
aji-148	474	4	takaku	takaku	NOUN
aji-148	474	5	m	m	PRON
aji-148	474	6	,	,	PUNCT
aji-148	474	7	zou	zou	PROPN
aji-148	474	8	l	l	PROPN
aji-148	474	9	,	,	PUNCT
aji-148	474	10	gu	gu	NOUN
aji-148	474	11	ad	ad	NOUN
aji-148	474	12	,	,	PUNCT
aji-148	474	13	chou	chou	PROPN
aji-148	474	14	wc	wc	PROPN
aji-148	474	15	,	,	PUNCT
aji-148	474	16	zhang	zhang	PROPN
aji-148	474	17	g.	g.	PROPN
aji-148	474	18	reversing	reverse	VERB
aji-148	474	19	ski	ski	NOUN
aji-148	474	20	-	-	PUNCT
aji-148	474	21	smad4mediated	smad4mediate	VERB
aji-148	474	22	suppression	suppression	NOUN
aji-148	474	23	is	be	AUX
aji-148	474	24	essential	essential	ADJ
aji-148	474	25	for	for	ADP
aji-148	474	26	t(h)17	t(h)17	NOUN
aji-148	474	27	cell	cell	NOUN
aji-148	474	28	differentiation	differentiation	NOUN
aji-148	474	29	.	.	PUNCT
aji-148	475	1	nature	nature	NOUN
aji-148	475	2	.	.	PUNCT
aji-148	476	1	2017;551(7678):105–9	2017;551(7678):105–9	NOUN
aji-148	476	2	.	.	PROPN
aji-148	476	3	59	59	NUM
aji-148	476	4	.	.	PUNCT
aji-148	477	1	evans	evans	PROPN
aji-148	477	2	rl	rl	PROPN
aji-148	477	3	,	,	PUNCT
aji-148	477	4	wall	wall	PROPN
aji-148	477	5	dw	dw	PROPN
aji-148	477	6	,	,	PUNCT
aji-148	477	7	platsoucas	platsoucas	PROPN
aji-148	477	8	cd	cd	PROPN
aji-148	477	9	,	,	PUNCT
aji-148	477	10	siegal	siegal	PROPN
aji-148	477	11	fp	fp	PROPN
aji-148	477	12	,	,	PUNCT
aji-148	477	13	fikrig	fikrig	X
aji-148	477	14	sm	sm	PROPN
aji-148	477	15	,	,	PUNCT
aji-148	477	16	testa	testa	PROPN
aji-148	477	17	cm	cm	PROPN
aji-148	477	18	,	,	PUNCT
aji-148	477	19	et	et	PROPN
aji-148	477	20	al	al	PROPN
aji-148	477	21	.	.	PUNCT
aji-148	477	22	thymus	thymus	ADJ
aji-148	477	23	-	-	PUNCT
aji-148	477	24	dependent	dependent	ADJ
aji-148	477	25	membrane	membrane	NOUN
aji-148	477	26	antigens	antigen	NOUN
aji-148	477	27	in	in	ADP
aji-148	477	28	man	man	NOUN
aji-148	477	29	:	:	PUNCT
aji-148	477	30	inhibition	inhibition	NOUN
aji-148	477	31	of	of	ADP
aji-148	477	32	cell	cell	NOUN
aji-148	477	33	-	-	PUNCT
aji-148	477	34	mediated	mediate	VERB
aji-148	477	35	lympholysis	lympholysis	NOUN
aji-148	477	36	by	by	ADP
aji-148	477	37	monoclonal	monoclonal	NOUN
aji-148	477	38	antibodies	antibody	NOUN
aji-148	477	39	to	to	ADP
aji-148	477	40	th2	th2	PROPN
aji-148	477	41	antigen	antigen	PROPN
aji-148	477	42	.	.	PUNCT
aji-148	478	1	proc	proc	PROPN
aji-148	478	2	natl	natl	PROPN
aji-148	478	3	acad	acad	PROPN
aji-148	478	4	sci	sci	PROPN
aji-148	478	5	u	u	PROPN
aji-148	478	6	s	s	PROPN
aji-148	478	7	a.	a.	NOUN
aji-148	478	8	1981;78(1):544–8	1981;78(1):544–8	NUM
aji-148	478	9	.	.	PUNCT
aji-148	479	1	60	60	NUM
aji-148	479	2	.	.	PUNCT
aji-148	479	3	mortazavi	mortazavi	VERB
aji-148	479	4	a	a	PRON
aji-148	479	5	,	,	PUNCT
aji-148	479	6	leeper	leeper	PROPN
aji-148	479	7	thompson	thompson	PROPN
aji-148	479	8	ec	ec	PROPN
aji-148	479	9	,	,	PUNCT
aji-148	479	10	garcia	garcia	PROPN
aji-148	479	11	st	st	PROPN
aji-148	479	12	,	,	PUNCT
aji-148	479	13	myers	myers	PROPN
aji-148	479	14	rm	rm	PROPN
aji-148	479	15	,	,	PUNCT
aji-148	479	16	wold	wold	PROPN
aji-148	479	17	b.	b.	PROPN
aji-148	479	18	comparative	comparative	ADJ
aji-148	479	19	genomics	genomic	NOUN
aji-148	479	20	modeling	modeling	NOUN
aji-148	479	21	of	of	ADP
aji-148	479	22	the	the	DET
aji-148	479	23	nrsf	nrsf	NOUN
aji-148	479	24	/	/	PUNCT
aji-148	479	25	rest	rest	NOUN
aji-148	479	26	repressor	repressor	NOUN
aji-148	479	27	network	network	NOUN
aji-148	479	28	:	:	PUNCT
aji-148	479	29	from	from	ADP
aji-148	479	30	single	single	ADJ
aji-148	479	31	conserved	conserved	ADJ
aji-148	479	32	sites	site	NOUN
aji-148	479	33	to	to	ADP
aji-148	479	34	genome	genome	NOUN
aji-148	479	35	-	-	PUNCT
aji-148	479	36	wide	wide	ADJ
aji-148	479	37	repertoire	repertoire	NOUN
aji-148	479	38	.	.	PUNCT
aji-148	480	1	genome	genome	NOUN
aji-148	480	2	res	re	NOUN
aji-148	480	3	.	.	PUNCT
aji-148	481	1	2006;16(10):1208–21	2006;16(10):1208–21	NUM
aji-148	481	2	.	.	NOUN
aji-148	481	3	61	61	NUM
aji-148	481	4	.	.	PUNCT
aji-148	482	1	giammona	giammona	PROPN
aji-148	482	2	a	a	PRON
aji-148	482	3	,	,	PUNCT
aji-148	482	4	de	de	X
aji-148	482	5	vellis	vellis	X
aji-148	482	6	c	c	NOUN
aji-148	482	7	,	,	PUNCT
aji-148	482	8	crivaro	crivaro	PROPN
aji-148	482	9	e	e	NOUN
aji-148	482	10	,	,	PUNCT
aji-148	482	11	et	et	NOUN
aji-148	482	12	.	.	PUNCT
aji-148	483	1	al	al	PROPN
aji-148	483	2	.	.	PUNCT
aji-148	483	3	tumor	tumor	NOUN
aji-148	483	4	-	-	PUNCT
aji-148	483	5	derived	derive	VERB
aji-148	483	6	gli1	gli1	NOUN
aji-148	483	7	promotes	promote	VERB
aji-148	483	8	remodeling	remodeling	NOUN
aji-148	483	9	of	of	ADP
aji-148	483	10	the	the	DET
aji-148	483	11	immune	immune	ADJ
aji-148	483	12	tumor	tumor	NOUN
aji-148	483	13	microenvironment	microenvironment	NOUN
aji-148	483	14	in	in	ADP
aji-148	483	15	melanoma	melanoma	NOUN
aji-148	483	16	.	.	PUNCT
aji-148	484	1	j	j	PROPN
aji-148	484	2	exp	exp	PROPN
aji-148	484	3	clin	clin	PROPN
aji-148	484	4	cancer	cancer	NOUN
aji-148	484	5	res	re	NOUN
aji-148	484	6	.	.	PUNCT
aji-148	485	1	2024;43(1):214	2024;43(1):214	NUM
aji-148	485	2	.	.	PUNCT
aji-148	486	1	62	62	NUM
aji-148	486	2	.	.	PUNCT
aji-148	487	1	zhu	zhu	PROPN
aji-148	488	1	x	x	SYM
aji-148	488	2	,	,	PUNCT
aji-148	488	3	xu	xu	PROPN
aji-148	489	1	z	z	PROPN
aji-148	489	2	,	,	PUNCT
aji-148	489	3	li	li	PROPN
aji-148	489	4	b.	b.	PROPN
aji-148	489	5	editorial	editorial	PROPN
aji-148	489	6	:	:	PUNCT
aji-148	489	7	epigenetics	epigenetic	NOUN
aji-148	489	8	in	in	ADP
aji-148	489	9	cancer	cancer	NOUN
aji-148	489	10	:	:	PUNCT
aji-148	489	11	mechanisms	mechanism	NOUN
aji-148	489	12	and	and	CCONJ
aji-148	489	13	drug	drug	NOUN
aji-148	489	14	development	development	NOUN
aji-148	489	15	-	-	PUNCT
aji-148	489	16	volume	volume	NOUN
aji-148	489	17	ii	ii	PROPN
aji-148	489	18	.	.	PUNCT
aji-148	490	1	front	front	ADJ
aji-148	490	2	genet	genet	NOUN
aji-148	490	3	.	.	PUNCT
aji-148	491	1	2023;14:1242960	2023;14:1242960	X
aji-148	491	2	.	.	NOUN
aji-148	491	3	63	63	NUM
aji-148	491	4	.	.	PUNCT
aji-148	491	5	yuan	yuan	PROPN
aji-148	491	6	h	h	PROPN
aji-148	491	7	,	,	PUNCT
aji-148	491	8	huang	huang	PROPN
aji-148	491	9	y	y	PROPN
aji-148	491	10	,	,	PUNCT
aji-148	491	11	tao	tao	PROPN
aji-148	491	12	s	s	PROPN
aji-148	491	13	,	,	PUNCT
aji-148	491	14	li	li	PROPN
aji-148	491	15	b.	b.	PROPN
aji-148	491	16	editorial	editorial	PROPN
aji-148	491	17	:	:	PUNCT
aji-148	491	18	epigenetics	epigenetic	NOUN
aji-148	491	19	in	in	ADP
aji-148	491	20	cancer	cancer	NOUN
aji-148	491	21	:	:	PUNCT
aji-148	491	22	mechanisms	mechanism	NOUN
aji-148	491	23	and	and	CCONJ
aji-148	491	24	drug	drug	NOUN
aji-148	491	25	development	development	NOUN
aji-148	491	26	.	.	PUNCT
aji-148	492	1	front	front	ADJ
aji-148	492	2	genet	genet	NOUN
aji-148	492	3	.	.	PUNCT
aji-148	493	1	2022;13:831704	2022;13:831704	X
aji-148	493	2	.	.	NOUN
aji-148	493	3	64	64	NUM
aji-148	493	4	.	.	PUNCT
aji-148	494	1	ying	ying	PROPN
aji-148	494	2	x	x	PROPN
aji-148	494	3	,	,	PUNCT
aji-148	494	4	li	li	PROPN
aji-148	494	5	b.	b.	PROPN
aji-148	494	6	machine	machine	NOUN
aji-148	494	7	-	-	PUNCT
aji-148	494	8	learning	learn	VERB
aji-148	494	9	modeling	modeling	NOUN
aji-148	494	10	for	for	ADP
aji-148	494	11	personalized	personalize	VERB
aji-148	494	12	immunotherapyan	immunotherapyan	PROPN
aji-148	494	13	li	li	PROPN
aji-148	494	14	and	and	CCONJ
aji-148	494	15	li	li	PROPN
aji-148	494	16	;	;	PUNCT
aji-148	494	17	asian	asian	PROPN
aji-148	494	18	j.	j.	PROPN
aji-148	494	19	immunol	immunol	PROPN
aji-148	494	20	.	.	PROPN
aji-148	494	21	,	,	PUNCT
aji-148	494	22	vol	vol	NOUN
aji-148	494	23	.	.	PROPN
aji-148	494	24	7	7	NUM
aji-148	494	25	,	,	PUNCT
aji-148	494	26	no	no	INTJ
aji-148	494	27	.	.	NOUN
aji-148	494	28	1	1	NUM
aji-148	494	29	,	,	PUNCT
aji-148	494	30	pp	pp	ADJ
aji-148	494	31	.	.	PUNCT
aji-148	495	1	247	247	NUM
aji-148	495	2	-	-	SYM
aji-148	495	3	257	257	NUM
aji-148	495	4	,	,	PUNCT
aji-148	495	5	2024	2024	NUM
aji-148	495	6	;	;	PUNCT
aji-148	495	7	article	article	NOUN
aji-148	495	8	no.aji.126682	no.aji.126682	ADP
aji-148	495	9	257	257	NUM
aji-148	495	10	evaluation	evaluation	NOUN
aji-148	495	11	module	module	NOUN
aji-148	495	12	.	.	PUNCT
aji-148	495	13	biomed	biome	VERB
aji-148	495	14	j	j	PROPN
aji-148	495	15	sci	sci	PROPN
aji-148	495	16	tech	tech	NOUN
aji-148	495	17	res	re	NOUN
aji-148	495	18	.	.	PUNCT
aji-148	496	1	2022;47(2):38211	2022;47(2):38211	NUM
aji-148	496	2	-	-	SYM
aji-148	496	3	38216	38216	NUM
aji-148	496	4	.	.	PUNCT
aji-148	497	1	65	65	NUM
aji-148	497	2	.	.	PUNCT
aji-148	498	1	junker	junker	PROPN
aji-148	498	2	lh	lh	PROPN
aji-148	498	3	,	,	PUNCT
aji-148	498	4	li	li	PROPN
aji-148	498	5	b	b	PROPN
aji-148	498	6	,	,	PUNCT
aji-148	498	7	zhu	zhu	PROPN
aji-148	498	8	x.	x.	NOUN
aji-148	498	9	novel	novel	PROPN
aji-148	498	10	histone	histone	PROPN
aji-148	498	11	deacetylase	deacetylase	NOUN
aji-148	498	12	inhibitor	inhibitor	NOUN
aji-148	498	13	ct-101	ct-101	PROPN
aji-148	498	14	induces	induce	VERB
aji-148	498	15	γglobin	γglobin	NOUN
aji-148	498	16	gene	gene	NOUN
aji-148	498	17	expression	expression	NOUN
aji-148	498	18	in	in	ADP
aji-148	498	19	sickle	sickle	NOUN
aji-148	498	20	erythroid	erythroid	ADJ
aji-148	498	21	progenitors	progenitor	NOUN
aji-148	498	22	with	with	ADP
aji-148	498	23	targeted	target	VERB
aji-148	498	24	epigenetic	epigenetic	ADJ
aji-148	498	25	effects	effect	NOUN
aji-148	498	26	.	.	PUNCT
aji-148	499	1	blood	blood	NOUN
aji-148	499	2	cells	cell	NOUN
aji-148	499	3	mol	mol	ADP
aji-148	499	4	dis	dis	PROPN
aji-148	499	5	.	.	PUNCT
aji-148	499	6	2022	2022	NUM
aji-148	499	7	;	;	PUNCT
aji-148	499	8	93:102626	93:102626	X
aji-148	499	9	.	.	X
aji-148	499	10	66	66	NUM
aji-148	499	11	.	.	PUNCT
aji-148	500	1	li	li	PROPN
aji-148	500	2	b.	b.	PROPN
aji-148	500	3	personalized	personalize	VERB
aji-148	500	4	chemotherapy	chemotherapy	NOUN
aji-148	500	5	of	of	ADP
aji-148	500	6	tumor	tumor	NOUN
aji-148	500	7	disease	disease	NOUN
aji-148	500	8	based	base	VERB
aji-148	500	9	on	on	ADP
aji-148	500	10	system	system	NOUN
aji-148	500	11	modeling	modeling	NOUN
aji-148	500	12	.	.	PUNCT
aji-148	501	1	(	(	PUNCT
aji-148	501	2	singapore	singapore	PROPN
aji-148	501	3	:	:	PUNCT
aji-148	501	4	bentham	bentham	PROPN
aji-148	501	5	science	science	PROPN
aji-148	501	6	publishers	publisher	NOUN
aji-148	501	7	;)	;)	PUNCT
aji-148	501	8	.	.	PROPN
aji-148	501	9	2016;223–247	2016;223–247	NUM
aji-148	501	10	.	.	PUNCT
aji-148	502	1	67	67	NUM
aji-148	502	2	.	.	PUNCT
aji-148	503	1	xu	xu	PROPN
aji-148	503	2	yb	yb	PROPN
aji-148	503	3	,	,	PUNCT
aji-148	503	4	hu	hu	PROPN
aji-148	503	5	hl	hl	PROPN
aji-148	503	6	,	,	PUNCT
aji-148	503	7	zheng	zheng	PROPN
aji-148	503	8	j	j	PROPN
aji-148	503	9	,	,	PUNCT
aji-148	503	10	li	li	PROPN
aji-148	503	11	b.	b.	PROPN
aji-148	503	12	feasibility	feasibility	PROPN
aji-148	503	13	of	of	ADP
aji-148	503	14	whole	whole	ADJ
aji-148	503	15	rna	rna	NOUN
aji-148	503	16	sequencing	sequencing	NOUN
aji-148	503	17	from	from	ADP
aji-148	503	18	single‑cell	single‑cell	PROPN
aji-148	503	19	mrna	mrna	NOUN
aji-148	503	20	amplification	amplification	NOUN
aji-148	503	21	.	.	PUNCT
aji-148	504	1	genetics	genetics	PROPN
aji-148	504	2	research	research	PROPN
aji-148	504	3	international	international	PROPN
aji-148	504	4	.	.	PUNCT
aji-148	505	1	2013;1	2013;1	NUM
aji-148	505	2	-	-	SYM
aji-148	505	3	8	8	NUM
aji-148	505	4	.	.	PUNCT
aji-148	506	1	68	68	NUM
aji-148	506	2	.	.	PUNCT
aji-148	507	1	li	li	PROPN
aji-148	507	2	b.	b.	PROPN
aji-148	507	3	why	why	SCONJ
aji-148	507	4	do	do	AUX
aji-148	507	5	tumor	tumor	NOUN
aji-148	507	6	-	-	PUNCT
aji-148	507	7	infiltrating	infiltrate	VERB
aji-148	507	8	lymphocytes	lymphocyte	NOUN
aji-148	507	9	have	have	VERB
aji-148	507	10	variable	variable	ADJ
aji-148	507	11	efficacy	efficacy	NOUN
aji-148	507	12	in	in	ADP
aji-148	507	13	the	the	DET
aji-148	507	14	treatment	treatment	NOUN
aji-148	507	15	of	of	ADP
aji-148	507	16	solid	solid	ADJ
aji-148	507	17	tumors	tumor	NOUN
aji-148	507	18	?	?	PUNCT
aji-148	508	1	frontiers	frontier	NOUN
aji-148	508	2	in	in	ADP
aji-148	508	3	immunology	immunology	NOUN
aji-148	508	4	.	.	PUNCT
aji-148	509	1	2022;973881	2022;973881	NUM
aji-148	509	2	.	.	PUNCT
aji-148	510	1	69	69	NUM
aji-148	510	2	.	.	PUNCT
aji-148	511	1	li	li	PROPN
aji-148	511	2	b.	b.	PROPN
aji-148	511	3	personalized	personalize	VERB
aji-148	511	4	immunotherapy	immunotherapy	NOUN
aji-148	511	5	of	of	ADP
aji-148	511	6	patients	patient	NOUN
aji-148	511	7	:	:	PUNCT
aji-148	511	8	defining	define	VERB
aji-148	511	9	by	by	ADP
aji-148	511	10	single	single	ADJ
aji-148	511	11	-	-	PUNCT
aji-148	511	12	cell	cell	NOUN
aji-148	511	13	rna	rna	NOUN
aji-148	511	14	-	-	PUNCT
aji-148	511	15	seq	seq	NOUN
aji-148	511	16	with	with	ADP
aji-148	511	17	artificial	artificial	ADJ
aji-148	511	18	intelligence	intelligence	NOUN
aji-148	511	19	.	.	PUNCT
aji-148	512	1	medical	medical	ADJ
aji-148	512	2	research	research	NOUN
aji-148	512	3	archives	archive	NOUN
aji-148	512	4	.	.	PUNCT
aji-148	513	1	2023;11(9):8	2023;11(9):8	NUM
aji-148	513	2	.	.	PUNCT
aji-148	514	1	70	70	NUM
aji-148	514	2	.	.	PUNCT
aji-148	514	3	li	li	PROPN
aji-148	514	4	b.	b.	PROPN
aji-148	514	5	surgery	surgery	NOUN
aji-148	514	6	and	and	CCONJ
aji-148	514	7	specimen	speciman	NOUN
aji-148	514	8	biobanks	biobank	VERB
aji-148	514	9	tumor	tumor	NOUN
aji-148	514	10	tissues	tissue	NOUN
aji-148	514	11	and	and	CCONJ
aji-148	514	12	precision	precision	NOUN
aji-148	514	13	medicine	medicine	NOUN
aji-148	514	14	.	.	PUNCT
aji-148	515	1	journal	journal	NOUN
aji-148	515	2	of	of	ADP
aji-148	515	3	surgery	surgery	NOUN
aji-148	515	4	.	.	PUNCT
aji-148	516	1	2024;9(11):8	2024;9(11):8	NUM
aji-148	516	2	.	.	PUNCT
aji-148	516	3	disclaimer	disclaimer	ADJ
aji-148	516	4	/	/	SYM
aji-148	516	5	publisher	publisher	NOUN
aji-148	516	6	’s	’s	PART
aji-148	516	7	note	note	NOUN
aji-148	516	8	:	:	PUNCT
aji-148	516	9	the	the	DET
aji-148	516	10	statements	statement	NOUN
aji-148	516	11	,	,	PUNCT
aji-148	516	12	opinions	opinion	NOUN
aji-148	516	13	and	and	CCONJ
aji-148	516	14	data	datum	NOUN
aji-148	516	15	contained	contain	VERB
aji-148	516	16	in	in	ADP
aji-148	516	17	all	all	DET
aji-148	516	18	publications	publication	NOUN
aji-148	516	19	are	be	AUX
aji-148	516	20	solely	solely	ADV
aji-148	516	21	those	those	PRON
aji-148	516	22	of	of	ADP
aji-148	516	23	the	the	DET
aji-148	516	24	individual	individual	ADJ
aji-148	516	25	author(s	author(s	PROPN
aji-148	516	26	)	)	PUNCT
aji-148	516	27	and	and	CCONJ
aji-148	516	28	contributor(s	contributor(s	NOUN
aji-148	516	29	)	)	PUNCT
aji-148	516	30	and	and	CCONJ
aji-148	516	31	not	not	PART
aji-148	516	32	of	of	ADP
aji-148	516	33	the	the	DET
aji-148	516	34	publisher	publisher	NOUN
aji-148	516	35	and/or	and/or	CCONJ
aji-148	516	36	the	the	DET
aji-148	516	37	editor(s	editor(s	NOUN
aji-148	516	38	)	)	PUNCT
aji-148	516	39	.	.	PUNCT
aji-148	517	1	this	this	DET
aji-148	517	2	publisher	publisher	NOUN
aji-148	517	3	and/or	and/or	CCONJ
aji-148	517	4	the	the	DET
aji-148	517	5	editor(s	editor(s	NOUN
aji-148	517	6	)	)	PUNCT
aji-148	517	7	disclaim	disclaim	VERB
aji-148	517	8	responsibility	responsibility	NOUN
aji-148	517	9	for	for	ADP
aji-148	517	10	any	any	DET
aji-148	517	11	injury	injury	NOUN
aji-148	517	12	to	to	ADP
aji-148	517	13	people	people	NOUN
aji-148	517	14	or	or	CCONJ
aji-148	517	15	property	property	NOUN
aji-148	517	16	resulting	result	VERB
aji-148	517	17	from	from	ADP
aji-148	517	18	any	any	DET
aji-148	517	19	ideas	idea	NOUN
aji-148	517	20	,	,	PUNCT
aji-148	517	21	methods	method	NOUN
aji-148	517	22	,	,	PUNCT
aji-148	517	23	instructions	instruction	NOUN
aji-148	517	24	or	or	CCONJ
aji-148	517	25	products	product	NOUN
aji-148	517	26	referred	refer	VERB
aji-148	517	27	to	to	ADP
aji-148	517	28	in	in	ADP
aji-148	517	29	the	the	DET
aji-148	517	30	content	content	NOUN
aji-148	517	31	.	.	PUNCT
aji-148	518	1	_	_	PUNCT
aji-148	519	1	_	_	PUNCT
aji-148	520	1	_	_	PUNCT
aji-148	521	1	_	_	PUNCT
aji-148	522	1	_	_	PUNCT
aji-148	523	1	_	_	PUNCT
aji-148	524	1	_	_	PUNCT
aji-148	525	1	_	_	PUNCT
aji-148	526	1	_	_	PUNCT
aji-148	527	1	_	_	PUNCT
aji-148	528	1	_	_	PUNCT
aji-148	529	1	_	_	PUNCT
aji-148	530	1	_	_	PUNCT
aji-148	531	1	_	_	PUNCT
aji-148	532	1	_	_	PUNCT
aji-148	533	1	_	_	PUNCT
aji-148	534	1	_	_	PUNCT
aji-148	535	1	_	_	PUNCT
aji-148	536	1	_	_	PUNCT
aji-148	537	1	_	_	PUNCT
aji-148	538	1	_	_	PUNCT
aji-148	539	1	_	_	PUNCT
aji-148	540	1	_	_	PUNCT
aji-148	541	1	_	_	PUNCT
aji-148	542	1	_	_	PUNCT
aji-148	543	1	_	_	PUNCT
aji-148	544	1	_	_	PUNCT
aji-148	545	1	_	_	PUNCT
aji-148	546	1	_	_	PUNCT
aji-148	547	1	_	_	PUNCT
aji-148	548	1	_	_	PUNCT
aji-148	549	1	_	_	PUNCT
aji-148	550	1	_	_	PUNCT
aji-148	551	1	_	_	PUNCT
aji-148	552	1	_	_	PUNCT
aji-148	553	1	_	_	PUNCT
aji-148	554	1	_	_	PUNCT
aji-148	555	1	_	_	PUNCT
aji-148	556	1	_	_	PUNCT
aji-148	557	1	_	_	PUNCT
aji-148	558	1	_	_	PUNCT
aji-148	559	1	_	_	PUNCT
aji-148	560	1	_	_	PUNCT
aji-148	561	1	_	_	PUNCT
aji-148	562	1	_	_	PUNCT
aji-148	563	1	_	_	PUNCT
aji-148	564	1	_	_	PUNCT
aji-148	565	1	_	_	PUNCT
aji-148	566	1	_	_	PUNCT
aji-148	567	1	_	_	PUNCT
aji-148	568	1	_	_	PUNCT
aji-148	569	1	_	_	PUNCT
aji-148	570	1	_	_	PUNCT
aji-148	571	1	_	_	PUNCT
aji-148	572	1	_	_	PUNCT
aji-148	573	1	_	_	PUNCT
aji-148	574	1	_	_	PUNCT
aji-148	575	1	_	_	PUNCT
aji-148	576	1	_	_	PUNCT
aji-148	577	1	_	_	PUNCT
aji-148	578	1	_	_	PUNCT
aji-148	579	1	_	_	PUNCT
aji-148	580	1	_	_	PUNCT
aji-148	581	1	_	_	PUNCT
aji-148	582	1	_	_	PUNCT
aji-148	583	1	_	_	PUNCT
aji-148	584	1	_	_	PUNCT
aji-148	585	1	_	_	PUNCT
aji-148	586	1	_	_	PUNCT
aji-148	587	1	_	_	PUNCT
aji-148	588	1	_	_	PUNCT
aji-148	589	1	_	_	PUNCT
aji-148	590	1	_	_	PUNCT
aji-148	591	1	_	_	PUNCT
aji-148	592	1	_	_	PUNCT
aji-148	593	1	_	_	PUNCT
aji-148	594	1	_	_	PUNCT
aji-148	595	1	_	_	PUNCT
aji-148	596	1	_	_	PUNCT
aji-148	597	1	_	_	PUNCT
aji-148	598	1	_	_	PUNCT
aji-148	599	1	©	©	PRON
aji-148	599	2	copyright	copyright	NOUN
aji-148	599	3	(	(	PUNCT
aji-148	599	4	2024	2024	NUM
aji-148	599	5	):	):	PUNCT
aji-148	599	6	author(s	author(s	NOUN
aji-148	599	7	)	)	PUNCT
aji-148	599	8	.	.	PUNCT
aji-148	600	1	the	the	DET
aji-148	600	2	licensee	licensee	NOUN
aji-148	600	3	is	be	AUX
aji-148	600	4	the	the	DET
aji-148	600	5	journal	journal	PROPN
aji-148	600	6	publisher	publisher	NOUN
aji-148	600	7	.	.	PUNCT
aji-148	601	1	this	this	PRON
aji-148	601	2	is	be	AUX
aji-148	601	3	an	an	DET
aji-148	601	4	open	open	ADJ
aji-148	601	5	access	access	NOUN
aji-148	601	6	article	article	NOUN
aji-148	601	7	distributed	distribute	VERB
aji-148	601	8	under	under	ADP
aji-148	601	9	the	the	DET
aji-148	601	10	terms	term	NOUN
aji-148	601	11	of	of	ADP
aji-148	601	12	the	the	DET
aji-148	601	13	creative	creative	ADJ
aji-148	601	14	commons	common	NOUN
aji-148	601	15	attribution	attribution	NOUN
aji-148	601	16	license	license	NOUN
aji-148	601	17	(	(	PUNCT
aji-148	601	18	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	NOUN
aji-148	601	19	)	)	PUNCT
aji-148	601	20	,	,	PUNCT
aji-148	601	21	which	which	PRON
aji-148	601	22	permits	permit	VERB
aji-148	601	23	unrestricted	unrestricted	ADJ
aji-148	601	24	use	use	NOUN
aji-148	601	25	,	,	PUNCT
aji-148	601	26	distribution	distribution	NOUN
aji-148	601	27	,	,	PUNCT
aji-148	601	28	and	and	CCONJ
aji-148	601	29	reproduction	reproduction	NOUN
aji-148	601	30	in	in	ADP
aji-148	601	31	any	any	DET
aji-148	601	32	medium	medium	NOUN
aji-148	601	33	,	,	PUNCT
aji-148	601	34	provided	provide	VERB
aji-148	601	35	the	the	DET
aji-148	601	36	original	original	ADJ
aji-148	601	37	work	work	NOUN
aji-148	601	38	is	be	AUX
aji-148	601	39	properly	properly	ADV
aji-148	601	40	cited	cite	VERB
aji-148	601	41	.	.	PUNCT
aji-148	602	1	peer	peer	NOUN
aji-148	602	2	-	-	PUNCT
aji-148	602	3	review	review	NOUN
aji-148	602	4	history	history	NOUN
aji-148	602	5	:	:	PUNCT
aji-148	602	6	the	the	DET
aji-148	602	7	peer	peer	NOUN
aji-148	602	8	review	review	NOUN
aji-148	602	9	history	history	NOUN
aji-148	602	10	for	for	ADP
aji-148	602	11	this	this	DET
aji-148	602	12	paper	paper	NOUN
aji-148	602	13	can	can	AUX
aji-148	602	14	be	be	AUX
aji-148	602	15	accessed	access	VERB
aji-148	602	16	here	here	ADV
aji-148	602	17	:	:	PUNCT
aji-148	602	18	https://www.sdiarticle5.com/review-history/126682	https://www.sdiarticle5.com/review-history/126682	NOUN
aji-148	603	1	https://augusta.elsevierpure.com/en/publications/personalized-chemotherapy-of-tumor-disease-based-on-system-modeli	https://augusta.elsevierpure.com/en/publications/personalized-chemotherapy-of-tumor-disease-based-on-system-modeli	ADJ
aji-148	604	1	https://augusta.elsevierpure.com/en/publications/personalized-chemotherapy-of-tumor-disease-based-on-system-modeli	https://augusta.elsevierpure.com/en/publications/personalized-chemotherapy-of-tumor-disease-based-on-system-modeli	PROPN
aji-148	604	2	https://www.frontiersin.org/articles/10.3389/fimmu.2022.973881/full	https://www.frontiersin.org/articles/10.3389/fimmu.2022.973881/full	PROPN
aji-148	604	3	https://www.frontiersin.org/articles/10.3389/fimmu.2022.973881/full	https://www.frontiersin.org/articles/10.3389/fimmu.2022.973881/full	PROPN
aji-148	604	4	https://www.frontiersin.org/articles/10.3389/fimmu.2022.973881/full	https://www.frontiersin.org/articles/10.3389/fimmu.2022.973881/full	PROPN
aji-148	604	5	https://esmed.org/mra/mra/article/view/4293	https://esmed.org/mra/mra/article/view/4293	PROPN
aji-148	604	6	https://esmed.org/mra/mra/article/view/4293	https://esmed.org/mra/mra/article/view/4293	PROPN
aji-148	604	7	https://esmed.org/mra/mra/article/view/4293	https://esmed.org/mra/mra/article/view/4293	PROPN
aji-148	604	8	https://www.sdiarticle5.com/review-history/126682	https://www.sdiarticle5.com/review-history/126682	PROPN